TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	3

ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	Condensed consolidated balance sheets	3

	Condensed consolidated statements of operations	4

	Condensed consolidated statements of changes in equity and income	65

	Condensed consolidated statements of cash flows	76

	Notes to condensed consolidated financial statements	87

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	3426

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	6143

ITEM 4.	CONTROLS AND PROCEDURES	6244

PART II	OTHER INFORMATION	6345

ITEM 1.	LEGAL PROCEEDINGS	6345

ITEM 1A.	RISK FACTORS	6546

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	6547

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	6647

ITEM 4.	MINE SAFETY DISCLOSURES	6647

ITEM 5.	OTHER INFORMATION	6647

ITEM 6.	EXHIBITS	6647

SIGNATURES

PART I FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

Select Medical Holdings Corporation

Select Medical Corporation

December 31,

September 30,

December 31,

September 30,

2015

2016

2015

2016

ASSETS

Current Assets:

Cash and cash equivalents

$
14,435

$
68,223

$
14,435

$
68,223

Accounts receivable, net of allowance for doubtful accounts of $61,133 and $61,084 at 2015 and 2016, respectively

603,558

592,711

603,558

592,711

Current deferred tax asset

28,688

50,647

28,688

50,647

Prepaid income taxes

16,694

11,474

16,694

11,474

Other current assets

85,779

82,680

85,779

82,680

Total Current Assets

749,154

805,735

749,154

805,735

Property and equipment, net

864,124

863,485

864,124

863,485

Goodwill

2,314,624

2,674,623

2,314,624

2,674,623

Other identifiable intangibles, net

318,675

338,220

318,675

338,220

Other assets

142,101

163,342

142,101

163,342

Total Assets

$
4,388,678

$
4,845,405

$
4,388,678

$
4,845,405

Current Liabilities:

Bank overdrafts

$
28,615

$
20,151

$
28,615

$
20,151

Current portion of long-term debt and notes payable

225,166

12,690

225,166

12,690

Accounts payable

137,409

114,181

137,409

114,181

Accrued payroll

120,989

138,090

120,989

138,090

Accrued vacation

73,977

78,776

73,977

78,776

Accrued interest

9,401

32,964

9,401

32,964

Accrued other

133,728

142,431

133,728

142,431

Due to third party payors

—

11,065

—

11,065

Total Current Liabilities

729,285

550,348

729,285

550,348

Long-term debt, net of current portion

2,160,730

2,642,115

2,160,730

2,642,115

Non-current deferred tax liability

218,705

210,000

218,705

210,000

Other non-current liabilities

133,220

136,527

133,220

136,527

Total Liabilities

3,241,940

3,538,990

3,241,940

3,538,990

Commitments and contingencies (Note 11)

Redeemable non-controlling interests

238,221

246,429

238,221

246,429

Stockholders’ Equity:

Common stock of Holdings, $0.001 par value, 700,000,000 shares authorized, 131,282,798 and 132,395,317 shares issued and outstanding at 2015 and 2016, respectively

131

132

—

—

Common stock of Select, $0.01 par value, 100 shares issued and outstanding

—

—

0

0

Capital in excess of par

424,506

440,316

904,375

921,069

Retained earnings (accumulated deficit)

434,616

528,593

(45,122
)
47,972

Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity

859,253

969,041

859,253

969,041

Non-controlling interest

49,264

90,945

49,264

90,945

Total Equity

908,517

1,059,986

908,517

1,059,986

Total Liabilities and Equity

$
4,388,678

$
4,845,405

$
4,388,678

$
4,845,405

~~The accompanying notes are an integral part of these condensed consolidated financial statements.~~

~~Condensed Consolidated Statements of Operations~~

~~(unaudited)~~

~~(in thousands, except per share amounts)~~

Select Medical Holdings Corporation

Select Medical Corporation

For the Three Months Ended September 30,

For the Three Months Ended September 30,

2015

2016

2015

2016

Net operating revenues

$
1,021,123

$
1,053,795

$
1,021,123

$
1,053,795

Costs and expenses:

Cost of services

900,949

915,703

900,949

915,703

General and administrative

22,201

27,088

22,201

27,088

Bad debt expense

18,287

17,677

18,287

17,677

Depreciation and amortization

31,472

37,165

31,472

37,165

Total costs and expenses

972,909

997,633

972,909

997,633

Income from operations

48,214

56,162

48,214

56,162

Other income and expense:

Loss on early retirement of debt

—

(10,853
)
—

(10,853
)
Equity in earnings of unconsolidated subsidiaries

6,348

5,268

6,348

5,268

Non-operating gain (loss)

29,647

(1,028
)
29,647

(1,028
)
Interest expense

(33,052
)
(44,482
)
(33,052
)
(44,482
)

Income before income taxes

51,157

5,067

51,157

5,067

Income tax expense

18,347

1,075

18,347

1,075

Net income

32,810

3,992

32,810

3,992

Less: Net income (loss) attributable to non-controlling interests

3,404

(2,479
)
3,404

(2,479
)

Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation

$
29,406

$
6,471

$
29,406

$
6,471

Basic

$
0.22

$
0.05

Diluted

$
0.22

$
0.05

Weighted average shares outstanding:

Basic

127,386

127,848

Diluted

127,649

127,989

	Select Medical Holdings Corporation				Select Medical Corporation
	December 31,		March 31,		December 31,			March 31,
	2016		2017		2016			2017

ASSETS
Current Assets:
Cash and cash equivalents	$	99,029	$	65,211	$	99,029		$	65,211
Accounts receivable, net of allowance for doubtful accounts of $63,787 and $67,792 at 2016 and 2017, respectively	573,752		691,520		573,752			691,520
Prepaid income taxes	12,423		2,402		12,423			2,402
Other current assets	77,699		85,081		77,699			85,081
Total Current Assets	762,903		844,214		762,903			844,214

Property and equipment, net	892,217		897,146		892,217			897,146
Goodwill	2,751,000		2,759,764		2,751,000			2,759,764
Identifiable intangible assets, net	340,562		337,076		340,562			337,076
Other assets	173,944		164,737		173,944			164,737

Total Assets	$	4,920,626	$	5,002,937	$	4,920,626		$	5,002,937

LIABILITIES AND EQUITY
Current Liabilities:
Bank overdrafts	$	39,362	$	22,299	$	39,362		$	22,299
Current portion of long-term debt and notes payable	13,656		22,013		13,656			22,013
Accounts payable	126,558		125,118		126,558			125,118
Accrued payroll	146,397		110,196		146,397			110,196
Accrued vacation	83,261		88,736		83,261			88,736
Accrued interest	22,325		21,558		22,325			21,558
Accrued other	140,076		143,180		140,076			143,180
Income taxes payable	—		5,399		—			5,399
Total Current Liabilities	571,635		538,499		571,635			538,499

Long-term debt, net of current portion	2,685,333		2,771,410		2,685,333			2,771,410
Non-current deferred tax liability	199,078		195,729		199,078			195,729
Other non-current liabilities	136,520		142,208		136,520			142,208

Total Liabilities	3,592,566		3,647,846		3,592,566			3,647,846

Commitments and contingencies (Note 9)

Redeemable non-controlling interests	422,159		462,680		422,159			462,680

Stockholders’ Equity:
Common stock of Holdings, $0.001 par value, 700,000,000 shares authorized, 132,596,758 and 132,753,444 shares issued and outstanding at 2016 and 2017, respectively	132		132		—			—
Common stock of Select, $0.01 par value, 100 shares issued and outstanding	—		—		0			0
Capital in excess of par	443,908		450,373		925,111			931,661
Retained earnings (accumulated deficit)	371,685		351,224		(109,386		)	(129,932		)
Total Select Medical Holdings Corporation and Select Medical Corporation Stockholders’ Equity	815,725		801,729		815,725			801,729
Non-controlling interest	90,176		90,682		90,176			90,682
Total Equity	905,901		892,411		905,901			892,411

Total Liabilities and Equity	$	4,920,626	$	5,002,937	$	4,920,626		$	5,002,937

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	Select Medical Holdings Corporation						Select Medical Corporation						Select Medical Holdings Corporation						Select Medical Corporation
	For the Nine Months Ended September 30,						For the Nine Months Ended September 30,						For the Three Months Ended March 31,						For the Three Months Ended March 31,
	2015			2016			2015			2016			2016			2017			2016			2017

Net operating revenues	$	2,703,531		$	3,239,756		$	2,703,531		$	3,239,756		$	1,088,330		$	1,111,361		$	1,088,330		$	1,111,361

Costs and expenses:
Cost of services	2,309,213			2,754,950			2,309,213			2,754,950			922,262			928,357			922,262			928,357
General and administrative	67,917			81,226			67,917			81,226			28,268			28,075			28,268			28,075
Bad debt expense	43,243			51,591			43,243			51,591			16,397			20,625			16,397			20,625
Depreciation and amortization	70,668			107,887			70,668			107,887			34,517			42,539			34,517			42,539
Total costs and expenses	2,491,041			2,995,654			2,491,041			2,995,654			1,001,444			1,019,596			1,001,444			1,019,596

Income from operations	212,490			244,102			212,490			244,102			86,886			91,765			86,886			91,765

Other income and expense:
Loss on early retirement of debt	—			(11,626		)	—			(11,626		)	(773		)	(19,719		)	(773		)	(19,719		)
Equity in earnings of unconsolidated subsidiaries	12,788			14,466			12,788			14,466			4,652			5,521			4,652			5,521
Non-operating gain	29,647			37,094			29,647			37,094
Non-operating gain (loss)													25,087			(49		)	25,087			(49		)
Interest expense	(79,728		)	(127,662		)	(79,728		)	(127,662		)	(38,848		)	(40,853		)	(38,848		)	(40,853		)

Income before income taxes	175,197			156,374			175,197			156,374			77,004			36,665			77,004			36,665

Income tax expense	65,048			51,585			65,048			51,585			17,060			13,202			17,060			13,202
Net income	110,149			104,789			110,149			104,789			59,944			23,463			59,944			23,463

Less: Net income attributable to non-controlling interests	8,740			9,550			8,740			9,550			5,111			7,593			5,111			7,593

Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	101,409		$	95,239		$	101,409		$	95,239
Net income attributable to Select Medical Holdings
Corporation and Select Medical Corporation													$	54,833		$	15,870		$	54,833		$	15,870

Basic	$	0.77		$	0.72								$	0.42		$	0.12
Diluted	$	0.77		$	0.72								$	0.42		$	0.12

Dividends paid per share	$	0.10		$	—

Weighted average shares outstanding:
Basic	127,541			127,659									127,500			128,464
Diluted	127,844			127,804									127,581			128,628

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated ~~Statement~~Statements of Changes in Equity and Income

(unaudited)

(in thousands)

Select Medical Holdings Corporation Stockholders

Non-

Comprehensive Income

Total

Common Stock
Issued

Common Stock Par
Value

Capital in Excess
of Par

Retained Earnings

controlling
Interests

Balance at December 31, 2015

$
908,517

131,283

$
131

$
424,506

$
434,616

$
49,264

Net income

$
93,037

93,037

95,239

(2,202
)
Net income - attributable to redeemable non-controlling interests

11,752

Total comprehensive income

$
104,789

Issuance and vesting of restricted stock

12,344

1,089

1

12,343

Tax benefit from stock based awards

514

514

Repurchase of common shares

(1,939
)
(155
)
0

(883
)
(1,056
)

Stock option expense

4

4

Exercise of stock options

1,488

178

0

1,488

Non-controlling interests acquired in business combination

2,514

2,514

Distributions to non-controlling interests

(6,939
)

(6,939
)
Issuance of non-controlling interests

50,178

2,377

47,801

Purchase of redeemable non-controlling interests

466

466

Other

(198
)

(33
)
(672
)
507

Balance at September 30, 2016

$
1,059,986

132,395

$
132

$
440,316

$
528,593

$
90,945

				Select Medical Holdings Corporation Stockholders
	Redeemable Non-controlling interests			Common Stock Issued		Common Stock Par Value		Capital in Excess of Par			Retained Earnings			Total Stockholders’ Equity			Non-controlling Interests			Total Equity
Balance at December 31, 2016	$	422,159		132,597		$	132	$	443,908		$	371,685		$	815,725		$	90,176		$	905,901
Net income attributable to Select Medical Holdings Corporation											15,870			15,870						15,870
Net income attributable to non-controlling interests	6,090													—			1,503			1,503
Issuance and vesting of restricted stock				101		0		4,280						4,280						4,280
Repurchase of common shares				(12	)	0		(85		)	(71		)	(156		)				(156		)
Exercise of stock options				67		0		617						617						617
Issuance of non-controlling interests								1,653						1,653			441			2,094
Purchase of non-controlling interests	(57		)								7			7						7
Distributions to non-controlling interests	(2,075		)											—			(1,532		)	(1,532		)
Redemption adjustment on non-controlling interests	36,292										(36,292		)	(36,292		)				(36,292		)
Other	271										25			25			94			119
Balance at March 31, 2017	$	462,680		132,753		$	132	$	450,373		$	351,224		$	801,729		$	90,682		$	892,411

Select Medical Corporation Stockholders

Non-

Comprehensive Income

Total

Common Stock
Issued

Common Stock Par
Value

Capital in Excess
of Par

Retained Earnings
(Accumulated Deficit)

controlling
Interests

Balance at December 31, 2015

$
908,517

0

$
0

$
904,375

$
(45,122
)
$
49,264

Net income

$
93,037

93,037

95,239

(2,202
)
Net income - attributable to redeemable non-controlling interests

11,752

Total comprehensive income

$
104,789

Additional investment by Holdings

1,488

1,488

Dividends declared and paid to Holdings

(1,939
)

(1,939
)

Contribution related to restricted stock awards and stock option issuances by Holdings

12,348

12,348

Tax benefit from stock based awards

514

514

Non-controlling interests acquired in business combination

2,514

2,514

Distributions to non-controlling interests

(6,939
)

(6,939
)
Issuance of non-controlling interests

50,178

2,377

47,801

Purchase of redeemable non-controlling interests

466

466

Other

(198
)

(33
)
(672
)
507

Balance at September 30, 2016

$
1,059,986

0

$
0

$
921,069

$
47,972

$
90,945

				Select Medical Corporation Stockholders
	Redeemable Non-controlling interests			Common Stock Issued	Common Stock Par Value		Capital in Excess of Par		Retained Earnings			Total Stockholders’ Equity			Non-controlling Interests			Total Equity
Balance at December 31, 2016	$	422,159		0	$	0	$	925,111	$	(109,386	)	$	815,725		$	90,176		$	905,901
Net income attributable to Select Medical Corporation									15,870			15,870						15,870
Net income attributable to non-controlling interests	6,090											—			1,503			1,503
Additional investment by Holdings							617					617						617
Dividends declared and paid to Holdings									(156		)	(156		)				(156		)
Contribution related to restricted stock awards and stock option issuances by Holdings							4,280					4,280						4,280
Issuance of non-controlling interests							1,653					1,653			441			2,094
Purchase of non-controlling interests	(57		)						7			7						7
Distributions to non-controlling interests	(2,075		)									—			(1,532		)	(1,532		)
Redemption adjustment on non-controlling interests	36,292								(36,292		)	(36,292		)				(36,292		)
Other	271								25			25			94			119
Balance at March 31, 2017	$	462,680		0	$	0	$	931,661	$	(129,932	)	$	801,729		$	90,682		$	892,411

The accompanying notes are an integral part of these condensed consolidated financial statements.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	Select Medical Holdings Corporation						Select Medical Corporation						Select Medical Holdings Corporation						Select Medical Corporation
	For the Nine Months Ended September 30,						For the Nine Months Ended September 30,						For the Three Months Ended March 31,						For the Three Months Ended March 31,
	2015			2016			2015			2016			2016			2017			2016			2017

Operating activities
Net income	$	110,149		$	104,789		$	110,149		$	104,789		$	59,944		$	23,463		$	59,944		$	23,463
Adjustments to reconcile net income to net cash provided by operating activities:
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	11,814			16,145			11,814			16,145			8,305			4,911			8,305			4,911
Depreciation and amortization	70,668			107,887			70,668			107,887			34,517			42,539			34,517			42,539
Amortization of leasehold interests	—			457			—			457
Provision for bad debts	43,243			51,591			43,243			51,591			16,397			20,625			16,397			20,625
Equity in earnings of unconsolidated subsidiaries	(12,788		)	(14,466		)	(12,788		)	(14,466		)	(4,652		)	(5,521		)	(4,652		)	(5,521		)
Loss on early retirement of debt	—			11,626			—			11,626			773			6,527			773			6,527
Loss on disposal of assets	—			282			—			282
Gain on sale of assets and businesses	(1,264		)	(42,192		)	(1,264		)	(42,192		)	(30,393		)	(4,609		)	(30,393		)	(4,609		)
Gain on sale of equity investment	(29,647		)	(241		)	(29,647		)	(241		)
Impairment of equity investment	—			5,339			—			5,339			5,339			—			5,339			—
Stock compensation expense	9,244			12,924			9,244			12,924			3,976			4,586			3,976			4,586
Amortization of debt discount, premium and issuance costs	6,746			11,845			6,746			11,845			3,691			3,422			3,691			3,422
Deferred income taxes	(6,925		)	(13,088		)	(6,925		)	(13,088		)	(3,475		)	(3,425		)	(3,475		)	(3,425		)
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(48,778		)	(40,776		)	(48,778		)	(40,776		)	(39,164		)	(138,113		)	(39,164		)	(138,113		)
Other current assets	(4,580		)	12,094			(4,580		)	12,094			7,560			(7,621		)	7,560			(7,621		)
Other assets	4,540			4,689			4,540			4,689			(891		)	(48		)	(891		)	(48		)
Accounts payable	3,047			(17,752		)	3,047			(17,752		)	(21,322		)	412			(21,322		)	412
Accrued expenses	32,716			52,996			32,716			52,996			51,193			(18,429		)	51,193			(18,429		)
Due to third party payors	—			11,065			—			11,065
Income taxes	15,246			5,033			15,246			5,033			19,370			15,420			19,370			15,420
Net cash provided by operating activities	203,431			280,247			203,431			280,247
Net cash provided by (used in) operating activities													111,168			(55,861		)	111,168			(55,861		)

Investing activities
Acquisition of businesses, net of cash acquired													(412,883		)	(9,566		)	(412,883		)	(9,566		)
Purchases of property and equipment	(113,992		)	(118,260		)	(113,992		)	(118,260		)	(46,768		)	(50,653		)	(46,768		)	(50,653		)
Investment in businesses													(623		)	(500		)	(623		)	(500		)
Proceeds from sale of assets and businesses	1,542			71,388			1,542			71,388			62,600			19,512			62,600			19,512
Investment in businesses	(1,703		)	(3,140		)	(1,703		)	(3,140		)
Proceeds from sale of equity investment	33,096			1,241			33,096			1,241
Acquisition of businesses, net of cash acquired	(1,049,872		)	(414,231		)	(1,049,872		)	(414,231		)
Net cash used in investing activities	(1,130,929		)	(463,002		)	(1,130,929		)	(463,002		)	(397,674		)	(41,207		)	(397,674		)	(41,207		)

Financing activities
Borrowings on revolving facilities	840,000			420,000			840,000			420,000			190,000			530,000			190,000			530,000
Payments on revolving facilities	(675,000		)	(545,000		)	(675,000		)	(545,000		)	(175,000		)	(415,000		)	(175,000		)	(415,000		)
Net proceeds from term loans	623,575			795,344			623,575			795,344
Proceeds from term loans													600,127			1,139,822			600,127			1,139,822
Payments on term loans	(26,884		)	(434,842		)	(26,884		)	(434,842		)	(226,962		)	(1,170,817		)	(226,962		)	(1,170,817		)
Revolving facility debt issuance costs													—			(3,887		)	—			(3,887		)
Borrowings of other debt	11,041			23,801			11,041			23,801			6,727			6,571			6,727			6,571
Principal payments on other debt	(13,167		)	(15,477		)	(13,167		)	(15,477		)	(4,464		)	(5,275		)	(4,464		)	(5,275		)
Dividends paid to common stockholders	(13,129		)	—			—			—
Repayments of bank overdrafts													(28,615		)	(17,062		)	(28,615		)	(17,062		)
Repurchase of common stock													—			(156		)	—			—
Dividends paid to Holdings	—			—			(26,751		)	(1,939		)	—			—			—			(156		)
Repurchase of common stock	(13,622		)	(1,939		)	—			—
Proceeds from issuance of common stock	1,604			1,488			—			—
Proceeds from exercise of stock options													21			617			—			—
Equity investment by Holdings	—			—			1,604			1,488			—			—			21			617
Proceeds from issuance of non-controlling interest	217,065			11,846			217,065			11,846
Proceeds from (repayments of) bank overdrafts	2,353			(8,464		)	2,353			(8,464		)
Tax benefit from stock based awards	383			514			383			514
Proceeds from issuance of non-controlling interests													—			2,094			—			2,094
Purchase of non-controlling interests	—			(1,530		)	—			(1,530		)	(1,294		)	(50		)	(1,294		)	(50		)
Distributions to non-controlling interests	(7,440		)	(9,198		)	(7,440		)	(9,198		)	(3,061		)	(3,607		)	(3,061		)	(3,607		)
Net cash provided by financing activities	946,779			236,543			946,779			236,543			357,479			63,250			357,479			63,250

Net increase in cash and cash equivalents	19,281			53,788			19,281			53,788
Net increase (decrease) in cash and cash equivalents													70,973			(33,818		)	70,973			(33,818		)

Cash and cash equivalents at beginning of period	3,354			14,435			3,354			14,435			14,435			99,029			14,435			99,029
Cash and cash equivalents at end of period	$	22,635		$	68,223		$	22,635		$	68,223		$	85,408		$	65,211		$	85,408		$	65,211

Supplemental Cash Flow Information
Supplemental Information
Cash paid for interest	$	59,937		$	92,928		$	59,937		$	92,928		$	21,544		$	38,565		$	21,544		$	38,565
Cash paid for taxes	$	55,905		$	59,937		$	55,905		$	59,937		$	1,209		$	1,207		$	1,209		$	1,207

The accompanying notes are an integral part of these condensed consolidated financial statements.

SELECT MEDICAL HOLDINGS CORPORATION AND SELECT MEDICAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) and Select Medical Corporation (“Select”) as of ~~September 30, 2016,~~March 31, 2017, and for the three ~~and nine~~ month periods ended ~~September 30, 2015~~March 31, 2016 and ~~2016,~~2017, have been prepared in accordance with generally accepted accounting principles (“GAAP”). In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated. The results of operations for the three ~~and nine~~ months ended ~~September 30, 2016~~March 31, 2017 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, ~~2016.~~2017. Holdings and Select and their subsidiaries are collectively referred to as the “Company.” The condensed consolidated financial statements of Holdings include the accounts of its wholly owned subsidiary, Select. Holdings conducts substantially all of its business through Select and its subsidiaries.

Certain information and disclosures normally included in the notes to consolidated financial statements have been condensed or omitted consistent with the rules and regulations of the Securities and Exchange Commission (the “SEC”), although the Company believes the disclosure is adequate to make the information presented not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, ~~2015~~2016 contained in the Company’s Annual Report on Form 10-K filed with the SEC on February ~~26, 2016.~~23, 2017.

2. Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, ~~and~~including disclosure of contingent assets and liabilities, at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ ~~materially~~ from those estimates.

Recent Accounting Pronouncements

In ~~August 2016,~~February 2017, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) ~~2016-15~~2017-05, Other Income—Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20) —Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Asset. The standard provides guidance for recognizing gains and losses from the transfer of nonfinancial assets and in-substance non-financial assets in contracts with non-customers, unless other specific guidance applies. The standard requires a company to derecognize nonfinancial assets once it transfers control. Additionally, when a company transfers its controlling interest in a nonfinancial asset, but retains a noncontrolling ownership interest, the company is required to measure any non-controlling interest it receives or retains at fair value. The standard will be effective for fiscal years beginning after December 15, 2017. The standard requires the selection of a retrospective or cumulative effect transition method. The Company is currently evaluating the standard to determine the impact it will have on its consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business, ~~Statement~~which clarifies the definition of ~~Cash Flows~~a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. ASU 2017-01 states that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the transaction should be accounted for as an asset acquisition. In addition, the ASU clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017. Early adoption is permitted.

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic ~~230)~~740), ~~Classification~~Intra-Entity Transfers of ~~Certain Cash Receipts~~Assets Other Than Inventory. Current GAAP prohibits the recognition of current and ~~Cash Payments,~~ ~~which addresses~~deferred income taxes for an intra-entity asset transfer until the ~~diversity in practice in how certain cash receipts and cash payments are presented and classified in~~asset has been sold to an outside party. The ASU requires an entity to recognize the ~~statement~~income tax consequences of ~~cash flows.~~an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard will be effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the standard to determine the impact it will have on its consolidated financial statements.

~~In March 2016, the FASB issued ASU 2016-09,~~ ~~Compensation-Stock Compensation~~, which simplifies various aspects of accounting for share-based payments to employees. The areas for simplification involve several aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard will be effective for fiscal years beginning after December 15, 2016. The Company is currently evaluating the standard to determine the impact it will have on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. This ASU includes a lessee accounting model that recognizes two types of leases; finance and operating. This ASU requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees willneed to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as a finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

The amendments in ASU 2016-02 will take effect for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted as of the beginning of an interim or annual reporting period. A modified retrospective approach is required for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. ~~The Company is currently evaluating the standard to determine the impact it will have on its consolidated financial statements.~~

~~In November 2015,~~Upon adoption, the ~~FASB issued ASU No. 2015-17,~~ ~~Balance Sheet Classification~~Company will recognize significant assets and liabilities on the consolidated balance sheets as a result of ~~Deferred Taxes~~~~, which changes~~ the ~~presentation~~operating lease obligations of ~~deferred income taxes. The intent is to simplify~~ the ~~presentation~~Company. Operating lease expense will still be recognized as rent expense on a straight-line basis over the respective lease terms in the consolidated statements of deferred income taxes through the requirement that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The revised guidance is effective for annual fiscal periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the standard to determine the impact it will have on its consolidated financial statements.operations.

In May 2014, March 2016, April 2016, and ~~April~~December 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, ASU 2016-08, Revenue from Contracts with Customers, Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing, ~~and~~ ASU 2016-12, Revenue from Contracts with Customers, Narrow Scope Improvements and Practical Expedients, and ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customer (collectively “the standards”), respectively, which supersede most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The original standards were effective for fiscal years beginning after December 15, 2016; however, in July 2015, the FASB approved a one-year deferral of these standards, with a new effective date for fiscal years beginning after December 15, 2017. The standards require the selection of a ~~modified~~ retrospective or cumulative effect transition ~~method for retrospective application. The Company is currently evaluating the standards to determine the impact they will have on its consolidated financial statements.~~method.

The Company will be prepared to implement the new standards beginning January 1, 2018, using the retrospective transition method. Adoption of the new standard will result in material changes to the presentation of net operating revenues and bad debt expense in the consolidated statements of operations, but the presentation of the amount of income from operations and net income will be unchanged upon adoption of the new standards. The principal change the Company will experience under the new standards is how the Company accounts for amounts estimated as being realizable from a customer on the date which services have been provided. Under the current standards, the Company’s estimate for unrealizable amounts based upon historical experience was recorded to bad debt expense. Under the new standards, the Company’s estimate for unrealizable amounts based upon historical experience will be recognized as a direct reduction to revenue. Accounts receivable will continue to be subject to estimates of collectability, and bad debt expense and related allowances for doubtful accounts will continue to be recognized if estimates of collectability change in future periods. If accounts receivable become uncollectible due to bankruptcy, financial hardship or other factors that may arise and impact the Company’s ability to realize amounts owed to us, the Company will write-off these uncollectible accounts through the allowance for doubtful accounts.

The Company’s remaining implementation efforts will be focused principally on refining the accounting processes, disclosure processes, and internal controls.

Recently Adopted Accounting Pronouncements

In ~~April and August~~November 2015, the FASB issued ASU ~~2015-03 and ASU 2015-15, each titled~~No. 2015-17, ~~Interest- Imputation~~Balance Sheet Classification of ~~Interest~~Deferred Taxes, ~~to simplify~~which changed the presentation of ~~debt issuance costs.~~deferred income taxes. The standard ~~requires debt issuance costs~~changed the presentation of deferred income taxes through the requirement that all deferred tax liabilities and assets be ~~presented~~classified as noncurrent in ~~the balance sheet as~~ a ~~direct deduction from the carrying value~~classified statement of ~~the debt liability. The FASB clarified that debt issuance costs related to line-of-credit arrangements can be presented as an asset and amortized over the term of the arrangement.~~financial position. The Company adopted the standard on January 1, 2017. The consolidated balance sheet at ~~the beginning~~December 31, 2016 has been retrospectively adjusted. Adoption of the ~~first quarter of 2016. The~~new standard impacted the Company’s previously reported results as follows:

	December 31, 2016
	As Reported		As Adjusted
	(in thousands)
Current deferred tax asset	$	45,165	$	—
Total current assets	808,068		762,903
Other assets	152,548		173,944
Total assets	4,944,395		4,920,626

Non-current deferred tax liability	222,847		199,078
Total liabilities	3,616,335		3,592,566
Total liabilities and equity	4,944,395		4,920,626

Reclassifications

Certain reclassifications have been made to prior year amounts in order to conform to current year presentation. As discussed above, the prior year balance sheet ~~as of December 31, 2015 was retrospectively conformed~~presentation has been changed in order to ~~reflect~~conform to the

current year balance sheet presentation for the adoption of ~~the standard and approximately $38.0 million~~ASU No. 2015-17, Balance Sheet Classification of ~~unamortized debt issuance costs were reclassified to be a direct reduction of debt, rather than a component of other assets.~~Deferred Taxes.

3. Acquisitions~~Acquisitions~~

Physiotherapy Acquisition

On March 4, 2016, Select acquired 100% of the issued and outstanding equity securities of Physiotherapy Associates Holdings, Inc. (“Physiotherapy”) for $406.3 million, net of $12.3 million of cash acquired. ~~Select financed~~

For the acquisition using a combination of cash on hand and proceeds from an incremental term loan facility under the Select credit facilities, as defined below (see Note 7 for more details). During the nine months ended September 30, 2016, $3.2 million of Physiotherapy acquisition, ~~costs were recognized in general and administrative expense.~~

Physiotherapy is a national provider of outpatient physical rehabilitation care offering a wide range of services, including general orthopedics, spinal care and neurological rehabilitation, as well as orthotics and prosthetics services.

~~The Physiotherapy acquisition is being accounted for under~~ the ~~provisions of Accounting Standards Codification (“ASC”) 805, Business Combinations. The~~ Company ~~has prepared a preliminary allocation of~~allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair ~~values. The~~value in accordance with the provisions of Accounting Standards Codification (“ASC”) 805, Business Combinations. During the three months ended March 31, 2017, the Company ~~is in~~finalized the process of completing its assessment of fair values for identifiable tangible and intangible assets, and liabilities assumed; therefore, the values set forth below are subject to adjustment during the measurement period for such activities as estimating useful lives of long-lived assets and finite lived intangibles and completing assessment of fair values by obtaining appraisals. The amount of these potential adjustments could be significant. The Company expects to complete its purchase price ~~allocation activities by December 31, 2016.~~allocation.

The following table ~~summarizes~~reconciles the ~~preliminary~~ allocation of the ~~purchase price~~consideration given for identifiable net assets and goodwill acquired to the ~~fair value of identifiable assets~~net cash paid for the acquired ~~and liabilities assumed, in accordance with the acquisition method of accounting~~business (in thousands):

Cash and cash equivalents

$
12,340

Identifiable tangible assets, excluding cash and cash equivalents

92,981

Identifiable intangible assets

32,484

Goodwill

319,145

Total assets

456,950

Total liabilities

35,792

Acquired non-controlling interests

2,514

Net assets acquired

418,644

Less: Cash and cash equivalents acquired

(12,340
)
Net cash paid

$
406,304

Cash and cash equivalents	$	12,340
Identifiable tangible assets, excluding cash and cash equivalents	87,832
Identifiable intangible assets	32,484
Goodwill	343,187
Total assets	475,843
Total liabilities	54,685
Acquired non-controlling interests	2,514
Net assets acquired	418,644
Less: Cash and cash equivalents acquired	(12,340		)
Net cash paid	$	406,304

Goodwill of ~~$319.1~~$343.2 million has been recognized in the ~~transaction,~~business combination, representing the excess of the ~~purchase price~~consideration given over the fair value of ~~the tangible and intangible~~identifiable net assets ~~acquired and liabilities assumed.~~acquired. The ~~factors considered in determining the~~value of goodwill ~~that resulted~~is derived from ~~the Physiotherapy purchase price included~~ Physiotherapy’s future earnings potential and ~~the value of the~~its assembled workforce. ~~The goodwill~~Goodwill has been ~~allocated~~assigned to the outpatient rehabilitation ~~segment~~reporting unit and is not deductible for tax purposes. However, prior to its acquisition by the Company, Physiotherapy completed certain acquisitions that resulted in tax deductible goodwill with an estimated value of $8.8 million, ~~that is deductible for tax purposes,~~ which the Company will deduct through 2030.

Due to the ~~integrated nature~~integration of Physiotherapy into our outpatient rehabilitation operations, it is not practicable to separately identify net revenue and earnings of Physiotherapy on a stand-alone basis.

~~Concentra Acquisition~~

On June 1, 2015, MJ Acquisition Corporation, a joint venture that Select created with Welsh, Carson, Anderson & Stowe XII, L.P., consummated the acquisition of Concentra, Inc. (“Concentra”), the indirect operating subsidiary of Concentra Group Holdings, LLC, and its subsidiaries. Pursuant to the terms of the stock purchase agreement, dated as of March 22, 2015, by and among MJ Acquisition Corporation, Concentra and Humana Inc., MJ Acquisition Corporation acquired 100% of the issued and outstanding equity securities of Concentra from Humana, Inc. for $1,047.2 million, net of $3.8 million of cash acquired.

During the year ended December 31, 2015, the Company finalized the purchase price allocation to identifiable intangible assets, fixed assets, non-controlling interests, and certain pre-acquisition contingencies. During the quarter ended June 30, 2016, the Company completed the accounting for certain deferred tax matters.

The following table summarizes the allocation of the purchase price to the fair value of identifiable assets acquired and liabilities assumed, in accordance with the acquisition method of accounting (in thousands):

Cash and cash equivalents

$
3,772

Identifiable tangible assets, excluding cash and cash equivalents

406,926

Identifiable intangible assets

254,990

Goodwill

651,152

Total assets

1,316,840

Total liabilities

248,797

Acquired non-controlling interests

17,084

Net assets acquired

1,050,959

Less: Cash and cash equivalents acquired

(3,772
)
Net cash paid

$
1,047,187

Goodwill of $651.2 million was recognized in the transaction, representing the excess of the purchase price over the value of the tangible and intangible assets acquired and liabilities assumed. The factors considered in determining the goodwill that resulted from the Concentra purchase price included Concentra’s future earnings potential and the value of Concentra’s assembled workforce. The goodwill is allocated to the Concentra segment and is not deductible for tax purposes. However, prior to its acquisition by MJ Acquisition Corporation, Concentra completed certain acquisitions that resulted in goodwill with an estimated value of $23.9 million that is deductible for tax purposes, which the Company will deduct through 2025.

For the three months ended September 30, 2016, Concentra contributed net revenue of $258.5 million and net income of approximately $0.9 million, which are reflected in the Company’s consolidated statements of operations. For the nine months ended September 30, 2016, Concentra contributed net revenue of $764.3 million and net income of approximately $7.9 million, which are reflected in the Company’s consolidated statements of operations.

~~Pro Forma Results~~

The following pro forma unaudited results of operations have been prepared assuming the ~~acquisitions~~acquisition of ~~Concentra and~~ Physiotherapy occurred on January 1, ~~2014 and 2015, respectively.~~2015. These results are not necessarily indicative of results of future operations nor of the results that would have actually occurred had the ~~acquisitions~~acquisition been consummated on the aforementioned ~~dates.~~date. The Company’s results of operations for the three months ended ~~September 30, 2016~~March 31, 2017 include ~~both Concentra and~~ Physiotherapy for the entire period and there are no pro forma adjustments; therefore, no pro forma information is presented for the period.

For the Three Months
Ended September 30,

For the Nine Months
Ended September 30,

2015

2015

2016

(in thousands, except per share amounts)

Net revenue

$
1,099,857

$
3,350,131

$
3,293,286

Net income attributable to Holdings

26,277

88,502

93,407

Income per common share:

Basic

$
0.20

$
0.67

$
0.71

Diluted

$
0.20

$
0.67

$
0.71

	For the Three Months Ended March 31, 2016
	(in thousands, except per share amounts)
Net revenue	$	1,141,860
Net income	53,014
Income per common share:
Basic	$	0.40
Diluted	$	0.40

The pro forma financial information is based on the preliminary allocation of the purchase price of the Physiotherapy acquisition, and is therefore subject to adjustment upon finalizing the purchase price allocation, as described above, during the measurement period.

The net income tax impact was calculated at a statutory rate, as if ~~Concentra and~~ Physiotherapy had been ~~subsidiaries~~a subsidiary of the Company as of January 1, ~~2014 and 2015, respectively.~~

2015. Pro forma results for the ~~nine~~three months ended September 30, 2015 were adjusted to include $3.2 million of Physiotherapy acquisition costs and exclude $4.7 million of Concentra acquisition costs. Pro forma results for the nine months ended September 30,March 31, 2016 were adjusted to exclude approximately $3.2 million of Physiotherapy acquisition costs.

Other Acquisitions

~~In addition to the acquisition of Physiotherapy, the~~The Company completed ~~other~~ acquisitions ~~consisting of hospital, clinic,~~within our Concentra and ~~center businesses~~outpatient rehabilitation segments during the ~~nine~~three months ended September 30, 2016. The specialty hospital transactions were conducted principally through either the exchange of nonmonetary assets or issuance of equity interests. Assets transferred and equity interests issuedMarch 31, 2017. Consideration given for these acquisitions consisted of ~~$7.6~~$9.6 million inof cash, ~~payments,~~ net of cash received, $17.7 million for specialty hospitals exchanged, and issuance of $38.3 million of equity interests. The specialty hospital exchange transaction resulted in a non-operating gain totaling $6.5 million due, in part, to a bargain purchase because the fair values of the identifiable assets received in the exchange transaction exceeded the fair values of the transferred hospitals.received. The assets received in these acquisitions consisted principally of ~~cash, real~~accounts receivable, property and equipment, identifiable intangible assets, and goodwill, of which ~~$46.2 million, $0.9~~$8.6 million and ~~$4.1~~$0.3 million of goodwill was recognized in our ~~specialty hospital,~~Concentra and outpatient rehabilitation ~~and Concentra~~ reporting units, respectively.

4. ~~Sale of Businesses~~Intangible Assets and Liabilities

The Company recognized non-operating gains totaling $42.1 million for the nine months ended September 30, 2016, principally as the result of the sale of its contract therapy businesses for $65.0 million, resulting in a non-operating gain of $33.9 million. Additionally, the Company sold nine outpatient rehabilitation clinics to an entity in which the Company holds a non-controlling interest, resulting in a non-operating gain of $1.7 million.

5.~~Equity Investment~~ ~~Events~~

~~During the nine months ended September 30, 2016, an entity in which the Company owned a non-controlling interest was sold, which resulted in a non-operating loss of $5.1 million.~~

~~6. Intangible Assets~~

~~The net carrying value of the~~ Company’s goodwill and identifiable intangible assets and liabilities consist of the following:

					December 31,							March 31,
					2016							2017
	December 31, 2015		September 30, 2016		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
	(in thousands)				(in thousands)
Goodwill	$	2,314,624	$	2,674,623	$	2,751,000	$	—		$	2,751,000	$	2,759,764	$	—		$	2,759,764

Identifiable intangibles—Indefinite lived assets:
Trademarks	162,609		166,698		166,698		—			166,698		166,698		—			166,698
Certificates of need	13,022		13,070		17,026		—			17,026		17,152		—			17,152
Accreditations	2,045		2,045		2,235		—			2,235		2,143		—			2,143
Identifiable intangibles—Finite lived assets:
Customer relationships	132,751		122,095		142,198		(23,185		)	119,013		142,890		(26,908		)	115,982
Favorable leasehold interests	8,248		11,227		13,089		(2,317		)	10,772		13,177		(2,796		)	10,381
Non-compete agreements	—		23,085		26,655		(1,837		)	24,818		27,057		(2,337		)	24,720
Total identifiable intangibles	$	2,633,299	$	3,012,843
Total identifiable intangible assets					$	367,901	$	(27,339	)	$	340,562	$	369,117	$	(32,041	)	$	337,076

Identifiable intangibles—Finite lived liabilities:
Unfavorable leasehold interests					$	5,139	$	(1,410	)	$	3,729	$	5,343	$	(1,690	)	$	3,653

The Company’s customer relationships and non-compete ~~agreement assets~~agreements amortize over their estimated useful lives. Amortization expense was ~~$4.1~~$3.8 million and ~~$3.0~~$4.4 million for the three months ended ~~September 30,~~March 31, 2016 and ~~2015, respectively. Amortization expense was $12.2 million and $4.4 million for the nine months ended September 30, 2016 and 2015,~~2017, respectively. Estimated amortization expense of the Company’s customer relationships and non-compete agreements for each of the five succeeding years is ~~$16.3 million.~~

~~In addition, the Company has recognized unfavorable leasehold interests which are recorded as liabilities. The net carrying value of unfavorable leasehold interests was $4.0~~$16.4 million ~~and $3.0 million as of September 30, 2016 and December 31, 2015, respectively.~~annually.

The Company’s favorable leasehold interest assets and unfavorable leasehold interest liabilities are amortized to rent expense over the remaining term of their respective leases to reflect a market rent per period based upon the market conditions present at the acquisition date. The ~~net effect~~Company’s unfavorable leasehold interests are presented as part of ~~this amortization increased rent expense by $0.2 million for~~accrued other and other non-current liabilities on the ~~three months ended September 30, 2016 and $0.5 million for the nine months ended September 30, 2016.~~condensed consolidated balance sheets.

The Company’s accreditations and trademarks have renewal ~~terms. The~~terms and the costs to renew these ~~intangibles~~intangible assets are expensed as incurred. At ~~September 30, 2016,~~March 31, 2017, the accreditations and trademarks have a weighted average time until next renewal of 1.5 years and ~~3.1~~2.6 years, respectively.

The changes in ~~the carrying amount of~~ goodwill for the ~~Company’s reportable segments for the nine~~three months ended ~~September 30, 2016~~March 31, 2017 are as follows:

Specialty
Hospitals

Outpatient
Rehabilitation

Concentra

Total

(in thousands)

Balance as of December 31, 2015

$
1,357,379

$
306,595

$
650,650

$
2,314,624

Acquired

46,205

358,153

4,115

408,473

Measurement period adjustment

—

(38,148
)
4,825

(33,323
)
Disposed

(6,758
)
(8,393
)
—

(15,151
)
Balance as of September 30, 2016

$
1,396,826

$
618,207

$
659,590

$
2,674,623

	Specialty Hospitals			Outpatient Rehabilitation		Concentra		Total
	(in thousands)
Balance as of December 31, 2016	$	1,447,406		$	643,557	$	660,037	$	2,751,000
Acquired	—			311		8,627		8,938
Measurement period adjustment	(342		)	168		—		(174		)
Balance as of March 31, 2017	$	1,447,064		$	644,036	$	668,664	$	2,759,764

See Note 3 for details of the goodwill acquired during the period.

~~7. Indebtedness~~5.Long-Term Debt and Notes Payable

For purposes of this indebtedness footnote, references to Select exclude Concentra because the Concentra credit facilities are non-recourse to Holdings and Select.

The ~~components of~~Company’s long-term debt and notes payable ~~are shown in~~consist of the ~~following tables:~~following:

	December 31, 2015		September 30, 2016		December 31, 2016		March 31, 2017
	(in thousands)				(in thousands)
Select 6.375% senior notes(1)	$	700,867	$	702,124
Select 6.375% senior notes(1)					$	702,545	$	702,966
Select credit facilities:
Select revolving facility	295,000		175,000		220,000		335,000
Select term loans(2)	743,071		1,121,655
Select term loan(2)					1,122,203		1,122,052
Other—Select	11,987		22,802		22,688		24,842
Total Select debt	1,750,925		2,021,581		2,067,436		2,184,860
Less: Select current maturities	222,905		7,268		8,996		21,641
Select long-term debt maturities	$	1,528,020	$	2,014,313	$	2,058,440	$	2,163,219

Concentra credit facilities:
Concentra revolving facility	$	5,000	$	—
Concentra term loans(3)	624,659		627,262
Concentra term loans(3)					$	626,375	$	604,068
Other—Concentra	5,312		5,962		5,178		4,495
Total Concentra debt	634,971		633,224		631,553		608,563
Less: Concentra current maturities	2,261		5,422		4,660		372
Concentra long-term debt maturities	$	632,710	$	627,802	$	626,893	$	608,191

Total current maturities	$	225,166	$	12,690	$	13,656	$	22,013
Total long-term debt maturities	2,160,730		2,642,115		2,685,333		2,771,410
Total debt	$	2,385,896	$	2,654,805	$	2,698,989	$	2,793,423

(1) Includes unamortized premium of ~~$1.2~~$1.0 million and ~~$1.1~~$0.9 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively. Includes unamortized debt issuance costs of ~~$10.4~~$8.5 million and ~~$8.9~~$8.0 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively.

(2) Includes unamortized discounts of ~~$2.8~~$12.0 million and ~~$12.9~~$14.0 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively. Includes unamortized debt issuance costs of ~~$7.4~~$13.6 million and ~~$14.8~~$13.9 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively.

(3) Includes unamortized discounts of ~~$2.9~~$2.8 million and $2.6 million at ~~both~~ December 31, ~~2015~~2016 and ~~September 30, 2016.~~March 31, 2017, respectively. Includes unamortized debt issuance costs of ~~$20.2~~$13.1 million and ~~$13.7~~$12.5 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively.

Maturities of Long-Term Debt and Notes Payable

Maturities of the Company’s long-term debt and notes payable for the period ~~from October~~April 1, ~~2016~~2017 through December 31, ~~2016~~2017 and for the years after ~~2016~~2017 are approximately as follows:

Select

Concentra

Total

(in thousands)

October 1, 2016 — December 31, 2016

$
4,236

$
2,160

$
6,396

2017

16,731

7,890

24,621

2018

706,426

6,617

713,043

2019

18,084

6,636

24,720

2020

6,303

6,656

12,959

2021 and beyond

1,305,337

619,873

1,925,210

Total principal

2,057,117

649,832

2,706,949

Unamortized discounts and premiums

(11,811
)
(2,905
)
(14,716
)
Unamortized debt issuance costs

(23,725
)
(13,703
)
(37,428
)
Total

$
2,021,581

$
633,224

$
2,654,805

	Select			Concentra			Total
	(in thousands)
April 1, 2017 — December 31, 2017	$	18,072		$	343		$	18,415
2018	14,976			128			15,104
2019	23,327			144			23,471
2020	11,568			3,177			14,745
2021	721,514			6,680			728,194
2022 and beyond	1,430,385			613,198			2,043,583
Total principal	2,219,842			623,670			2,843,512
Unamortized discounts and premiums	(13,051		)	(2,641		)	(15,692		)
Unamortized debt issuance costs	(21,931		)	(12,466		)	(34,397		)
Total	$	2,184,860		$	608,563		$	2,793,423

~~Excess Cash Flow Payment~~Select Credit Facilities

On March ~~2, 2016,~~6, 2017, Select ~~made~~entered into a ~~principal prepayment of $10.2 million associated with its~~new senior secured credit agreement (the “Select credit agreement”) that provides for $1.6 billion in senior secured credit facilities comprising a $1.15 billion, seven-year term ~~loans~~loan (the “Select term ~~loans”~~loan”) ~~in accordance~~and a $450.0 million, five-year revolving credit facility (the “Select revolving facility” and together with the ~~provision in~~Select term loan, the “Select credit facilities”), including a $75.0 million sublimit for the issuance of standby letters of credit.

Select used borrowings under the Select credit facilities ~~that requires mandatory prepayments of~~to: (i) refinance in full the series E tranche B term loans ~~as a result of annual excess cash flow as defined~~due June 1, 2018, the series F tranche B term loans due March 31, 2021, and the revolving facility maturing March 1, 2018 under its then existing credit facilities; and (ii) pay fees and expenses in connection with the refinancing.

Borrowings under the Select credit ~~facilities.~~

~~Select Credit Facilities~~

On March 4, 2016, Select entered into an Additional Credit Extension Amendment (the “Additional Credit Extension Amendment”) to Select’s senior secured credit facility with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent and lender, and the additional lenders named therein (the “Select credit facilities”). The Additional Credit Extension Amendment (i) provided for the lenders named therein to make available an aggregate of $625.0 million of Series F Tranche B Term Loans, (ii) extended the financial covenants through March 3, 2021, (iii) added a 1.00% prepayment premium for prepayments made with new term loans on or prior to March 4, 2017 if such new term loans have a lower yield than the Series F Tranche B Term Loans, and (iv) made certain other technical amendments to the Select credit facilities. The Series F Tranche B Term Loansfacilities bear interest at a rate ~~per annum~~ equal toto: (i) in the case of the Select term loan, Adjusted LIBO ~~Rate~~ (as defined in the Select credit facilities, subject to an Adjusted LIBO Rate floor of 1.00%) plus 5.00% for Eurodollar Loans or the Alternate Base Rate (as defined in the Select credit facilities) plus 4.00% for Alternate Base Rate Loans (as defined in the Select credit facilities). Select is required to make principal payments on the Series F Tranche B Term Loans in quarterly installments on the last day of each of March, June, September and December, beginning June 30, 2016, in amounts equal to 0.25% of the aggregate principal amount of the Series F Tranche B Term Loans outstanding as of the date of the Additional Credit Extension Amendment. The balance of the

Series F Tranche B Term Loans is payable on March 3, 2021. Except as specifically set forth in the Additional Credit Extension Amendment, the terms and conditions of the Series F Tranche B Term Loans are identical to the terms of the outstanding Series E Term B Loans under the Select credit facilities and the other loan documents to which Select is party.

Select used the proceeds of the Series F Tranche B Term Loans to (i) refinance in full the Series D Tranche B Term Loans due December 20, 2016, (ii) consummate the acquisition of Physiotherapy, and (iii) pay fees and expenses incurred in connection with the acquisition of Physiotherapy, the refinancing, and the Additional Credit Extension Amendment.

As a result of the Additional Credit Extension Amendment relating to the Series F Tranche B Term Loans, the interest rate payable on the Series E Tranche B Term Loans was increased from Adjusted LIBO plus 4.00% (subject to an Adjusted LIBO rate floor of 1.00%), or Alternative Base Rate plus 3.00%, to Adjusted LIBO plus 5.00% (subject to an Adjusted LIBO rate floor of 1.00%), or Alternative Base Rate plus 4.00%.

During the nine months ended September 30, 2016, the Company recognized a loss on early retirement of debt of $0.8 million relating to the repayment of the Series D Tranche B Term Loans under the Select credit facilities.

~~Concentra Credit Facilities~~

On September 26, 2016, Concentra entered into Amendment No. 1 (the “Concentra Credit Agreement Amendment”) to its first lien credit agreement (the “Concentra first lien credit agreement”) dated June 1, 2015. The Concentra first lien credit agreement initially provided for $500.0 million in first lien credit facilities composed of $450.0 million, seven-year term loans (“Concentra first lien term loan”) and a $50.0 million, five-year revolving credit facility (“Concentra revolving facility”).

The Concentra Credit Agreement Amendment provided an additional $200.0 million of first lien term loans due June 1, 2022, the proceeds of which were used to prepay in full Concentra’s second lien term loan due June 1, 2023; and also amended certain restrictive covenants to give Concentra greater operational flexibility.

~~The Concentra first lien term loan continues to bear interest at a rate equal to Adjusted LIBO (as defined in the Concentra first lien credit~~ agreement) plus ~~3.00%~~3.50% (subject to an Adjusted LIBO floor of 1.00%), or Alternate Base Rate (as defined in the ~~Concentra first lien~~Select credit agreement) plus ~~2.00%~~2.50% (subject to an Alternate Base Rate floor of 2.00%). ; and (ii) in the case of the Select revolving facility, Adjusted LIBO plus a percentage ranging from 3.00% to 3.25% or Alternate Base Rate plus a percentage ranging from 2.00% to 2.25%, in each case based on Select’s leverage ratio.

The ~~Concentra first lien~~Select term loan amortizes in equal quarterly installments in amounts equal to 0.25% of ~~$1.6 million through~~the aggregate original principal amount of the Select term loan commencing on June 30, 2017. The balance of the Select term loan will be payable on March ~~31, 2022, with~~8, 2024; however, if the ~~remaining unamortized aggregate principal~~Select 6.375% senior notes, which are due June 1, 2021, are outstanding on March 1, 2021, the maturity ~~date.~~date for the Select term loan will become March 1, 2021. The Select revolving facility will be payable on March 8, 2022; however, if the Select 6.375% senior notes are outstanding on February 1, 2021, the maturity date for the Select revolving facility will become February 1, 2021.

Select will be required to prepay borrowings under the Select credit facilities with (i) 100% of the net cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and, to the extent required, the payment of certain indebtedness secured by liens having priority over the debt under the Select credit facilities or subject to a first lien intercreditor agreement, (ii) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (ii) 50% of excess cash flow (as defined in the Select credit agreement) if Select’s leverage ratio is greater than 4.50 to 1.00 and 25% of excess cash flow if Select’s leverage ratio is less than or equal to 4.50 to 1.00 and greater than 4.00 to 1.00, in each case, reduced by the aggregate amount of term loans, revolving loans and certain other debt optionally prepaid during the applicable fiscal year. Select will not be required to prepay borrowings with excess cash flow if Select’s leverage ratio is less than or equal to 4.00 to 1.00.

The ~~reacquisition price~~Select revolving facility requires Select to maintain a leverage ratio (as defined in the Select credit agreement), which is tested quarterly, not to exceed 6.25 to 1.00. After March 31, 2019, the leverage ratio must not exceed 6.00 to 1.00. Failure to comply with this covenant would result in an event of default under the Select revolving facility and, absent a waiver or an amendment from the revolving lenders, preclude Select from making further borrowings under the Select revolving facility and permit the revolving lenders to accelerate all outstanding borrowings under the Select revolving facility. The termination of the ~~second lien~~Select revolving facility commitments and the acceleration of amounts outstanding thereunder would constitute an event of default with respect to the Select term loan. As of March 31, 2017, Select’s leverage ratio was 6.01 to 1.00.

The Select credit facilities also contain a number of other affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The Select credit facilities contain events of default for non-payment of principal and interest when due (subject, as to interest, to a grace period), cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

Borrowings under the Select credit facilities are guaranteed by Holdings and substantially all of Select’s current domestic subsidiaries and will be guaranteed by substantially all of Select’s future domestic subsidiaries and secured by substantially all of Select’s existing and future property and assets and by a pledge of Select’s capital stock, the capital stock of Select’s domestic subsidiaries and up to 65% of the capital stock of Select’s foreign subsidiaries held directly by Select or a domestic subsidiary.

Loss on Early Retirement of Debt

During the three months ended March 31, 2017, the Company refinanced its senior secured credit facilities, which consisted of the series E tranche B term loans ~~was $202.0 million. The premium plus~~due June 1, 2018, the ~~expensing of unamortized deferred financing costs~~series F tranche B term loans due March 31, 2021, and ~~original issuance discount~~the revolving facility maturing March 1, 2018, which resulted in ~~a loss~~losses on early retirement of debt of ~~$10.9~~$19.7 million.

Excess Cash Flow Payment

On March 1, 2017, Concentra made a principal prepayment of $23.1 million ~~during~~associated with the ~~three months ended September 30, 2016.~~Concentra first lien term loans in accordance with the provision in the Concentra credit facilities that requires mandatory prepayments of term loans as a result of annual excess cash flow.

8.6. Fair Value

Financial instruments include cash and cash equivalents, notes payable, and long-term debt. The carrying amount of cash and cash equivalents approximates fair value because of the short-term maturity of these instruments.

December 31, 2015

September 30, 2016

Face
Value

Carrying
Value

Fair
Value

Face
Value

Carrying
Value

Fair
Value

(in thousands)

Select 6.375% senior notes(1)

$
710,000

$
700,867

$
623,948

$
710,000

$
702,124

$
698,853

Select credit facilities(2)

1,048,277

1,038,071

1,023,616

1,324,315

1,296,655

1,318,943

Concentra credit facilities(3)

652,750

629,659

645,392

643,870

627,262

642,260

The face values, carrying values, and fair values of the Company’s 6.375% senior notes and credit facilities are as follows:

	December 31, 2016						March 31, 2017
	Face Value		Carrying Value		Fair Value		Face Value		Carrying Value		Fair Value
	(in thousands)
Select 6.375% senior notes(1)	$	710,000	$	702,545	$	710,000	$	710,000	$	702,966	$	715,325
Select credit facilities(2)	1,367,751		1,342,203		1,370,460		1,485,000		1,457,052		1,474,013
Concentra credit facilities(3)	642,239		626,375		644,648		619,175		604,068		622,271

(1) The carrying value includes an unamortized premium of ~~$1.2~~$1.0 million and ~~$1.1~~$0.9 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively, and unamortized debt issuance costs of ~~$10.4~~$8.5 million and ~~$8.9~~$8.0 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively.

(2) The carrying value includes unamortized discounts of ~~$2.8~~$12.0 million and ~~$12.9~~$14.0 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively, and unamortized debt issuance costs of ~~$7.4~~$13.6 million and ~~$14.8~~$13.9 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively.

(3) The carrying value includes unamortized discounts of ~~$2.9~~$2.8 million and $2.6 million at ~~both~~ December 31, ~~2015~~2016 and ~~September 30, 2016~~March 31, 2017, respectively, and unamortized debt issuance costs of ~~$20.2~~$13.1 million and ~~$13.7~~$12.5 million at December 31, ~~2015~~2016 and ~~September 30, 2016,~~March 31, 2017, respectively.

The fair ~~value~~values of the Select credit facilities and the Concentra credit facilities ~~was~~were based on quoted market prices for this debt in the syndicated loan market. The fair value of Select’s 6.375% senior notes debt was based on quoted market prices.

The Company considers the inputs in the valuation process to be Level 2 in the fair value hierarchy. Level 2 in the fair value hierarchy is defined as inputs that are observable for the asset or liability, either directly or indirectly, which includes quoted prices for identical assets or liabilities in markets that are not active.

9. 7.Segment Information

The Company’s reportable segments consist of: ~~(i)~~ specialty hospitals, ~~(ii)~~ outpatient rehabilitation, and ~~(iii)~~ Concentra. Other activities include the Company’s corporate shared services and certain other non-consolidating joint ventures and minority investments in other healthcare related businesses. The accounting policies of the segments are the same as those described in the ~~summary of significant accounting policies.~~Annual Report on Form 10-K for the year ended December 31, 2016. The Company evaluates performance of the segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, ~~Concentra acquisition costs,~~ Physiotherapy acquisition costs, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries.

The following tables summarize selected financial data for the Company’s reportable segments. The segment results of Holdings are identical to those of Select.

Three Months Ended September 30, 2015

Specialty
Hospitals

Outpatient
Rehabilitation

Concentra

Other

Total

(in thousands)

Net operating revenues

$
562,328

$
199,593

$
258,969

$
233

$
1,021,123

Adjusted EBITDA

53,656

23,807

25,584

(18,536
)
84,511

Total assets

2,333,049

541,435

1,332,975

106,946

4,314,405

Capital expenditures

27,494

4,023

9,640

3,923

45,080

Three Months Ended September 30, 2016

Specialty
Hospitals

Outpatient
Rehabilitation(1)

Concentra

Other

Total

(in thousands)

Net operating revenues

$
544,491

$
250,710

$
258,507

$
87

$
1,053,795

Adjusted EBITDA

48,264

31,995

40,888

(23,070
)
98,077

Total assets

2,461,751

977,431

1,327,438

78,785

4,845,405

Capital expenditures

24,378

6,234

2,720

4,670

38,002

Nine Months Ended September 30, 2015

Specialty
Hospitals

Outpatient
Rehabilitation

Concentra(2)

Other

Total

(in thousands)

Net operating revenues

$
1,753,445

$
603,831

$
345,798

$
457

$
2,703,531

Adjusted EBITDA

241,575

74,662

36,783

(54,672
)
298,348

Total assets

2,333,049

541,435

1,332,975

106,946

4,314,405

Capital expenditures

81,329

11,048

13,494

8,121

113,992

Nine Months Ended September 30, 2016

Specialty
Hospitals

Outpatient
Rehabilitation(1)

Concentra

Other

Total

(in thousands)

Net operating revenues

$
1,729,261

$
745,720

$
764,252

$
523

$
3,239,756

Adjusted EBITDA

217,759

99,006

118,080

(66,696
)
368,149

Total assets

2,461,751

977,431

1,327,438

78,785

4,845,405

Capital expenditures

79,366

15,032

10,647

13,215

118,260

	Three Months Ended March 31, 2016
	Specialty Hospitals		Outpatient Rehabilitation(1)		Concentra		Other			Total
	(in thousands)
Net revenue	$	598,954	$	238,082	$	250,877	$	417		$	1,088,330
Adjusted EBITDA	86,756		28,879		34,153		(21,173		)	128,615
Total assets(2)	2,434,405		974,264		1,310,317		103,878			4,822,864
Capital expenditures	33,675		4,974		3,210		4,909			46,768

	Three Months Ended March 31, 2017
	Specialty Hospitals		Outpatient Rehabilitation		Concentra		Other			Total
	(in thousands)
Net revenue	$	598,787	$	255,817	$	256,149	$	608		$	1,111,361
Adjusted EBITDA	88,665		31,351		42,592		(23,718		)	138,890
Total assets	2,622,220		980,261		1,297,672		102,784			5,002,937
Capital expenditures	32,357		6,673		8,686		2,937			50,653

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended September 30, 2015															Three Months Ended March 31, 2016
	Specialty Hospitals			Outpatient Rehabilitation			Concentra			Other			Total			Specialty Hospitals			Outpatient Rehabilitation(1)			Concentra			Other			Total
	(in thousands)															(in thousands)
Adjusted EBITDA	$	53,656		$	23,807		$	25,584		$	(18,536	)				$	86,756		$	28,879		$	34,153		$	(21,173	)
Depreciation and amortization	(13,782		)	(3,247		)	(13,316		)	(1,127		)				(13,893		)	(4,036		)	(15,376		)	(1,212		)
Stock compensation expense	—			—			(811		)	(4,014		)				—			—			(192		)	(3,784		)
Physiotherapy acquisition costs																—			—			—			(3,236		)
Income (loss) from operations	$	39,874		$	20,560		$	11,457		$	(23,677	)	$	48,214		$	72,863		$	24,843		$	18,585		$	(29,405	)	$	86,886
Loss on early retirement of debt																												(773		)
Equity in earnings of unconsolidated subsidiaries																												4,652
Non-operating gain													29,647															25,087
Equity in earnings of unconsolidated subsidiaries													6,348
Interest expense													(33,052		)													(38,848		)
Income before income taxes													$	51,157														$	77,004

	Three Months Ended September 30, 2016
	Specialty Hospitals			Outpatient Rehabilitation (1)			Concentra			Other			Total
	(in thousands)
Adjusted EBITDA	$	48,264		$	31,995		$	40,888		$	(23,070	)
Depreciation and amortization	(14,317		)	(6,159		)	(15,278		)	(1,411		)
Stock compensation expense	—			—			(193		)	(4,557		)
Income (loss) from operations	$	33,947		$	25,836		$	25,417		$	(29,038	)	$	56,162
Non-operating loss													(1,028		)
Loss on early retirement of debt													(10,853		)
Equity in earnings of unconsolidated subsidiaries													5,268
Interest expense													(44,482		)
Income before income taxes													$	5,067

	Nine Months Ended September 30, 2015
	Specialty Hospitals			Outpatient Rehabilitation			Concentra(2)			Other			Total
	(in thousands)
Adjusted EBITDA	$	241,575		$	74,662		$	36,783		$	(54,672	)
Depreciation and amortization	(40,409		)	(9,564		)	(17,510		)	(3,185		)
Stock compensation expense	—			—			(811		)	(9,664		)
Concentra acquisition costs	—			—			(4,715		)	—
Income (loss) from operations	$	201,166		$	65,098		$	13,747		$	(67,521	)	$	212,490
Non-operating gain													29,647
Equity in earnings of unconsolidated subsidiaries													12,788
Interest expense													(79,728		)
Income before income taxes													$	175,197

	Nine Months Ended September 30, 2016															Three Months Ended March 31, 2017
	Specialty Hospitals			Outpatient Rehabilitation(1)			Concentra			Other			Total			Specialty Hospitals			Outpatient Rehabilitation			Concentra			Other			Total
	(in thousands)															(in thousands)
Adjusted EBITDA	$	217,759		$	99,006		$	118,080		$	(66,696	)				$	88,665		$	31,351		$	42,592		$	(23,718	)
Depreciation and amortization	(42,022		)	(16,397		)	(45,570		)	(3,898		)				(18,500		)	(6,340		)	(16,123		)	(1,576		)
Stock compensation expense	—			—			(577		)	(12,347		)				—			—			(306		)	(4,280		)
Physiotherapy acquisition costs	—			—			—			(3,236		)
Income (loss) from operations	$	175,737		$	82,609		$	71,933		$	(86,177	)	$	244,102		$	70,165		$	25,011		$	26,163		$	(29,574	)	$	91,765
Non-operating gain													37,094
Loss on early retirement of debt													(11,626		)													(19,719		)
Equity in earnings of unconsolidated subsidiaries													14,466															5,521
Non-operating loss																												(49		)
Interest expense													(127,662		)													(40,853		)
Income before income taxes													$	156,374														$	36,665

(1) The outpatient rehabilitation segment includes the operating results of the Company’s contract therapy businesses through March 31, 2016 and Physiotherapy beginning March 4, 2016. Total assets presented under outpatient rehabilitation at March 31, 2016 reflect the disposition of assets sold as a result of the sale of our contract therapy businesses.

(2) ~~The selected financial data for~~Reflects the ~~Company’s Concentra segment for the periods presented begins~~retrospective adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Total assets as of ~~June 1, 2015, which is~~March 31, 2016 were retrospectively conformed to reflect the ~~date~~adoption of the ~~Concentra acquisition was consummated.~~standard, resulting in a reduction to total assets of $25.1 million.

~~10.~~8. Income per Common Share

Holdings applies the two-class method for calculating and presenting income per common share. The two-class method is an earnings allocation formula that determines earnings per share for each class of stock participation rights in undistributed earnings.

The following table sets forth ~~for the periods indicated~~ the calculation of income per ~~common~~ share in Holdings’ condensed consolidated statements of operations and the differences between basic weighted average shares outstanding and diluted weighted average shares outstanding used to compute basic and diluted ~~income~~earnings per ~~common~~ share, ~~respectively:~~respectively.

For the Three Months Ended
September 30,

For the Nine Months Ended
September 30,

2015

2016

2015

2016

(in thousands, except per share amounts)

Numerator:

Net income attributable to Select Medical Holdings Corporation

$
29,406

$
6,471

$
101,409

$
95,239

Less: Earnings allocated to unvested restricted stockholders

923

209

2,925

2,852

Net income available to common stockholders

$
28,483

$
6,262

$
98,484

$
92,387

Denominator:

Weighted average shares — basic

127,386

127,848

127,541

127,659

Effect of dilutive securities:

Stock options

263

141

303

145

Weighted average shares — diluted

127,649

127,989

127,844

127,804

Basic income per common share

$
0.22

$
0.05

$
0.77

$
0.72

Diluted income per common share

$
0.22

$
0.05

$
0.77

$
0.72

	Three Months Ended March 31,
	2016		2017
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	54,833	$	15,870
Less: Earnings allocated to unvested restricted stockholders	1,582		507
Net income available to common stockholders	$	53,251	$	15,363
Denominator:
Weighted average shares—basic	127,500		128,464
Effect of dilutive securities:
Stock options	81		164
Weighted average shares—diluted	127,581		128,628

Basic income per common share:	$	0.42	$	0.12
Diluted income per common share:	$	0.42	$	0.12

~~11.~~ 9.Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance, subject to self-insured retention of $2.0 million per medical incident for professional liability claims and $2.0 million per occurrence for general liability claims. The Company also maintains umbrella liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the Company’s other insurance policies. These insurance policies also do not generally cover punitive damages and are subject to various deductibles and policy limits. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities. In the Company’s opinion, the outcome of these actions, individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations or cash flows.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

Evansville Litigation.

On October 19, 2015, the plaintiff-relators filed a Second Amended Complaint in United States of America, ex rel. Tracy Conroy, Pamela Schenk and Lisa Wilson v. Select Medical Corporation, Select Specialty Hospital—Evansville, LLC ~~(‘‘SSH-Evansville’’~~(“SSH-Evansville”), Select Employment Services, Inc., and Dr. Richard Sloan. The case is a civil action filed in the United States District Court for the Southern District of Indiana by private plaintiff-relators on behalf of the United States under the federal False Claims Act. The plaintiff-relators are the former CEO and two former case managers at SSH-Evansville, and the defendants currently include the Company, SSH-Evansville, a subsidiary of the Company serving as common paymaster for its employees, and a physician who practices at SSH-Evansville. The plaintiff-relators allege that ~~from 2006 until April 2012,~~ SSH-Evansville discharged patients too early or held patients too long, improperly discharged patients to and readmitted them from short stay hospitals, up-coded diagnoses at admission, and admitted patients for whom long-term acute care was not medically necessary. They also allege that the defendants engaged in retaliation in violation of federal and state law. The Second Amended Complaint replaces a prior complaint that was filed under seal on September 28, 2012 and served on the Company on February 15, 2013, after a federal magistrate judge unsealed it on January 8, 2013. All deadlines in the case had been stayed after the seal was lifted in order to allow the government time to complete its investigation and to decide whether or not to intervene. On June 19, 2015, the ~~U.S.~~United States Department of Justice notified the District Court of its decision not to intervene in the ~~case, and the District Court thereafter approved a case management plan imposing certain deadlines.~~case.

In December 2015, the defendants filed a Motion to Dismiss the Second Amended Complaint on multiple ~~grounds. One basis for~~grounds, including that the ~~Motion to Dismiss was~~action is disallowed by the False Claims Act’s public disclosure bar, which disqualifies qui tam actions that are based on fraud already publicly disclosed through enumerated sources, unless the relator is an original source. The Affordable Care Act, enacted on March 23, 2010, altered the public disclosure bar language of the False Claims Act by, among other things, giving the United States the right to oppose dismissal of a case based on the public disclosure bar. In their Motion to Dismiss, the defendants contended that the public disclosure bar applies because substantially the same conduct as the plaintiff-relators have alleged had previously been publicly disclosed, including in a New York Times articlesource, and ~~a prior qui tam case. A second basis for the defendants’ Motion to Dismiss was~~ that the plaintiff-relators did not plead their claims with sufficient particularity, as required by the Federal Rules of Civil Procedure.

~~Then, based on the Affordable Care Act’s changes to the public disclosure bar language of the False Claims Act,~~Thereafter, the United States filed a notice asserting a veto of the defendants’ use of the public disclosure bar for claims arising from conduct from and after March 23, ~~2010. The defendants filed briefs challenging the United States’ contention that the~~2010, which was based on certain statutory changes ~~gives it an unfettered right~~ to ~~veto the applicability of~~ the public disclosure ~~bar.~~bar language included in the Affordable Care Act. On September 30, 2016, the District Court partially granted and partially denied the defendants’ Motion to Dismiss. It ruled that the plaintiff-relators alleged substantially the same conduct as had been publicly disclosed and that the plaintiff relators are not original sources, so that the public disclosure bar requires dismissal of all non-retaliation claims arising from conduct before March 23, 2010. The District Court also ruled that the statutory changes to the public disclosure bar gave the United States the power to veto its applicability to claims arising from conduct on and after March 23, 2010, and therefore did not dismiss those claims based on the public disclosure bar. However,

the District Court ruled that the plaintiff-relators did not

plead certain of their claims relating to interrupted stay manipulation and premature discharging of patients with the requisite particularity, and dismissed those claims. The District Court declined to dismiss the ~~plaintiff-relators’~~plaintiff relators’ claims arising from conduct from and after March 23, 2010 relating to delayed discharging of patients and ~~upcoding~~up-coding and the ~~plaintiff-relators’~~plaintiff relators’ retaliation claims.

~~On October 17, 2016,~~ The plaintiff-relators then proposed a case management plan seeking nationwide discovery involving all of the Company’s LTCHs for the period from March 23, 2010 through the present, which the defendants filed a Motion seeking certification to file an interlocutory appeal with the United States Court of Appeals for the Seventh Circuit of the District Court’s ruling that the United States’ has the power to veto the application of the public disclosure bar to the defendants’ conduct from and after March 23, 2010.have opposed. The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Knoxville Litigation.

On July 13, 2015, the ~~federal~~United States District Court for the Eastern District of Tennessee unsealed a qui tam Complaint in Armes v. Garman, et al, No. 3:14-cv-00172-TAV-CCS, which named as defendants Select, Select Specialty Hospital—Knoxville, Inc. ~~(‘‘SSH-Knoxville’’~~(“SSH-Knoxville”), Select Specialty Hospital—North Knoxville, Inc. and ten current or former employees of these facilities. The Complaint was unsealed after the United States and the State of Tennessee notified the court on July 13, 2015 that each had decided not to intervene in the case. The Complaint is a civil action that was filed under seal on April 29, 2014 by a respiratory therapist formerly employed at SSH-Knoxville. The Complaint alleges violations of the federal False Claims Act and the Tennessee Medicaid False Claims Act based on extending patient stays to increase reimbursement and to increase average length of stay; artificially prolonging the lives of patients to increase Medicare reimbursements and decrease inspections; admitting patients who do not require medically necessary care; performing unnecessary procedures and services; and delaying performance of procedures to increase billing. The Complaint was served on some of the defendants during October 2015.

In November 2015, the defendants filed a Motion to Dismiss the Complaint on multiple grounds. The defendants first argued that False Claims Act’s first-to-file bar required dismissal of plaintiff-relator’s claims. Under the first-to-file bar, if a qui tam case is pending, no person may bring a related action based on the facts underlying the first action. The defendants asserted that the plaintiff-relator’s claims were based on the same underlying facts as were asserted in the Evansville litigation, discussed above. The defendants also argued that the plaintiff-relator’s claims must be dismissed under the public disclosure bar, and because the plaintiff-relator did not plead his claims with sufficient particularity.

In June 2016, the District Court granted the defendants’ Motion to Dismiss and dismissed the plaintiff-relator’s lawsuit in its entirety. The District Court ruled that the first-to-file bar precludes all but one of the plaintiff-relator’s claims, and that the remaining claim must also be dismissed because the plaintiff-relator failed to plead it with sufficient particularity. In July 2016, the plaintiff-relator filed a Notice of Appeal to the United States Court of Appeals for the Sixth Circuit. Then, on October 11, 2016, the plaintiff-relator filed a Motion to Remand the case to the District Court for further proceedings, arguing that the September 30, 2016 decision in the Evansville litigation, discussed above, undermines the basis for the District Court’s dismissal. After the Court of Appeals denied the Motion to Remand, the plaintiff-relator then sought an indicative ruling from the District Court that it would vacate its prior dismissal ruling and allow plaintiff-relator to supplement his Complaint, which the defendants have opposed. The Company intends to vigorously defend this action, but at this time the Company is unable to predict the timing and outcome of this matter.

Wilmington Litigation

On January 19, 2017, the United States District Court for the District of Delaware unsealed a qui tam Complaint in United States of America and State of Delaware ex rel. Theresa Kelly v. Select Specialty Hospital—Wilmington, Inc. (“SSH-Wilmington”), Select Specialty Hospitals, Inc., Select Employment Services, Inc., Select Medical Corporation, and Crystal Cheek, No. 16-347-LPS. The Complaint was initially filed under seal on May 12, 2016 by a former chief nursing officer at SSH-Wilmington and was unsealed after the United States filed a Notice of Election to Decline Intervention on January 13, 2017. The corporate defendants were served on March 6, 2017. In the complaint, the plaintiff-relator alleges that the Select defendants and an individual defendant, who is a former health information manager at SSH-Wilmington, violated the False Claims Act and the Delaware False Claims and Reporting Act based on allegedly falsifying medical practitioner signatures on medical records and failing to properly examine the credentials of medical practitioners at SSH-Wilmington. The Company intends to vigorously defend this action if the plaintiff-relator pursues it, but at this time the Company is unable to predict the timing and outcome of this matter.

Construction Commitments

At ~~September 30, 2016,~~March 31, 2017, the Company had outstanding commitments under construction contracts related to new construction, improvements, and renovations ~~at the Company’s long term acute care properties, inpatient rehabilitation facilities, and Concentra centers~~ totaling approximately ~~$16.2~~$69.9 million.

~~12.~~10. Financial Information for Subsidiary Guarantors and Non-Guarantor Subsidiaries under Select’s 6.375% Senior Notes

Select’s 6.375% senior notes are fully and unconditionally guaranteed, except for customary limitations, on a senior basis by all of Select’s wholly owned subsidiaries (the ~~‘‘Subsidiary Guarantors’’~~“Subsidiary Guarantors”) which is defined as a subsidiary where Select or a subsidiary of Select holds all of the outstanding ownership interests. Certain of Select’s subsidiaries did not guarantee the 6.375% senior notes (the ~~‘‘Non-Guarantor Subsidiaries,’’ including~~“Non-Guarantor Subsidiaries” and Concentra Group Holdings and its subsidiaries, ~~which were designated as Non-Guarantor subsidiaries by Select’s board of directors at~~ the ~~closing of the Concentra acquisition, the ‘‘Non-Guarantor Concentra’’~~“Non-Guarantor Concentra”).

Select conducts a significant portion of its business through its subsidiaries. Presented below is condensed consolidating financial information for Select, the Subsidiary Guarantors, the Non-Guarantor Subsidiaries, and Non-Guarantor Concentra at December 31, ~~2015~~2016 and ~~September 30, 2016~~March 31, 2017 and for the three ~~and nine~~ months ended ~~September 30, 2015~~March 31, 2016 and ~~2016.~~March 31, 2017.

The equity method has been used by Select with respect to investments in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in Non-Guarantor Subsidiaries. Separate financial statements for Subsidiary Guarantors are not presented.

Certain reclassifications have been made to prior reported amounts in order to conform to the current year guarantor structure.

Select Medical Corporation

Condensed Consolidating Balance Sheet

~~September 30, 2016~~March 31, 2017

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation		Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation
	(in thousands)															(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	71		$	4,692	$	4,140		$	59,320	$	—		$	68,223	$	72		$	6,836	$	3,405		$	54,898	$	—		$	65,211
Accounts receivable, net	—			385,135		91,629			120,516		(4,569		)(e)	592,711		—			442,132		125,079			124,309		—			691,520
Current deferred tax asset	13,208			23,273		4,023			10,143		—			50,647
Intercompany receivables	—			2,177,863		175,638			—		(2,353,501		)(a)	—		—			2,183,527		169,816			—		(2,353,343		) (a)	—
Prepaid income taxes	5,076			—		—			6,398		—			11,474		2,402			—		—			—		—			2,402
Other current assets	11,674			34,134		11,784			25,088		—			82,680		17,714			34,693		11,878			20,796		—			85,081
Total Current Assets	30,029			2,625,097		287,214			221,465		(2,358,070		)	805,735		20,188			2,667,188		310,178			200,003		(2,353,343		)	844,214

Property and equipment, net	45,241			580,519		45,701			192,024		—			863,485		49,309			609,822		54,118			183,897		—			897,146
Investment in affiliates	4,587,985			90,815		—			—		(4,678,800		)(b) (c)	—		4,513,416			100,095		—			—		(4,613,511		) (b) (c)	—
Goodwill	—			2,015,033		—			659,590		—			2,674,623		—			2,091,100		—			668,664		—			2,759,764
Other identifiable intangibles, net	—			103,511		—			234,709		—			338,220
Non-current deferred tax asset	15,215			—		—			—		(15,215		)(d)	—
Identifiable intangible assets, net																—			108,545		—			228,531		—			337,076
Other assets	7,723			81,266		54,703			19,650		—			163,342		50,355			86,384		38,882			16,577		(27,461		) (d)	164,737

Total Assets	$	4,686,193		$	5,496,241	$	387,618		$	1,327,438	$	(7,052,085	)	$	4,845,405	$	4,633,268		$	5,663,134	$	403,178		$	1,297,672	$	(6,994,315	)	$	5,002,937

Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	20,151		$	—	$	—		$	—	$	—		$	20,151	$	22,299		$	—	$	—		$	—	$	—		$	22,299
Current portion of long-term debt and notes payable	4,836			469		1,963			5,422		—			12,690		20,506			502		633			372					22,013
Accounts payable	10,206			72,890		17,329			13,756		—			114,181		13,349			78,195		17,429			16,145		—			125,118
Intercompany payables	2,177,863			175,638		—			—		(2,353,501		)(a)	—		2,183,527			169,816		—			—		(2,353,343		) (a)	—
Accrued payroll	13,877			75,189		11,502			37,522		—			138,090		4,268			76,290		2,488			27,150		—			110,196
Accrued vacation	3,286			46,583		15,809			13,098		—			78,776		3,740			57,763		11,968			15,265		—			88,736
Accrued interest	31,387			4		4			1,569		—			32,964		19,390			—		4			2,164		—			21,558
Accrued other	44,347			55,704		9,671			32,709		—			142,431		38,937			62,607		9,780			31,856		—			143,180
Due to third party payors	—			15,634		—			—		(4,569		)(e)	11,065
Income taxes payable																—			—		—			5,399		—			5,399
Total Current Liabilities	2,305,953			442,111		56,278			104,076		(2,358,070		)	550,348		2,306,016			445,173		42,302			98,351		(2,353,343		)	538,499

Long-term debt, net of current portion	2,004,106			599		9,607			627,803		—			2,642,115		1,482,768			525,263		155,188			608,191		—			2,771,410
Subordinate debt	(641,466		)	524,292		117,174			—		—			—
Non-current deferred tax liability	—			110,989		9,852			104,374		(15,215		)(d)	210,000		—			135,640		667			86,883		(27,461		) (d)	195,729
Other non-current liabilities	48,559			51,248		4,563			32,157		—			136,527		42,755			56,617		6,849			35,987		—			142,208

Total Liabilities	3,717,152			1,129,239		197,474			868,410		(2,373,285		)	3,538,990		3,831,539			1,162,693		205,006			829,412		(2,380,804		)	3,647,846

Redeemable non-controlling interests	—			—		10,639			235,790		—			246,429		—			—		9,899			452,781		—			462,680

Stockholder’s Equity:
Common stock	0			—		—			—		—			0		0			—		—			—		—			0
Capital in excess of par	921,069			—		—			—		—			921,069		931,661			—		—			—		—			931,661
Retained earnings (accumulated deficit)	47,972			1,290,294		(37,700		)	1,730		(1,254,324		)(c)	47,972		(129,932		)	1,318,340		(40,858		)	6,668		(1,284,150		) (c)	(129,932		)
Subsidiary investment	—			3,076,708		129,833			217,935		(3,424,476		)(b)	—		—			3,182,101		142,123			5,137		(3,329,361		) (b)	—
Total Select Medical Corporation Stockholder’s Equity	969,041			4,367,002		92,133			219,665		(4,678,800		)	969,041		801,729			4,500,441		101,265			11,805		(4,613,511		)	801,729

Non-controlling interest	—			—		87,372			3,573		—			90,945
Non-controlling interests																—			—		87,008			3,674		—			90,682
Total Equity	969,041			4,367,002		179,505			223,238		(4,678,800		)	1,059,986		801,729			4,500,441		188,273			15,479		(4,613,511		)	892,411

Total Liabilities and Equity	$	4,686,193		$	5,496,241	$	387,618		$	1,327,438	$	(7,052,085	)	$	4,845,405	$	4,633,268		$	5,663,134	$	403,178		$	1,297,672	$	(6,994,315	)	$	5,002,937

(a) Elimination of ~~intercompany.~~intercompany balances.

(b) Elimination of investments in consolidated subsidiaries.

~~(d) Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.~~

~~(e) Reclass of accounts receivable, net to report a net due to third party payor liability in consolidation.~~

~~Select Medical Corporation~~

~~Condensed Consolidating Statement of Operations~~

~~For the Three Months Ended September 30, 2016~~

~~(unaudited)~~

Select (Parent
Company Only)

Subsidiary
Guarantors

Non-Guarantor
Subsidiaries

Non-Guarantor
Concentra

Eliminations

Consolidated
Select Medical
Corporation

(in thousands)

Net operating revenues

$
85

$
654,966

$
140,237

$
258,507

$
—

$
1,053,795

Costs and expenses:

Cost of services

626

540,053

162,594

212,430

—

915,703

General and administrative

26,967

121

—

—

—

27,088

Bad debt expense

—

9,671

2,624

5,382

—

17,677

Depreciation and amortization

1,411

17,363

3,113

15,278

—

37,165

Total costs and expenses

29,004

567,208

168,331

233,090

—

997,633

Income (loss) from operations

(28,919
)
87,758

(28,094
)
25,417

—

56,162

Other income and expense:

Intercompany interest and royalty fees

(1,613
)
(26,871
)
28,484

—

—

—

Intercompany management fees

33,693

(25,728
)
(7,965
)
—

—

—

Loss on early retirement of debt

—

—

—

(10,853
)
—

(10,853
)
Equity in earnings of unconsolidated subsidiaries

—

5,238

30

—

—

5,268

Non-operating gain (loss)

(6,963
)
5,935

—

—

—

(1,028
)
Interest expense

(24,353
)
(8,013
)
(1,952
)
(10,164
)
—

(44,482
)

Income (loss) from operations before income taxes

(28,155
)
38,319

(9,497
)
4,400

—

5,067

Income tax expense (benefit)

5,701

(7,365
)
1,565

1,174

—

1,075

Equity in earnings of subsidiaries

40,327

(6,347
)
—

—

(33,980
)(a)
—

Net income (loss)

6,471

39,337

(11,062
)
3,226

(33,980
)
3,992

Less: Net income (loss) attributable to non-controlling interests

—

—

(4,810
)
2,331

—

(2,479
)

Net income (loss) attributable to Select Medical Corporation

$
6,471

$
39,337

$
(6,252
)
$
895

$
(33,980
)
$
6,471

~~(a) Elimination of equity in earnings of subsidiaries.~~

~~Select Medical Corporation~~

~~Condensed Consolidating Statement of Operations~~

~~For the Nine Months Ended September 30, 2016~~

~~(unaudited)~~

Select (Parent
Company Only)

Subsidiary
Guarantors

Non-Guarantor
Subsidiaries

Non-Guarantor
Concentra

Eliminations

Consolidated
Select Medical
Corporation

(in thousands)

Net operating revenues

$
522

$
2,086,884

$
388,098

$
764,252

$
—

$
3,239,756

Costs and expenses:

Cost of services

1,576

1,689,064

431,796

632,514

—

2,754,950

General and administrative

81,198

28

—

—

—

81,226

Bad debt expense

—

30,634

6,722

14,235

—

51,591

Depreciation and amortization

3,898

49,744

8,675

45,570

—

107,887

Total costs and expenses

86,672

1,769,470

447,193

692,319

—

2,995,654

Income (loss) from operations

(86,150
)
317,414

(59,095
)
71,933

—

244,102

Other income and expense:

Intercompany interest and royalty fees

(4,203
)
(76,817
)
81,020

—

—

—

Intercompany management fees

127,832

(107,532
)
(20,300
)
—

—

—

Loss on early retirement of debt

(773
)
—

—

(10,853
)
—

(11,626
)
Equity in earnings of unconsolidated subsidiaries

—

14,384

82

—

—

14,466

Non-operating gain

33,932

3,162

—

—

—

37,094

Interest expense

(70,243
)
(21,332
)
(5,442
)
(30,645
)
—

(127,662
)

Income (loss) from operations before income taxes

395

129,279

(3,735
)
30,435

—

156,374

Income tax expense

13,840

24,620

2,172

10,953

—

51,585

Equity in earnings of subsidiaries

108,684

(4,053
)
—

—

(104,631
)(a)
—

Net income (loss)

95,239

100,606

(5,907
)
19,482

(104,631
)
104,789

Less: Net income (loss) attributable to non-controlling interests

—

—

(2,082
)
11,632

—

9,550

Net income (loss) attributable to Select Medical Corporation

$
95,239

$
100,606

$
(3,825
)
$
7,850

$
(104,631
)
$
95,239

~~(a) Elimination of equity in earnings of subsidiaries.~~

~~Select Medical Corporation~~

~~Condensed Consolidating Statement of Cash Flows~~

~~For the Nine Months Ended September 30, 2016~~

~~(unaudited)~~

Select (Parent
Company Only)

Subsidiary
Guarantors

Non-Guarantor
Subsidiaries

Non-Guarantor
Concentra

Eliminations

Consolidated
Select Medical
Corporation

(in thousands)

Operating activities

Net income (loss)

$
95,239

$
100,606

$
(5,907
)
$
19,482

$
(104,631
)(a)
$
104,789

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

Distributions from unconsolidated subsidiaries

—

70

16,075

—

—

16,145

Depreciation and amortization

3,898

49,744

8,675

45,570

—

107,887

Amortization of leasehold interests

—

58

—

399

—

457

Provision for bad debts

—

30,634

6,722

14,235

—

51,591

Equity in earnings of unconsolidated subsidiaries

—

(14,384
)
(82
)
—

—

(14,466
)
Loss on early retirement of debt

773

—

—

10,853

—

11,626

Loss (gain) on disposal of assets

225

(107
)
185

(21
)
—

282

Gain on sale of assets and businesses

(33,932
)
(8,260
)
—

—

—

(42,192
)
Gain on sale of equity method investment

—

(241
)
—

—

—

(241
)
Impairment on equity investment

—

5,339

—

—

—

5,339

Stock compensation expense

12,347

—

—

577

—

12,924

Amortization of debt discount, premium and issuance costs

9,289

—

—

2,556

—

11,845

Deferred income taxes

(902
)
—

—

(12,186
)
—

(13,088
)
Changes in operating assets and liabilities, net of effects from acquisition of businesses:

Equity in earnings of subsidiaries

(108,684
)
4,053

—

—

104,631
(a)
—

Accounts receivable

—

3,772

(25,450
)
(19,098
)
—

(40,776
)
Other current assets

(1,153
)
9,685

(6,053
)
9,615

—

12,094

Other assets

(3,881
)
53,125

(54,044
)
9,489

—

4,689

Accounts payable

(239
)
(22,374
)
332

4,529

—

(17,752
)
Accrued expenses

19,692

22,231

13,606

(2,533
)
—

52,996

Due to third party payors

—

15,634

(4,569
)
—

—

11,065

Income taxes

2,716

—

—

2,317

—

5,033

Net cash provided by (used in) operating activities

(4,612
)
249,585

(50,510
)
85,784

—

280,247

Investing activities

Purchases of property and equipment

(13,315
)
(58,441
)
(35,857
)
(10,647
)
—

(118,260
)
Proceeds from sale of assets and businesses

63,418

7,964

6

—

—

71,388

Investment in businesses

—

(3,140
)
—

—

—

(3,140
)
Proceeds from sale of equity investment

—

1,241

—

—

—

1,241

Acquisition of businesses, net of cash acquired

(406,305
)
(3,523
)
—

(4,403
)
—

(414,231
)
Net cash used in investing activities

(356,202
)
(55,899
)
(35,851
)
(15,050
)
—

(463,002
)

Financing activities

Borrowings on revolving facilities

420,000

—

—

—

—

420,000

Payments on revolving facilities

(540,000
)
—

—

(5,000
)
—

(545,000
)
Net proceeds from term loans

600,127

—

—

195,217

—

795,344

Payments on term loans

(228,962
)
—

—

(205,880
)
—

(434,842
)
Borrowings of other debt

8,748

—

12,237

2,816

—

23,801

Principal payments on other debt

(10,971
)
(528
)
(1,813
)
(2,165
)
—

(15,477
)
Dividends paid to Holdings

(1,939
)
—

—

—

—

(1,939
)
Equity investment by Holdings

1,488

—

—

—

—

1,488

Intercompany

116,274

(190,878
)
74,604

—

—

—

Proceeds from issuance of non-controlling interest

—

—

11,846

—

—

11,846

Repayments of bank overdrafts

(8,464
)
—

—

—

—

(8,464
)
Tax benefit from stock based awards

514

—

—

—

—

514

Purchase of non-controlling interests

—

(1,294
)
(236
)
—

—

(1,530
)
Distributions to non-controlling interests

—

—

(6,762
)
(2,436
)
—

(9,198
)

Net cash provided by (used in) financing activities

356,815

(192,700
)
89,876

(17,448
)
—

236,543

Net increase (decrease) in cash and cash equivalents

(3,999
)
986

3,515

53,286

—

53,788

Cash and cash equivalents at beginning of period

4,070

3,706

625

6,034

14,435

Cash and cash equivalents at end of period

$
71

$
4,692

$
4,140

$
59,320

$
—

$
68,223

~~(a) Elimination of equity in earnings of consolidated subsidiaries.~~

~~Select Medical Corporation~~

~~Condensed Consolidating Balance Sheet~~

~~December 31, 2015~~

Select (Parent
Company Only)

Subsidiary
Guarantors

Non-Guarantor
Subsidiaries

Non-Guarantor
Concentra

Eliminations

Consolidated
Select Medical
Corporation

(in thousands)

Assets

Current Assets:

Cash and cash equivalents

$
4,070

$
3,706

$
625

$
6,034

$
—

$
14,435

Accounts receivable, net

—

419,554

68,332

115,672

—

603,558

Current deferred tax asset

11,556

6,733

4,761

5,638

—

28,688

Intercompany receivables

—

1,974,229

127,373

—

(2,101,602
)(a)
—

Prepaid income taxes

7,979

—

—

8,715

—

16,694

Other current assets

10,521

34,887

5,731

34,640

—

85,779

Total Current Assets

34,126

2,439,109

206,822

170,699

(2,101,602
)
749,154

Property and equipment, net

38,872

548,820

61,126

215,306

—

864,124

Investment in affiliates

4,111,682

66,015

—

—

(4,177,697
)(b) (c)
—

Goodwill

—

1,663,974

—

650,650

—

2,314,624

Other identifiable intangibles, net

—

72,776

—

245,899

—

318,675

Non-current deferred tax asset

12,297

—

—

—

(12,297
)(d)
—

Other assets

3,842

108,524

659

29,076

—

142,101

Total Assets

$
4,200,819

$
4,899,218

$
268,607

$
1,311,630

$
(6,291,596
)
$
4,388,678

Liabilities and Equity

Current Liabilities:

Bank overdrafts

$
28,615

$
—

$
—

$
—

$
—

$
28,615

Current portion of long-term debt and notes payable

221,769

197

939

2,261

—

225,166

Accounts payable

10,445

101,156

16,997

8,811

—

137,409

Intercompany payables

1,974,229

127,373

—

—

(2,101,602
)(a)
—

Accrued payroll

22,970

66,908

3,916

27,195

—

120,989

Accrued vacation

6,406

50,254

9,363

7,954

—

73,977

Accrued interest

6,315

3

—

3,083

—

9,401

Accrued other

38,883

42,939

9,866

42,040

—

133,728

Total Current Liabilities

2,309,632

388,830

41,081

91,344

(2,101,602
)
729,285

Long-term debt, net of current portion

984,744

452,417

90,860

632,709

—

2,160,730

Non-current deferred tax liability

—

114,394

9,239

107,369

(12,297
)(d)
218,705

Other non-current liabilities

47,190

41,904

4,798

39,328

—

133,220

��
Total Liabilities

3,341,566

997,545

145,978

870,750

(2,113,899
)
3,241,940

Redeemable non-controlling interests

—

870

11,224

226,127

—

238,221

Stockholder’s Equity:

Common stock

0

—

—

—

—

0

Capital in excess of par

904,375

—

—

—

—

904,375

Retained earnings (accumulated deficit)

(45,122
)
1,189,688

(8,932
)
(6,120
)
(1,174,636
)(c)
(45,122
)
Subsidiary investment

—

2,711,115

74,011

217,935

(3,003,061
)(b)
—

Total Select Medical Corporation Stockholder’s Equity

859,253

3,900,803

65,079

211,815

(4,177,697
)
859,253

Non-controlling interest

—

—

46,326

2,938

—

49,264

Total Equity

859,253

3,900,803

111,405

214,753

(4,177,697
)
908,517

Total Liabilities and Equity

$
4,200,819

$
4,899,218

$
268,607

$
1,311,630

$
(6,291,596
)
$
4,388,678

~~(a) Elimination of intercompany.~~

~~(b) Elimination of investments in consolidated subsidiaries.~~

~~(c) Elimination of investments in consolidated subsidiaries’ earnings.~~

(d) Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended ~~September 30, 2015~~March 31, 2017

(unaudited)

Select (Parent
Company Only)

Subsidiary
Guarantors

Non-Guarantor
Subsidiaries

Non-Guarantor
Concentra

Eliminations

Consolidated
Select Medical
Corporation

(in thousands)

Net operating revenues

$
233

$
644,458

$
117,463

$
258,969

$
—

$
1,021,123

Costs and expenses:

Cost of services

581

568,272

102,400

229,696

—

900,949

General and administrative

22,169

32

—

—

—

22,201

Bad debt expense

—

12,002

1,785

4,500

—

18,287

Depreciation and amortization

1,128

14,338

2,690

13,316

—

31,472

Total costs and expenses

23,878

594,644

106,875

247,512

—

972,909

Income (loss) from operations

(23,645
)
49,814

10,588

11,457

—

48,214

Other income and expense:

Intercompany interest and royalty fees

(355
)
347

8

—

—

—

Intercompany management fees

(1,967
)
7,955

(5,988
)
—

—

—

Non-operating gain

—

29,647

—

—

—

29,647

Equity in earnings of unconsolidated subsidiaries

—

6,319

29

—

—

6,348

Interest expense

(15,029
)
(6,091
)
(1,577
)
(10,355
)
—

(33,052
)

Income (loss) from operations before income taxes

(40,996
)
87,991

3,060

1,102

—

51,157

Income tax expense (benefit)

(13,708
)
32,841

(346
)
(440
)
—

18,347

Equity in earnings of subsidiaries

56,694

1,226

—

—

(57,920
)(a)
—

Net income

29,406

56,376

3,406

1,542

(57,920
)
32,810

Less: Net income attributable to non-controlling interests

—

10

2,121

1,273

—

3,404

Net income attributable to Select Medical Corporation

$
29,406

$
56,366

$
1,285

$
269

$
(57,920
)
$
29,406

~~(a) Elimination of equity in earnings of subsidiaries.~~

~~Select Medical Corporation~~

~~Condensed Consolidating Statement of Operations~~

~~For the Nine Months Ended September 30, 2015~~

~~(unaudited)~~

																			Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation			(in thousands)
	(in thousands)
Net operating revenues	$	457		$	1,994,703		$	362,573		$	345,798		$	—		$	2,703,531		$	608		$	684,902		$	169,702		$	256,149		$	—		$	1,111,361

Costs and expenses:
Cost of services	1,591			1,693,968			309,206			304,448			—			2,309,213			532			577,885			141,648			208,292			—			928,357
General and administrative	63,387			(185		)	—			4,715			—			67,917			28,036			39			—			—			—			28,075
Bad debt expense	—			30,737			7,128			5,378			—			43,243			—			11,699			3,355			5,571			—			20,625
Depreciation and amortization	3,186			42,020			7,952			17,510			—			70,668			1,575			21,221			3,620			16,123			—			42,539
Total costs and expenses	68,164			1,766,540			324,286			332,051			—			2,491,041			30,143			610,844			148,623			229,986			—			1,019,596

Income (loss) from operations	(67,707		)	228,163			38,287			13,747			—			212,490			(29,535		)	74,058			21,079			26,163			—			91,765

Other income and expense:
Intercompany interest and royalty fees	(952		)	933			19			—			—			—			(1,896		)	3,415			(1,519		)	—			—			—
Intercompany management fees	37,320			(18,911		)	(18,409		)	—			—			—			61,698			(52,421		)	(9,277		)	—			—			—
Non-operating gain	—			29,647			—			—			—			29,647
Loss on early retirement of debt																			(19,719		)	—			—			—			—			(19,719		)
Equity in earnings of unconsolidated subsidiaries	—			12,718			70			—			—			12,788			—			5,493			28			—			—			5,521
Non-operating loss																			—			(49		)	—			—			—			(49		)
Interest expense	(43,210		)	(18,177		)	(4,617		)	(13,724		)	—			(79,728		)	(22,808		)	(8,070		)	(2,476		)	(7,499		)	—			(40,853		)

Income (loss) from operations before income taxes	(74,549		)	234,373			15,350			23			—			175,197
Income (loss) before income taxes																			(12,260		)	22,426			7,835			18,664			—			36,665

Income tax expense (benefit)	(25,644		)	93,461			(1,634		)	(1,135		)	—			65,048
Income tax expense																			126			5,936			304			6,836			—			13,202
Equity in earnings of subsidiaries	150,314			9,536			—			—			(159,850		)(a)	—			28,256			6,247			—			—			(34,503		)(a)	—

Net income	101,409			150,448			16,984			1,158			(159,850		)	110,149			15,870			22,737			7,531			11,828			(34,503		)	23,463

Less: Net income attributable to non-controlling interests	—			41			7,402			1,297			—			8,740			—			—			1,069			6,524			—			7,593

Net income (loss) attributable to Select Medical Corporation	$	101,409		$	150,407		$	9,582		$	(139	)	$	(159,850	)	$	101,409
Net income attributable to Select Medical Corporation																			$	15,870		$	22,737		$	6,462		$	5,304		$	(34,503	)	$	15,870

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the ~~Nine~~Three Months Ended ~~September 30, 2015~~March 31, 2017

(unaudited)

																			Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation			(in thousands)
	(in thousands)
Operating activities
Net income	$	101,409		$	150,448		$	16,984		$	1,158		$	(159,850	)(a)	$	110,149		$	15,870		$	22,737		$	7,531		$	11,828		$	(34,503	)(a)	$	23,463
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Adjustments to reconcile net income to net cash
provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			11,737			77			—			—			11,814			—			4,893			18			—			—			4,911
Depreciation and amortization	3,186			42,020			7,952			17,510			—			70,668			1,575			21,221			3,620			16,123			—			42,539
Provision for bad debts	—			30,737			7,128			5,378			—			43,243			—			11,699			3,355			5,571			—			20,625
Equity in earnings of unconsolidated subsidiaires	—			(12,718		)	(70		)	—			—			(12,788		)
Gain on sale of assets and businesses	—			(1,257		)	(6		)	(1		)	—			(1,264		)
Gain on sale of equity investment	—			(29,647		)	—			—			—			(29,647		)
Equity in earnings of unconsolidated subsidiaries																			—			(5,493		)	(28		)	—			—			(5,521		)
Equity in earnings of consolidated subsidiaries																			(28,256		)	(6,247		)	—			—			34,503		(a)	—
Loss on early retirement of debt																			6,527			—			—			—			—			6,527
Loss (gain) on sale of assets and businesses																			—			62			(4,671		)	—			—			(4,609		)
Stock compensation expense	8,433			—			—			811			—			9,244			4,280			—			—			306			—			4,586
Amortization of debt discount, premium and issuance costs	5,500			—			—			1,246			—			6,746			2,590			—			—			832			—			3,422
Deferred income taxes	(6,925		)	—			—			—			—			(6,925		)	1,005			—			—			(4,430		)	—			(3,425		)
Changes in operating assets and liabilities, net of effects from acquisition of businesses:
Equity in earnings of subsidiaries	(150,314		)	(9,536		)	—			—			159,850		(a)	—
Changes in operating assets and liabilities, net of
effects of business combinations:
Accounts receivable	—			(35,725		)	(6,085		)	(6,968		)	—			(48,778		)	—			(92,404		)	(28,521		)	(17,188		)	—			(138,113		)
Other current assets	(2,090		)	(2,006		)	(12		)	(472		)	—			(4,580		)	(5,761		)	(1,129		)	(1,511		)	780			—			(7,621		)
Other assets	5,833			(1,546		)	253			—			—			4,540			(3,753		)	(11,531		)	15,072			164			—			(48		)
Accounts payable	(572		)	8,139			(2,011		)	(2,509		)	—			3,047			2,574			694			(5,410		)	2,554			—			412
Accrued expenses	12,541			15,433			2,713			2,029			—			32,716			(13,406		)	(3,673		)	3,940			(5,290		)	—			(18,429		)
Income taxes	18,410			—			—			(3,164		)	—			15,246			4,256			—			—			11,164			—			15,420
Net cash provided by (used in) operating activities	(4,589		)	166,079			26,923			15,018			—			203,431			(12,499		)	(59,171		)	(6,605		)	22,414			—			(55,861		)

Investing activities
Acquisition of businesses, net of cash acquired																			—			(445		)	—			(9,121		)	—			(9,566		)
Purchases of property and equipment	(8,119		)	(87,070		)	(5,309		)	(13,494		)	—			(113,992		)	(2,937		)	(29,268		)	(9,762		)	(8,686		)	—			(50,653		)
Proceeds from sale of assets	—			1,519			9			14			—			1,542
Investment in businesses	—			(826		)	(877		)	—			—			(1,703		)	—			(500		)	—			—			—			(500		)
Proceeds from sale of equity investment	—			33,096			—			—			—			33,096
Acquisition of businesses, net of cash acquired	—			—			(2,686		)	(1,047,186		)	—			(1,049,872		)
Net cash used in investing activities	(8,119		)	(53,281		)	(8,863		)	(1,060,666		)	—			(1,130,929		)
Proceeds from sale of assets and businesses																			—			7			19,505			—			—			19,512
Net cash provided by (used in) investing activities																			(2,937		)	(30,206		)	9,743			(17,807		)	—			(41,207		)

Financing activities
Borrowings on revolving facilities	830,000			—			—			10,000			—			840,000			530,000			—			—			—			—			530,000
Payments on revolving facilities	(665,000		)	—			—			(10,000		)	—			(675,000		)	(415,000		)	—			—			—			—			(415,000		)
Net proceeds from term loans	—			—			—			623,575			—			623,575
Proceeds from term loans																			1,139,822			—			—			—			—			1,139,822
Payments on term loans	(26,884		)	—			—			—			—			(26,884		)	(1,147,752		)	—			—			(23,065		)	—			(1,170,817		)
Revolving facility debt issuance costs																			(3,887		)	—			—			—			—			(3,887		)
Borrowings of other debt	6,486			—			1,547			3,008			—			11,041			6,571			—			—			—			—			6,571
Principal payments on other debt	(8,800		)	(1,313		)	(796		)	(2,258		)	—			(13,167		)	(3,704		)	(80		)	(695		)	(796		)	—			(5,275		)
Repayments of bank overdrafts																			(17,062		)	—			—			—			—			(17,062		)
Dividends paid to Holdings	(26,751		)	—			—			—			—			(26,751		)	(156		)	—			—			—			—			(156		)
Equity investment by Holdings	1,604			—			—			—			—			1,604			617			—			—			—			—			617
Intercompany																			(85,012		)	89,876			(4,864		)	—			—			—
Proceeds from issuance of non-controlling interests	—			—			—			217,065			—			217,065			—			—			2,094			—			—			2,094
Proceeds from bank overdrafts	2,353			—			—			—			—			2,353
Tax benefit from stock based awards	383			—			—			—			—			383
Intercompany	(95,683		)	(109,796		)	(12,456		)	217,935			—			—
Purchase of non-controlling interests																			—			(50		)	—			—			—			(50		)
Distributions to non-controlling interests	—			—			(6,470		)	(970		)	—			(7,440		)	—			—			(1,324		)	(2,283		)	—			(3,607		)
Net cash provided by (used in) financing activities	17,708			(111,109		)	(18,175		)	1,058,355			—			946,779			4,437			89,746			(4,789		)	(26,144		)	—			63,250

Net increase (decrease) in cash and cash equivalents	5,000			1,689			(115		)	12,707			—			19,281			(10,999		)	369			(1,651		)	(21,537		)	—			(33,818		)

Cash and cash equivalents at beginning of period	70			2,454			830			—			—			3,354			11,071			6,467			5,056			76,435			—			99,029
Cash and cash equivalents at end of period	$	5,070		$	4,143		$	715		$	12,707		$	—		$	22,635		$	72		$	6,836		$	3,405		$	54,898		$	—		$	65,211

(a) Elimination of equity in earnings of consolidated subsidiaries.

Select Medical Corporation

Condensed Consolidating Balance Sheet

December 31, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors		Non-Guarantor Subsidiaries			Non-Guarantor Concentra		Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Assets
Current Assets:
Cash and cash equivalents	$	11,071		$	6,467	$	5,056		$	76,435	$	—		$	99,029
Accounts receivable, net	—			361,327		99,913			112,512		—			573,752
Intercompany receivables	—			2,237,362		157,324			—		(2,394,686		) (a)	—
Prepaid income taxes	6,658			—		—			5,765		—			12,423
Other current assets	11,953			33,860		10,367			21,519		—			77,699
Total Current Assets	29,682			2,639,016		272,660			216,231		(2,394,686		)	762,903

Property and equipment, net	48,697			601,426		52,851			189,243		—			892,217
Investment in affiliates	4,515,998			92,389		—			—		(4,608,387		) (b) (c)	—
Goodwill	—			2,090,963		—			660,037		—			2,751,000
Identifiable intangible assets, net	—			109,132		—			231,430		—			340,562
Other assets	45,636			84,803		53,954			16,235		(26,684		) (d)	173,944

Total Assets	$	4,640,013		$	5,617,729	$	379,465		$	1,313,176	$	(7,029,757	)	$	4,920,626

Liabilities and Equity
Current Liabilities:
Bank overdrafts	$	39,362		$	—	$	—		$	—	$	—		$	39,362
Current portion of long-term debt and notes payable	7,227			445		1,324			4,660		—			13,656
Accounts payable	10,775			78,166		22,839			14,778		—			126,558
Intercompany payables	2,237,362			157,324		—			—		(2,394,686		) (a)	—
Accrued payroll	16,963			92,187		4,275			32,972		—			146,397
Accrued vacation	3,440			55,297		10,857			13,667		—			83,261
Accrued interest	20,114			—		—			2,211		—			22,325
Accrued other	39,155			60,871		6,152			33,898		—			140,076
Total Current Liabilities	2,374,398			444,290		45,447			102,186		(2,394,686		)	571,635

Long-term debt, net of current portion	1,407,066			513,938		137,436			626,893		—			2,685,333
Non-current deferred tax liability	—			133,852		596			91,314		(26,684		) (d)	199,078
Other non-current liabilities	42,824			53,399		5,865			34,432		—			136,520

Total Liabilities	3,824,288			1,145,479		189,344			854,825		(2,421,370		)	3,592,566

Redeemable non-controlling interests	—			—		10,169			411,990		—			422,159

Stockholder’s Equity:
Common stock	0			—		—			—		—			0
Capital in excess of par	925,111			—		—			—		—			925,111
Retained earnings (accumulated deficit)	(109,386		)	1,295,603		(39,546		)	1,364		(1,257,421		) (c)	(109,386		)
Subsidiary investment	—			3,176,647		132,890			41,429		(3,350,966		) (b)	—
Total Select Medical Corporation Stockholder’s Equity	815,725			4,472,250		93,344			42,793		(4,608,387		)	815,725

Non-controlling interests	—			—		86,608			3,568		—			90,176
Total Equity	815,725			4,472,250		179,952			46,361		(4,608,387		)	905,901

Total Liabilities and Equity	$	4,640,013		$	5,617,729	$	379,465		$	1,313,176	$	(7,029,757	)	$	4,920,626

(a) Elimination of intercompany balances.

(b) Elimination of investments in consolidated subsidiaries.

(d) Reclass of non-current deferred tax asset to report net non-current deferred tax liability in consolidation.

Select Medical Corporation

Condensed Consolidating Statement of Operations

For the Three Months Ended March 31, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)

Net operating revenues	$	417		$	711,868		$	125,168		$	250,877		$	—		$	1,088,330

Costs and expenses:
Cost of services	344			602,521			106,195			213,202			—			922,262
General and administrative	28,387			(119		)	—			—			—			28,268
Bad debt expense	—			10,698			1,985			3,714			—			16,397
Depreciation and amortization	1,211			15,211			2,719			15,376			—			34,517
Total costs and expenses	29,942			628,311			110,899			232,292			—			1,001,444

Income (loss) from operations	(29,525		)	83,557			14,269			18,585			—			86,886

Other income and expense:
Intercompany interest and royalty fees	(1,058		)	2,854			(1,796		)	—			—			—
Intercompany management fees	55,357			(49,525		)	(5,832		)	—			—			—
Loss on early retirement of debt	(773		)	—			—			—			—			(773		)
Equity in earnings of unconsolidated subsidiaries	—			4,627			25			—			—			4,652
Non-operating gain (loss)	30,432			(5,345		)	—			—			—			25,087
Interest expense	(20,346		)	(6,634		)	(1,639		)	(10,229		)	—			(38,848		)

Income before income taxes	34,087			29,534			5,027			8,356			—			77,004

Income tax expense (benefit)	8,612			5,615			(65		)	2,898			—			17,060
Equity in earnings of subsidiaries	29,358			3,117			—			—			(32,475		) (a)	—

Net income	54,833			27,036			5,092			5,458			(32,475		)	59,944

Less: Net income attributable to non-controlling interests	—			—			1,886			3,225			—			5,111

Net income attributable to Select Medical Corporation	$	54,833		$	27,036		$	3,206		$	2,233		$	(32,475	)	$	54,833

(a) Elimination of equity in earnings of subsidiaries.

Select Medical Corporation

Condensed Consolidating Statement of Cash Flows

For the Three Months Ended March 31, 2016

(unaudited)

	Select (Parent Company Only)			Subsidiary Guarantors			Non-Guarantor Subsidiaries			Non-Guarantor Concentra			Eliminations			Consolidated Select Medical Corporation
	(in thousands)
Operating activities
Net income	$	54,833		$	27,036		$	5,092		$	5,458		$	(32,475	)(a)	$	59,944
Adjustments to reconcile net income to net cash
provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	—			8,283			22			—			—			8,305
Depreciation and amortization	1,211			15,211			2,719			15,376			—			34,517
Provision for bad debts	—			10,698			1,985			3,714			—			16,397
Equity in earnings of unconsolidated subsidiaries	—			(4,627		)	(25		)	—			—			(4,652		)
Equity in earnings of consolidated subsidiaries	(29,358		)	(3,117		)	—			—			32,475		(a)	—
Loss on early retirement of debt	773			—			—			—			—			773
Loss (gain) on sale of assets and business	(30,432		)	23			16			—			—			(30,393		)
Impairment of equity investment	—			5,339			—			—			—			5,339
Stock compensation expense	3,784			—			—			192			—			3,976
Amortization of debt discount, premium and issuance costs	2,838			—			—			853			—			3,691
Deferred income taxes	(3,294		)	—			—			(181		)	—			(3,475		)
Changes in operating assets and liabilities, net of
effects of business combinations:
Accounts receivable	—			(18,362		)	(13,913		)	(6,889		)	—			(39,164		)
Other current assets	(5,472		)	4,411			(522		)	9,143			—			7,560
Other assets	155			(70		)	19			(995		)	—			(891		)
Accounts payable	(12		)	(18,456		)	(4,242		)	1,388			—			(21,322		)
Accrued expenses	(2,149		)	50,917			1,040			1,385			—			51,193
Income taxes	16,483			—			—			2,887			—			19,370
Net cash provided by (used in) operating activities	9,360			77,286			(7,809		)	32,331			—			111,168

Investing activities
Acquisition of businesses, net of cash acquired	(408,654		)	(605		)	—			(3,624		)	—			(412,883		)
Purchases of property and equipment	(4,909		)	(32,571		)	(6,078		)	(3,210		)	—			(46,768		)
Investment in businesses	—			(623		)	—			—			—			(623		)
Proceeds from sale of assets and business	62,597			—			3			—			—			62,600
Net cash used in investing activities	(350,966		)	(33,799		)	(6,075		)	(6,834		)	—			(397,674		)

Financing activities
Borrowings on revolving facilities	190,000			—			—			—			—			190,000
Payments on revolving facilities	(170,000		)	—			—			(5,000		)	—			(175,000		)
Proceeds from term loans	600,127			—			—			—			—			600,127
Payments on term loans	(225,837		)	—			—			(1,125		)	—			(226,962		)
Borrowings of other debt	6,727			—			—			—			—			6,727
Principal payments on other debt	(3,028		)	(37		)	(557		)	(842		)	—			(4,464		)
Repayments of bank overdrafts	(28,615		)	—			—			—			—			(28,615		)
Equity investment by Holdings	21			—			—			—			—			21
Intercompany	17,341			(36,170		)	18,829			—			—			—
Purchase of non-controlling interests	—			(1,294		)	—			—			—			(1,294		)
Distributions to non-controlling interests	(2,432		)	—			—			(629		)	—			(3,061		)
Net cash provided by (used in) financing activities	384,304			(37,501		)	18,272			(7,596		)	—			357,479

Net increase in cash and cash equivalents	42,698			5,986			4,388			17,901			—			70,973

Cash and cash equivalents at beginning of period	4,070			3,706			625			6,034			—			14,435
Cash and cash equivalents at end of period	$	46,768		$	9,692		$	5,013		$	23,935		$	—		$	85,408

(a) Elimination of equity in earnings of consolidated subsidiaries.

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with our unaudited condensed consolidated financial statements and accompanying notes.

Forward-Looking Statements

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” ~~“intend”~~“intend,” and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs, and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions, and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

· changes in government reimbursement for our services due to the implementation of healthcare reform legislation, deficit reduction measures, and/or new payment policies (including, for example, the expiration of the moratorium limiting the full application of the 25 Percent Rule that would reduce our Medicare payments for those patients admitted to a long term acute care hospital from a referring hospital in excess of an applicable percentage admissions threshold) may result in a reduction in net operating revenues, an increase in costs, and a reduction in profitability;

· the impact of the Bipartisan Budget Act of 2013 ~~(“BBA~~(the “BBA of 2013”), which ~~establishes new~~established payment limits for Medicare patients who do not meet specified criteria, may result in a reduction in net operating revenues and profitability of our long term acute care hospitals (“LTCHs”);

· the failure of our specialty hospitals to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;

· the failure of our facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;

· a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

· acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;

· ~~our plans and expectations related to the Concentra and Physiotherapy acquisitions and our inability to realize anticipated synergies;~~

· private third-party payors for our services may ~~undertake future cost containment initiatives~~adopt payment policies that could limit our future net operating revenues and profitability;

· the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;

· shortages in qualified nurses, therapists, physicians, or other licensed providers could increase our operating costs significantly or limit our ability to staff our facilities;

· competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;

· the loss of key members of our management team could significantly disrupt our operations;

· the effect of claims asserted against us could subject us to substantial uninsured liabilities; and

· other factors discussed from time to time in our filings with the SEC, including factors discussed under the ~~section entitled,~~heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2015~~2016, as such risk factors may be updated from time to time in our periodic filings with the SEC.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

Overview

We began operations in 1997 and, ~~we believe that we~~based on number of facilities, are one of the largest operators of specialty hospitals, ~~and~~ outpatient rehabilitation clinics, and occupational medicine centers in the United ~~States based on number of facilities. On March 4, 2016, we acquired Physiotherapy, a national provider of outpatient physical rehabilitation care, which operated 574 clinics nationwide.~~States. As of ~~September 30, 2016,~~March 31, 2017, we had operations in 46 states and the District of Columbia. As of March 31, 2017, we operated ~~123~~122 specialty hospitals in 27 states and ~~1,603~~1,610 outpatient rehabilitation clinics in 37 states and the District of Columbia. Concentra, which is operated through a joint venture subsidiary, ~~provides occupational medicine, consumer health, physical therapy, and veteran’s healthcare services throughout the United States. As of September 30, 2016, Concentra~~ operated ~~301~~308 medical centers in 38 ~~states.~~states as of March 31, 2017. Concentra also provides contract services at employer worksites and ~~operates~~ Department of Veterans Affairs community-based outpatient clinics, ~~(‘‘CBOCs”). On March 31, 2016, we sold our contract therapy businesses. As of September 30, 2016, we had operations in 46 states and the District of Columbia.~~or “CBOCs.”

We manage our Company through three business segments: specialty hospitals, outpatient rehabilitation, and ~~the Concentra segment.~~Concentra. We had net operating revenues of ~~$3,239.8~~$1,111.4 million for the ~~nine~~three months ended ~~September 30, 2016.~~March 31, 2017. Of this total, we earned approximately ~~53%~~54% of our net operating revenues from our specialty hospitals segment, approximately 23% from our outpatient rehabilitation segment, and approximately ~~24%~~23% from our Concentra segment. Our specialty hospitals segment consists of hospitals designed to serve the needs of long term acute care patients and hospitals designed to serve patients that require intensive medical rehabilitation care. Patients are typically admitted to our specialty hospitals from general acute care hospitals. These patients have specialized needs, ~~and~~with serious and often complex medical ~~conditions such as respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders, and cancer.~~conditions. Our outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. ~~Our outpatient rehabilitation patients are typically diagnosed with musculoskeletal impairments that restrict their ability to perform normal activities of daily living.~~ Our Concentra segment consists of medical centers and contract services provided at employer worksites and Department of Veterans Affairs CBOCs that deliver occupational medicine, ~~consumer health,~~ physical therapy, ~~and~~ veteran’s healthcare, and consumer health services.

Non-GAAP Measure

We believe that the presentation of Adjusted EBITDA ~~income (loss) (“Adjusted EBITDA”)~~ is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our operating ~~units.~~segments. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles (“GAAP”). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation, or as an alternative to or substitute for net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, ~~Concentra acquisition costs,~~ Physiotherapy acquisition costs, non-operating gain (loss), and equity in earnings (losses) of unconsolidated subsidiaries. We will refer to Adjusted EBITDA throughout the remainder of Management’s Discussion and Analysis of Financial Condition and Results of Operations. ~~You should refer to the following table which~~

The below table reconciles ~~the relationship of~~ net income and income from operations to Adjusted EBITDA ~~whenever~~and should be referred to when we ~~refer to~~discuss Adjusted ~~EBITDA:~~EBITDA.

~~Non-GAAP Measure Reconciliation~~

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2015			2016			2015			2016			2016			2017
	(in thousands)												(in thousands)
Net income	$	32,810		$	3,992		$	110,149		$	104,789		$	59,944		$	23,463
Income tax expense	18,347			1,075			65,048			51,585			17,060			13,202
Interest expense	33,052			44,482			79,728			127,662			38,848			40,853
Non-operating loss (gain)	(29,647		)	1,028			(29,647		)	(37,094		)	(25,087		)	49
Equity in earnings of unconsolidated subsidiaries	(6,348		)	(5,268		)	(12,788		)	(14,466		)	(4,652		)	(5,521		)
Loss on early retirement of debt	—			10,853			—			11,626			773			19,719
Income from operations	$	48,214		$	56,162		$	212,490		$	244,102		86,886			91,765
Stock compensation expense:
Included in general and administrative	3,433			3,932			8,073			10,771			3,248			3,749
Included in cost of services	1,392			818			2,402			2,153			728			837
Depreciation and amortization	31,472			37,165			70,668			107,887			34,517			42,539
Physiotherapy acquisition costs	—			—			—			3,236			3,236			—
Concentra acquisition costs	—			—			4,715			—
Adjusted EBITDA	$	84,511		$	98,077		$	298,348		$	368,149		$	128,615		$	138,890

Summary Financial Results

~~Consolidated Operating Results for the~~ Three Months Ended ~~September 30, 2016~~March 31, 2017

For the three months ended ~~September 30, 2016,~~March 31, 2017, our net operating revenues increased ~~3.2%~~2.1% to ~~$1,053.8~~$1,111.4 million, compared to ~~$1,021.1~~$1,088.3 million for the three months ended ~~September 30, 2015. We had income~~March 31, 2016. Income from operations ~~of $56.2~~increased 5.6% to $91.8 million for the three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$48.2~~$86.9 million for the three months ended ~~September 30, 2015.~~March 31, 2016. Net income was ~~$4.0~~$23.5 million for the three months ended ~~September 30,~~March 31, 2017, which includes a pre-tax loss on early retirement of debt of $19.7 million. Net income was $59.9 million for the three months ended March 31, 2016, which includes a pre-tax non-operating ~~loss~~gain of ~~$1.0~~$25.1 million and a pre-tax loss on early retirement of debt of ~~$10.9~~$0.8 million. ~~Net income was $32.8~~Our Adjusted EBITDA increased 8.0% to $138.9 million for the three months ended ~~September 30, 2015, which includes a pre-tax non-operating gain of $29.6 million. Our Adjusted EBITDA for the three months ended September 30, 2016 increased 16.1% to $98.1 million,~~March 31, 2017, compared to ~~$84.5~~$128.6 million for the three months ended ~~September 30, 2015, and our~~March 31, 2016. Our Adjusted EBITDA margin was ~~9.3%~~12.5% for the three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~8.3%~~11.8% for the three months ended ~~September 30, 2015.~~March 31, 2016.

~~Consolidated Operating Results for the Nine Months Ended September 30, 2016~~

For the nine months ended September 30, 2016, our net operating revenues increased 19.8% to $3,239.8 million, compared to $2,703.5 million for the nine months ended September 30, 2015. We had income from operations of $244.1 million for the nine months ended September 30, 2016, compared to $212.5 million for the nine months ended September 30, 2015. Net income was $104.8 million for the nine months ended September 30, 2016, which includes a pre-tax non-operating gain of $37.1 million and a pre-tax loss on early retirement of debt of $11.6 million. Net income was $110.1 million for the nine months ended September 30, 2015, which includes a pre-tax non-operating gain of $29.6 million. Our Adjusted EBITDA for the nine months ended September 30, 2016 increased 23.4% to $368.1 million, compared to $298.3 million for the nine months ended

~~September 30, 2015, and our Adjusted EBITDA margin was 11.4% for the nine months ended September 30, 2016, compared to 11.0% for the nine months ended September 30, 2015.~~

~~Medicare Reimbursement of LTCH Services — Patient Criteria~~

~~As discussed below under “~~~~Regulatory Changes — Medicare Reimbursement of LTCH Services — Patient Criteria~~,” new Medicare regulations, which establish new payment limits for Medicare patients discharged from an LTCH who do not meet specified patient criteria, began to be phased in to our LTCHs in the fourth quarter of 2015. As of September 30, 2016, all of our LTCHs are now operating under the new payment rules.

~~New Specialty Hospitals~~

Select’s development of new specialty hospitals can result in start-up costs exceeding net operating revenues, if any, causing Adjusted EBITDA losses during the start-up period. Adjusted EBITDA losses for start-up hospitals were $9.0 million for the three months ended September 30, 2016, compared to $3.1 million for the three months ended September 30, 2015. ~~Adjusted EBITDA losses for start-up hospitals were $19.4 million for the nine months ended September 30, 2016, compared to $11.9 million for the nine months ended September 30, 2015.~~

Significant Events

~~Physiotherapy Acquisition~~Refinancing

On March ~~4, 2016,~~6, 2017, Select ~~consummated the acquisition of 100% of the issued and outstanding equity securities of Physiotherapy. Select financed the acquisition using~~entered into a ~~combination of cash on hand~~new senior secured credit agreement that provides for $1.6 billion in senior secured credit facilities comprising a $1.15 billion, seven-year term loan and a ~~portion~~$450.0 million, five-year revolving credit facility, including a $75.0 million sublimit for the issuance of ~~the proceeds from the Series F Tranche B Term Loans~~standby letters of credit. Select used borrowings under the new Select credit facilities ~~as discussed below. Acquisition costs of $3.2 million were recognized as part of general and administrative expense on~~to: (i) repay the ~~consolidated statements of operations.~~

~~Sale of Businesses~~

The Company recognized a non-operating gain of $42.1 million for the nine months ended September 30, 2016. The Company sold its contract therapy businesses for $65.0 million, resulting in a non-operating gain of $33.9 million. The Company also transferred five specialty hospitals in an exchange transaction and sold nine outpatient rehabilitation clinics, to a non-consolidating subsidiary, which resulted in non-operating gains of $6.5 million and $1.7 million, respectively.

~~Indebtedness~~

On September 26, 2016, Concentra entered into the Concentra Credit Agreement Amendment to the Concentra first lien credit agreement. The amended agreement provided an additional $200.0 million of first lienseries E tranche B term loans due June 1, ~~2022,~~2018, the ~~net proceeds of which, together with cash on hand, were used to prepay in full Concentra’s second lien term loan due June 1, 2023. The reacquisition price of the second lien~~series F tranche B term loans ~~was $202.0 million,~~due March 31, 2021, and the ~~prepayment resulted in a loss on early retirement of debt of $10.9 million during the three months ended September 30, 2016.~~

Onrevolving facility maturing March ~~4, 2016, Select entered into an additional~~1, 2018 under Select’s 2011 senior secured credit extension amendment to the Select credit facilities, which among other changes, provided for the lenders named therein to make available an aggregate of $625.0 million of Series F Tranche B Term Loans. Select used the proceeds of the Series F Tranche B Term

~~Loans~~facility; and ~~cash on hand to (i) refinance in full the Series D Tranche B Term Loans due December 20, 2016,~~ (ii) ~~consummate the acquisition of Physiotherapy, and (iii)~~ pay fees and expenses ~~incurred~~ in connection with the ~~transactions. During the nine months ended September 30, 2016, we recognized a loss on early retirement of debt of $0.8 million.~~refinancing.

Regulatory Changes

Our Annual Report on Form 10-K for the year ended December 31, ~~2015,~~2016, filed with the SEC on February ~~26, 2016,~~23, 2017, contains a detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations. The following is a discussion of ~~recent~~some of the more significant healthcare regulatory changes that have affected our ~~results of operations~~financial performance in ~~2015~~the periods covered by this report or are likely to affect our financial performance and ~~2016 or may have an effect on our future results of operations.~~financial condition in the future. The information below should be read in conjunction with the more detailed discussion of regulations contained in our Form 10-K.

Medicare Reimbursement

The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services and CMS. Net operating revenues generated directly from the Medicare program represented approximately 30% of our ~~consolidated~~ net operating revenues for both the ~~nine~~three months ended ~~September 30, 2016~~March 31, 2017 and ~~37% of our consolidated net operating revenues~~ for the year ended December 31, 2015. The principal causes of the decrease in Medicare net operating revenues as a percentage of our total net operating revenues are the acquisitions of Concentra on June 1, 2015, and Physiotherapy on March 4, 2016, which both have a significantly lower relative percentage of Medicare net operating revenues as compared to our historical business prior to the acquisitions. Since the percentage of net operating revenues generated directly from the Medicare program have been historically higher in our specialty hospitals segment as compared to our outpatient rehabilitation and Concentra segments, we anticipate that the percentage of net operating revenues generated directly from the Medicare program will continue to decrease to the extent growth in our outpatient rehabilitation and Concentra segments outpaces growth in our specialty hospitals segment.2016.

~~The Medicare program reimburses our LTCHs, inpatient rehabilitation facilities (“IRFs”) and outpatient rehabilitation providers, using different payment methodologies.~~

The Medicare Access and CHIP Reauthorization Act of 2015, enacted on April 16, 2015, reforms Medicare payment policy for services paid under the Medicare physician fee schedule, including our outpatient rehabilitation services. The law repeals the sustainable growth rate (the ‘‘SGR’’) formula effective January 1, 2015, and establishes a new payment framework consisting of specified updates to the Medicare physician fee schedule, a new Merit-Based Incentive Payment System (‘‘MIPS’’), and incentives for participation in alternative payment models (‘‘APMs’’). To finance these provisions, the Medicare Access and CHIP Reauthorization Act of 2015 reduces market basket updates for post-acute care providers, including LTCHs and IRFs, among other Medicare payment cuts. As noted below, the law sets the annual prospective payment system update for fiscal year 2018 at 1% for LTCHs and IRFs, as well as skilled nursing facilities, home health agencies, and hospices. The law also extends the exceptions process for outpatient therapy caps through December 31, 2017.

Medicare Reimbursement of LTCH Services

There have been significant regulatory changes affecting LTCHs that have affected our net operating revenues and, in some cases, caused us to change our operating models and strategies. We have been subject to regulatory changes that occur through the rulemaking procedures of CMS. All Medicare payments to our LTCHs are made in accordance with ~~long-term~~the long term care hospital prospective payment system (“LTCH-PPS”). Proposed rules specifically related to LTCHs are generally published in April or May, finalized in August, and effective on October 1st of each year.

The following is a summary of significant changes to the Medicare prospective payment system for LTCHs which have affected our ~~results of operations, as well as proposed policy and payment rate changes that~~financial performance in the periods covered by this report or may affect our ~~future results of operations.~~financial performance and financial condition in the future.

Fiscal Year ~~2015.~~2016 On August 22, 2014, CMS published the final rule updating policies and payment rates for LTCH-PPS for fiscal year 2015 (affecting discharges and cost reporting periods beginning on or after October 1, 2014 through September 30, 2015). The standard federal rate was set at $41,044, an increase from the standard federal rate applicable during fiscal year 2014 of $40,607. The update to the standard federal rate for fiscal year 2015 included a market basket increase of 2.9%, less a productivity adjustment of 0.5%, less a reduction of 0.2% mandated by the Affordable Care Act (“ACA”), and less a budget neutrality adjustment of 1.266%. The fixed-loss amount for high cost outlier cases was set at $14,972, an increase from the fixed-loss amount in the 2014 fiscal year of $13,314.

~~Fiscal Year 2016.~~ On August 17, 2015, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2016 (affecting discharges and cost reporting periods beginning on or after October 1, 2015 through September 30, 2016). The standard federal rate was set at $41,763, an increase from the standard federal rate applicable during fiscal year 2015 of $41,044. The update to the standard federal rate for fiscal year 2016 ~~includes~~included a market basket increase of 2.4%, less a productivity adjustment of 0.5%, and less a reduction of 0.2% mandated by the ~~ACA.~~Affordable Care Act (“ACA”). The ~~fixed-loss~~fixed loss amount for high cost outlier cases paid under LTCH-PPS was set at $16,423, an increase from the ~~fixed-loss~~fixed loss amount in the 2015 fiscal year of $14,972. The ~~fixed-loss~~fixed loss amount for high cost outlier cases paid under the ~~site-neutral~~site neutral payment rate described below was set at $22,538.

Fiscal Year ~~2017.~~2017. On August 22, 2016, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2017 (affecting discharges and cost reporting periods beginning on or after October 1, 2016 through September 30, 2017). The standard federal rate was set at $42,476, an increase from the standard federal rate applicable during fiscal year 2016 of $41,763. The update to the standard federal rate for fiscal year 2017 ~~includes~~included a market basket increase of 2.8%, less a productivity adjustment of 0.3%, and less a reduction of 0.75% mandated by the ACA. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at $21,943, an increase from the fixed-loss amount in the 2016 fiscal year of $16,423. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at ~~$23,570,~~$23,573, an increase from the fixed-loss amount in the 2016 fiscal year of $22,538.

~~Medicare Market Basket Adjustments~~Fiscal Year 2018

~~The ACA instituted a market basket~~. On April 14, 2017, CMS released an advanced copy of the proposed policies and payment ~~adjustment to LTCHs. In fiscal years 2017 through 2019,~~rates for the ~~market basket update will be reduced by 0.75%. The Medicare Access and CHIP Reauthorization Act of 2015 sets the annual update~~LTCH-PPS for fiscal year 2018 ~~at 1% after taking into account the market basket payment reduction of 0.75% mandated by the ACA. The ACA specifically allows these market basket reductions to result in less than a 0% payment update~~(affecting discharges and ~~payment rates that are less than the prior year. For fiscal year 2017, CMS is rebasing the LTCH-specific market basket by replacing the 2009-based LTCH-specific market basket~~

~~with a 2013-based LTCH-specific market basket that is based on Medicare cost report data from~~ cost reporting periods beginning on or after October 1, ~~2012~~2017 through September 30, 2018). The standard federal rate would be set at $41,497, a decrease from the standard federal rate applicable during fiscal year 2017 of $42,476. The update to the standard federal rate for fiscal year 2018, if adopted, would include a market basket increase of 2.8%, less a productivity adjustment of 0.4%, and ~~before October 1, 2013.~~less a reduction of 0.75% mandated by the ACA. The standard federal rate would be further reduced by the proposed short-stay outlier changes, as described below. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS, if adopted, would be set at $30,081, an increase from the fixed-loss amount in the 2017 fiscal year of $21,943. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate, if adopted, would be set at $26,713, an increase from the fixed-loss amount in the 2017 fiscal year of $23,573.

Patient Criteria

The BBA of 2013, enacted December 26, 2013, establishes ~~new payment limits~~a dual-rate LTCH-PPS for Medicare patients discharged from an ~~LTCH who do not meet specified criteria.~~LTCH. Specifically, for Medicare patients discharged in cost reporting periods beginning on or after October 1, 2015, LTCHs will be reimbursed ~~under~~at the LTCH-PPS standard federal payment rate only if, immediately preceding the patient’s LTCH admission, the patient was discharged from a ~~general~~“subsection (d) hospital” (generally, a short-term acute care hospital paid under ~~IPPS~~the inpatient prospective payment system, or “IPPS”) and either the patient’s stay included at least three days in an intensive care unit (ICU) or coronary care unit (CCU) at the subsection (d) hospital, or the patient iswas assigned to a Medicare severity diagnosis-related group (“MS-LTC-DRG”) for LTCHs ~~(“MS-LTC-DRG”)~~ for cases receiving at least 96 hours of ventilator services in the LTCH. In addition, to be paid ~~under~~at the LTCH-PPS standard federal payment rate, the patient’s discharge from the LTCH may not include a principal diagnosis relating to psychiatric or rehabilitation services. For any Medicare patient who does not meet ~~the new~~these criteria, the LTCH will be paid a lower ~~“site-neutral”~~“site neutral” payment rate, which will be the lower ~~of (1) the inpatient prospective payment system (“IPPS”)~~of: (i) IPPS comparable ~~per-diem~~per diem payment rate capped at the Medicare severity diagnosis-related group (“MS-DRG”) ~~including~~payment rate plus any outlier ~~payments,~~payments; or ~~(2)~~(ii) 100 percent of the estimated costs for services.

The BBA of 2013 provides for a transition to the site-neutral payment rate for those patients not paid ~~under LTCH-PPS.~~at the LTCH-PPS standard federal payment rate. During the transition period ~~(cost~~(applicable to hospital cost reporting periods beginning on or after October 1, 2015 ~~through~~and on or before September 30, 2017), a blended rate will be paid for Medicare patients not meeting the new ~~criteria. The blended rate will comprise half~~criteria that is equal to 50% of the site-neutral payment rate amount and ~~half~~50% of the ~~LTCH-PPS~~standard federal payment ~~rate.~~rate amount. Thereafter, an LTCH will be paid solely based on the site-neutral payment rate for Medicare patients not meeting the patient criteria. For discharges in cost reporting periods beginning on or after October 1, 2017, only the site-neutral payment rate will apply for Medicare patients not meeting the new criteria.

In addition, for cost reporting periods beginning on or after October 1, 2019, qualifying discharges from an LTCH will continue to be paid at the LTCH-PPS standard federal payment rate, unless the number of discharges for which payment is made under the site-neutral payment rate is greater than 50% of the total number of discharges from the ~~LTCH.~~LTCH for that period. If the number of discharges for which payment is made under the site-neutral payment rate is greater than 50%, then beginning in the next cost reporting period all discharges from the LTCH will be reimbursed at the site-neutral payment rate. The BBA of 2013 requires CMS to establish a process for an LTCH subject to only the site-neutral payment rate to ~~re-qualify~~be reinstated for payment under the dual-rate LTCH-PPS.

Payment adjustments, including the interrupted stay policy and the 25 Percent Rule (discussed below), apply to LTCH discharges regardless of whether the case is paid at the ~~LTCH-PPS~~standard federal payment rate or the site-neutral payment rate. However, short stay outlier payment adjustments do not apply to cases paid at the site-neutral payment ~~rate after the transition period. Beginning in fiscal year 2016,~~rate. CMS calculates the annual recalibration of the MS-LTC-DRG relative payment weighting factors using only data from LTCH discharges that meet the criteria for exclusion from the site-neutral payment rate. In addition, ~~beginning in fiscal year 2016,~~ CMS applies the IPPS fixed-loss amount for high cost outliers to site-neutral cases, rather than the ~~LTCH PPS~~LTCH-PPS fixed-loss amount. CMS calculates the LTCH-PPS fixed-loss amount using only data from cases paid at the LTCH-PPS payment rate, excluding cases paid at the site-neutral rate.

~~Each~~Medicare Market Basket Adjustments

The ACA instituted a market basket payment adjustment to LTCHs. In fiscal years 2018 and 2019, the market basket update will be reduced by 0.75%. The Medicare Access and CHIP Reauthorization Act of ~~our LTCHs has their own unique~~2015 sets the annual ~~cost reporting period. As~~update for fiscal year 2018 at 1% after taking into account the market basket payment reduction of 0.75% mandated by the ACA. The ACA specifically allows these market basket reductions to result in less than a ~~result,~~0% payment update and payment rates that are less than the new payment limits became effective for each LTCH at different points in time over the twelve month period that began on October 1, 2015. As of September 30, 2016, all of our LTCHs were operating under the new payment rules.prior year.

25 Percent Rule

The “25 Percent Rule” is a downward payment adjustment that applies if the percentage of Medicare patients discharged from LTCHs who were admitted from a referring hospital (regardless of whether the LTCH or LTCH satellite is co-located with the referring hospital) exceeds the applicable percentage admissions threshold during a particular cost reporting period. ~~As more fully~~For Medicare patients above the applicable percentage admissions threshold, the LTCH is reimbursed at a rate equivalent to that under general acute care hospital IPPS, which is generally lower than LTCH-PPS rates. Cases that reach outlier status in the referring hospital do not count toward the admissions threshold and are paid under LTCH-PPS.

Current law, as amended by the 21st Century Cures Act, precludes CMS from applying the 25 Percent Rule for freestanding LTCHs to cost reporting years beginning before July 1, 2016 and for discharges occurring on or after October 1, 2016 and before October 1, 2017. In addition, current law applies higher percentage admissions thresholds under the 25 Percent Rule for most hospitals within hospitals (“HIHs”) for cost reporting years beginning before July 1, 2016 and effective for discharges occurring on or after October 1, 2016 and before October 1, 2017. For freestanding LTCHs the percentage admissions threshold is suspended during the relief periods. For HIHs the percentage admissions threshold is raised from 25% to 50% during the relief periods. In the special case of rural LTCHs, LTCHs co-located with an urban single hospital, or LTCHs co-located with a Metropolitan Statistical Area (“MSA”) dominant hospital the referral percentage was raised from 50% to 75%. Grandfathered HIHs are exempt from the 25 Percent Rule regulations.

After the expiration of the statutory relief, as described ~~under “~~~~Business—Government Regulations~~~~,” various legislation has limited~~above, our LTCHs (whether freestanding, HIH or ~~deferred~~satellite) will be subject to a downward payment adjustment for any Medicare patients who were admitted from a co-located or a non-co-located hospital and that exceed the ~~full application~~applicable percentage admissions threshold of all Medicare patients discharged from the LTCH during the cost reporting period. These regulatory changes will have an adverse financial impact on the net operating revenues and profitability of many of these hospitals for discharges on or after October 1, 2017.

For fiscal year 2018, CMS is proposing a regulatory moratorium on the implementation of the 25 Percent Rule. Each of our LTCHs has their own unique annual cost reporting period. As a result, the new payment limits will become effective for each of our LTCHs at different periods of time, commencing on or after July 1, 2016. In the third quarter 2016, 6 of our LTCHs became subject to the new payment limits. During the fourth quarter of 2016, and the first, second, and third quarters of 2017, 14, 36, 16, and 31 of our LTCHs will become subject to the new payment limits, respectively. The effect on our net operating revenues for the third quarter of 2016 was immaterial. We expect the effect on our net operating revenuesIf adopted in the fourth quarter of 2016 to be immaterial. We currently project that our net operating revenue for 2017 may be adversely affected by approximately $12.0 million if we are unable to mitigate the effects of the new payment limits.

~~For discharges that occurred prior to October 1, 2016,~~final rule, the 25 Percent Rule ~~payment adjustments are found in two Medicare regulations, one that applies~~would apply to Medicare patients admitted from a co-located referring hospital and one that applies to Medicare patients admitted from a referring hospital not co-located with the LTCH. After October 1, 2016, a single consolidated 25 Percent Rule applies to all LTCH discharges that occur in the LTCH’s cost reporting period that begins after the statutory moratoria on the full implementation of the 25 Percent Rule expires. The moratorium on the full application of the 25 Percent Rule applicable to co-located hospitals expired beginning with LTCH cost reporting periods beginning on or after July 1, 2016, while the moratorium on the full application of the 25 Percent Rule applicable to LTCHs not co-located with a referring hospital expired beginning with LTCH cost reporting periods beginningoccurring on or after October 1, ~~2016. Consequently, LTCHs that are subject~~2018. Moreover, if this proposal is not finalized, CMS proposes to ~~both Medicare regulations will continue to be subject to the moratorium on the full application of~~apply the 25 Percent Rule ~~applicable~~ to ~~co-located hospitals until their cost reports beginning~~discharges occurring on or after October 1, ~~2016.~~2017.

~~Under~~Short Stay Outlier Policy

CMS established a different payment methodology for Medicare patients with a length of stay less than or equal to five-sixths of the ~~single consolidated 25 Percent Rule,~~geometric average length of stay for that particular MS-LTC-DRG, referred to as a short stay outlier, or “SSO.” SSO cases are paid based on the lesser of (i) 100% of the average cost of the case, (ii) 120% of the MS-LTC-DRG specific per diem amount multiplied by the patient’s length of stay, (iii) the full MS-LTC-DRG payment, or (iv) a per diem rate derived from blending 120% of the MS-LTC-DRG specific per diem amount with a per diem rate based on the general acute care hospital IPPS.

For fiscal year 2018, CMS ~~calculates the percentage of LTCH discharges referred from any hospital~~is proposing to change SSO policy such that all SSO cases discharged on ~~a provider number basis only. An LTCH’s percentage of Medicare discharges from all locations of a given referring hospital~~or after October 1, 2017 would be ~~determined during settlement~~paid using only the last of these four options - a ~~cost report by dividing~~per diem rate derived from blending 120% of the ~~LTCH’s total number of Medicare discharges in the cost reporting period (based~~MS-LTC-DRG specific per diem amount with a per diem rate based on the general acute care hospital IPPS. If adopted, CMS ~~Certification Number (CCN) on the claims)~~anticipates that were admitted directly from a given referring hospital (again determined by the CCN on the referring hospital’s claims) by the LTCH’s total number of Medicare discharges in the cost reporting period. LTCH discharges that reach high cost outlier status at the referring hospital are not subjectthis proposed change to the ~~25 Percent Rule~~ payment formula for SSO cases would result in a net increase in aggregate Medicare LTCH payments compared to aggregate Medicare LTCH payments under the current methodology, which would be offset by a budget neutrality adjustment ~~(that is, such discharges would only be included in an LTCH’s total Medicare discharges and would not count as having been admitted from that referring hospital), and~~decreasing payment to the extent the LTCH is exclusively located in an MSA-dominant area or rural area, the LTCH would have an increased applicable threshold under proposed special treatment for exclusively MSA-dominant or exclusively rural LTCHs.non-SSO cases.

Moratorium on New LTCHs, LTCH Satellite Facilities and LTCH ~~Beds~~beds

~~The Medicare, Medicaid, SCHIP Extension Act of 2007 imposed~~Current law imposes a moratorium on the establishment and classification of new LTCHs, LTCH satellite facilities and LTCH beds in existing LTCHs or satellite facilities subject to certain exceptions through December 28, 2012. The BBA of 2013, as amended by the PAMA, reinstated the moratorium on the establishment and classification of new LTCHs or LTCH satellite facilities, and on the increase of LTCH beds in existing LTCHs or satellite facilities ~~beginning April 1, 2014~~ through

September 30, ~~2017 with certain~~2017. There are three exceptions to the moratorium for projects that ~~are applicable to the establishment and classification of new LTCHs or LTCH satellite facilities~~were under development ~~prior to~~when the moratorium began on April 1, 2014. Only one exception needs to apply.

Medicare Reimbursement of Inpatient Rehabilitation Facility Services

The following is a summary of significant changes to the Medicare prospective payment system for ~~IRFs~~inpatient rehabilitation facilities (“IRFs”) which have affected our ~~results of operations during~~financial performance in the periods ~~presented in~~covered by this report ~~as well as the policies and payment rates for fiscal year 2016 which~~or may affect our ~~patient discharges~~financial performance and ~~cost reporting periods beginning on or after October 1, 2015.~~financial condition in the future. Medicare payments to our IRFs are made in accordance with the inpatient rehabilitation facility prospective payment system (“IRF-PPS”).

Fiscal Year ~~2015.~~2016 On August 6, 2014, CMS published the final rule updating policies and payment rates for IRF-PPS for fiscal year 2015 (affecting discharges and cost reporting periods beginning on or after October 1, 2014 through September 30, 2015). The standard payment conversion factor for discharges for fiscal year 2015 was set at $15,198, an increase from the standard payment conversion factor applicable during fiscal year 2014 of $14,846. The update to the standard payment conversion factor for fiscal year 2015 included a market basket increase of 2.9%, less a productivity adjustment of 0.5%, and less a reduction of 0.2% mandated by the ACA. CMS decreased the outlier threshold amount for fiscal year 2015 to $8,848 from $9,272 established in the final rule for fiscal year 2014.

~~Fiscal Year 2016.~~ On August 6, 2015, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2016 (affecting discharges and cost reporting periods beginning on or after October 1, 2015 through September 30, 2016). The standard payment conversion factor for discharges for fiscal year 2016 was set at $15,478, an increase from the standard payment conversion factor applicable during fiscal year 2015 of $15,198. The update to the standard payment conversion factor for fiscal year 2016 ~~includes~~included a market basket increase of 2.4%, less a productivity adjustment of 0.5%, and less a reduction of 0.2% mandated by the ACA. CMS decreased the outlier threshold amount for fiscal year 2016 to $8,658 from $8,848 established in the final rule for fiscal year 2015.

Fiscal Year ~~2017.~~2017. On August 5, 2016, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2017 (affecting discharges and cost reporting periods beginning on or after October 1, 2016 through September 30, 2017). The standard payment conversion factor for discharges for fiscal year 2017 was set at $15,708, an increase from the standard payment conversion factor applicable during fiscal year 2016 of $15,478. The update to the standard payment conversion factor for fiscal year 2017 ~~includes~~included a market basket increase of 2.7%, less a productivity adjustment of 0.3%, and less a reduction of 0.75% mandated by the ACA. CMS decreased the outlier threshold amount for fiscal year 2017 to $7,984 from $8,658 established in the final rule for fiscal year 2016.

Fiscal Year 2018. On April 27, 2017, CMS released an advanced copy of the proposed policies and payment rates for the IRF-PPS for fiscal year 2018 (affecting discharges and cost reporting periods beginning on or after October 1, 2017 through September 30, 2018). The standard payment conversion factor for discharges for fiscal year 2018 would be set at $15,835, an increase from the standard payment conversion factor applicable during fiscal year 2017 of $15,708. The update to the standard payment conversion factor for fiscal year 2018, if adopted, would include a market basket increase of 2.7%, less a productivity adjustment of 0.4%, and less a reduction of 0.75% mandated by the ACA. As noted below, the proposed update to the standard payment conversion factor for fiscal year 2018 is impacted further by the Medicare Access and CHIP Reauthorization Act of 2015, which limits the update for fiscal year 2018 to 1.0%. CMS proposed to increase the outlier threshold amount for fiscal year 2018 to $8,656 from $7,984 established in the final rule for fiscal year 2017.

Medicare Market Basket Adjustments

The ACA instituted a market basket payment adjustment for IRFs. In fiscal years ~~2017 through~~2018 and 2019, the market basket update will be reduced by 0.75%. The Medicare Access and CHIP Reauthorization Act of 2015 sets the annual update for fiscal year 2018 at 1% after taking into account the market basket payment reduction of 0.75% mandated by the ACA. The ACA specifically allows these market basket reductions to result in less than a 0% payment update and payment rates that are less than the prior year.

Patient Classification Criteria

In order to qualify as an IRF a hospital must demonstrate that during its most recent twelve month cost reporting period it served an inpatient population of whom at least 60% required intensive rehabilitation services for one or more of 13 conditions specified by regulation. Compliance with the 60% rule is demonstrated through either medical review or the “presumptive” method, in which a patient’s diagnosis codes are compared to a “presumptive compliance” list. For fiscal year 2018, CMS is proposing changes to the 60% rule’s presumptive methodology, including (i) addressing certain International Classification of Diseases, Tenth Revision, Clinical Modification (“ICD-10-CM”) diagnosis codes for patients with traumatic brain injury and hip fracture conditions; (ii) identifying major multiple trauma codes that did not translate exactly (one-for-one) between International Classification of Diseases, Ninth Revision, Clinical Modification (“ICD-9-CM”) and ICD-10-CM; (iii) removing certain non-specific and arthritis diagnosis codes that were inadvertently re-introduced through the ICD-10-CM conversion process; and (iv) removing one ICD-10-CM code, G72.89—Other specified myopathies.

Medicare Reimbursement of Outpatient Rehabilitation Services

The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule. Historically, the Medicare physician fee schedule rates have updated annually based on the SGR formula. The SGR formula has resulted in automatic reductions in rates every year since 2002; however, for

each year through March 31, 2015, CMS or Congress has taken action to prevent the SGR formula reductions. The Medicare Access and CHIP Reauthorization Act of 2015 repeals the SGR formula effective for services provided on or after January 1, 2015, and establishes a new payment framework consisting of specified updates to the Medicare physician fee schedule, a new MIPS, and APMs. For services provided between January 1, 2015 and June 30, 2015, a 0% payment update was applied to the Medicare physician fee schedule payment rates. For services provided between July 1, 2015 and December 31, 2015, a 0.5% update was applied to the fee schedule payment rates. For services provided in ~~2016~~2017 through 2019, a 0.5% update will be applied each year to the fee schedule payment rates, subject to ~~MIPS~~an adjustment beginning in ~~2019.~~2019 under the Merit-Based Incentive Payment System (“MIPS”). For services provided in 2020 through 2025, a 0.0% percent update will be applied each year to the fee schedule payment rates, subject to adjustments under MIPS and ~~APM adjustments. Finally, in~~the alternative payment models (“APMs”). In 2026 and subsequent years eligible professionals participating in APMs that meet certain criteria would receive annual updates of 0.75%, while all other professionals would receive annual updates of 0.25%.

~~The Medicare Access and CHIP Reauthorization Act of 2015 requires that~~Beginning in 2019, payments under the fee schedule ~~be adjusted starting in 2019~~are subject to adjustment based on performance in MIPS, which ~~will consolidate the three existing incentive programs focused~~measures performance based on certain quality metrics, resource use, and meaningful use of electronic health records. ~~The law requires the Secretary of Health and Human Services to establish~~Under the MIPS requirements ~~under which~~ a provider’s performance is assessed according to established performance standards and used to determine an adjustment factor that is then applied to the professional’s payment for a year. Each year from ~~2019-2024~~2019 through 2024 professionals who receive a significant share of their revenues through an APM (such as accountable care organizations or bundled payment arrangements) that involves risk of financial losses and a quality measurement component will receive a 5% bonus. The bonus payment for APM participation is intended to encourage participation and testing of new APMs and ~~promotes~~to promote the alignment of incentives across payors. The specifics of the MIPS and APM adjustments beginning in 2019 and 2020, respectively, will be subject to future notice and comment rule-making. ~~For the year ended December 31, 2015, we received approximately 11% of our outpatient rehabilitation net operating revenues from Medicare.~~

Operating Statistics

The following ~~tables set~~table sets forth operating statistics for ~~each of~~ our operating segments for each of the periods presented. The operating statistics reflect data for the period of time we managed these operations:

Three Months Ended
September 30,

Nine Months Ended
September 30,

2015

2016

2015

2016

Specialty Hospitals Data(1):

Number of hospitals owned - start of period

119

116

120

118

Number of hospitals acquired

—

1

1

4

Number of hospital start-ups

—

1

1

2

Number of hospitals closed/sold

(1
)
(3
)
(4
)
(9
)
Number of hospitals owned - end of period

118

115

118

115

Number of hospitals managed - end of period

9

8

9

8

Total number of hospitals (all) - end of period

127

123

127

123

Long term acute care hospitals

110

104

110

104

Rehabilitation hospitals

17

19

17

19

Available licensed beds (2)

5,150

5,208

5,150

5,208

Admissions (2)

13,927

12,586

42,352

39,541

Patient days (2)

338,412

296,202

1,034,166

951,292

Average length of stay (days) (2)

24

24

24

24

Net revenue per patient day (2)(3)

$
1,522

$
1,642

$
1,563

$
1,651

Occupancy rate (2)

71
%
62
%
72
%
67
%
Percent patient days - Medicare (2)

59
%
53
%
60
%
55
%

Three Months Ended
September 30,

Nine Months Ended
September 30,

2015

2016

2015

2016

Outpatient Rehabilitation Data:

Number of clinics owned - start of period

881

1,435

880

896

Number of clinics acquired

—

3

7

546

Number of clinic start-ups

11

7

19

20

Number of clinics closed/sold

(2
)
(8
)
(16
)
(25
)
Number of clinics owned - end of period

890

1,437

890

1,437

Number of clinics managed - end of period

143

166

143

166

Total number of clinics (all) - end of period

1,033

1,603

1,033

1,603

Number of visits (2)

1,306,637

2,052,678

3,879,409

5,751,562

Net revenue per visit (2)(4)

$
103

$
102

$
103

$
102

~~(Operating statistics by business segment and related footnotes are continued next page)~~

Three Months Ended
September 30,

Nine Months Ended
September 30,

2015

2016

2015

2016

Concentra Data:

Number of centers owned - start of period

300

301

—

300

Number of centers acquired

—

1

300

3

Number of centers start-ups

—

—

—

—

Number of centers closed/sold

—

(1
)
—

(2
)
Total number of centers - end of period

300

301

300

301

Number of visits (5)

1,980,496

1,906,242

2,654,330

5,642,305

Net revenue per visit (5)(6)

$
114

$
119

$
114

$
118

	Three Months Ended March 31,
	2016			2017
Specialty hospitals data:(1)
Number of hospitals owned—start of period	118			115
Number of hospitals acquired	—			—
Number of hospital start-ups	—			—
Number of hospitals closed/sold	—			(1		)
Number of hospitals owned—end of period	118			114
Number of hospitals managed—end of period	9			8
Total number of hospitals (all)—end of period	127			122
Long term acute care hospitals	109			102
Rehabilitation hospitals	18			20
Available licensed beds(2)	5,172			5,148
Admissions(2)	13,861			13,895
Patient days(2)	337,971			317,365
Average length of stay (days)(2)	24			23
Net revenue per patient day(2)(3)	$	1,632		$	1,716
Occupancy rate(2)	72		%	68		%
Percent patient days—Medicare(2)	57		%	55		%

Outpatient rehabilitation data:
Number of clinics owned—start of period	896			1,445
Number of clinics acquired	543			1
Number of clinic start-ups	6			8
Number of clinics closed/sold	(4		)	(9		)
Number of clinics owned—end of period	1,441			1,445
Number of clinics managed—end of period	160			165
Total number of clinics (all)—end of period	1,601			1,610
Number of visits(2)	1,576,554			2,075,790
Net revenue per visit(2)(4)	$	103		$	102

Concentra data:
Number of centers owned—start of period	300			300
Number of centers acquired	2			6
Number of center start-ups	—			2
Number of centers closed/sold	(1		)	—
Number of centers owned—end of period	301			308
Number of visits(5)	1,845,715			1,886,815
Net revenue per visit(5)(6)	$	118		$	118

(1) Specialty hospitals consist of LTCHs and IRFs.

(2) Data excludes specialty hospitals and outpatient clinics managed by the Company.

(3) Net revenue per patient day is calculated by dividing specialty hospitals direct patient service revenues by the total number of patient days.

(4) Net revenue per visit is calculated by dividing outpatient rehabilitation clinic direct patient service revenue by the total number of ~~visits and excludes~~visits. For purposes of this computation, outpatient rehabilitation direct patient service clinic revenue does not include managed clinics or contract therapy ~~revenue for all periods presented.~~revenue.

(5) Data excludes onsite clinics and CBOCs.

(6) Net revenue per visit is calculated by dividing center direct patient service revenue by the total number of center visits.

Results of Operations

The following table outlines selected operating data as a percentage of net operating revenues for the periods indicated:

	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
	2015		2016		2015		2016		2016		2017
Net operating revenues	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services(1)	88.2		86.9		85.4		85.0
Cost of services(1)									84.7		83.5
General and administrative	2.2		2.6		2.5		2.5		2.6		2.5
Bad debt expense	1.8		1.7		1.6		1.6		1.5		1.9
Depreciation and amortization	3.1		3.5		2.6		3.4		3.2		3.8
Income from operations	4.7		5.3		7.9		7.5		8.0		8.3
Loss on early retirement of debt	—		(1.0	)	—		(0.4	)	(0.1	)	(1.8	)
Equity in earnings of unconsolidated subsidiaries	0.6		0.5		0.5		0.5		0.4		0.5
Non-operating gain (loss)	2.9		(0.1	)	1.1		1.1		2.3		(0.0	)
Interest expense	(3.2	)	(4.2	)	(3.0	)	(3.9	)	(3.5	)	(3.7	)
Income before income taxes	5.0		0.5		6.5		4.8		7.1		3.3
Income tax expense	1.8		0.1		2.4		1.6		1.6		1.2
Net income	3.2		0.4		4.1		3.2		5.5		2.1
Net income (loss) attributable to non-controlling interests	0.3		(0.2	)	0.3		0.3
Net income attributable to non-controlling interests									0.5		0.7
Net income attributable to Holdings and Select	2.9	%	0.6	%	3.8	%	2.9	%	5.0	%	1.4	%

(1) Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense and other operating costs.

The following ~~tables summarize~~table summarizes selected financial data by business segment for the periods indicated:

For the Three Months Ended
September 30,

For the Nine Months Ended
September 30,

2015

2016

% Change

2015

2016

% Change

Net operating revenues:

Specialty hospitals

$
562,328

$
544,491

(3.2
)%
$
1,753,445

$
1,729,261

(1.4
)%
Outpatient rehabilitation(1)

199,593

250,710

25.6

603,831

745,720

23.5

Concentra(2)

258,969

258,507

(0.2
)
345,798

764,252

N/M

Other(3)

233

87

(62.7
)
457

523

14.4

Total company

$
1,021,123

$
1,053,795

3.2
%
$
2,703,531

$
3,239,756

19.8
%

Income (loss) from operations:

Specialty hospitals

$
39,874

$
33,947

(14.9
)%
$
201,166

$
175,737

(12.6
)%
Outpatient rehabilitation(1)

20,560

25,836

25.7

65,098

82,609

26.9

Concentra(2)

11,457

25,417

121.8

13,747

71,933

N/M

Other(3)

(23,677
)
(29,038
)
(22.6
)
(67,521
)
(86,177
)
(27.6
)
Total company

$
48,214

$
56,162

16.5
%
$
212,490

$
244,102

14.9
%

Adjusted EBITDA:

Specialty hospitals

$
53,656

$
48,264

(10.0
)%
$
241,575

$
217,759

(9.9
)%
Outpatient rehabilitation(1)

23,807

31,995

34.4

74,662

99,006

32.6

Concentra(2)

25,584

40,888

59.8

36,783

118,080

N/M

Other(3)

(18,536
)
(23,070
)
(24.5
)
(54,672
)
(66,696
)
(22.0
)
Total company

$
84,511

$
98,077

16.1
%
$
298,348

$
368,149

23.4
%

Adjusted EBITDA margin:

Specialty hospitals

9.5
%
8.9
%

13.8
%
12.6
%

Outpatient rehabilitation(1)

11.9

12.8

12.4

13.3

Concentra(2)

9.9

15.8

10.6

15.5

Other(3)

N/M

N/M

N/M

N/M

Total company

8.3
%
9.3
%

11.0
%
11.4
%

Purchases of property and equipment:

Specialty hospitals

$
27,494

$
24,378

$
81,329

$
79,366

Outpatient rehabilitation(1)

4,023

6,234

11,048

15,032

Concentra(2)

9,640

2,720

13,494

10,647

Other(3)

3,923

4,670

8,121

13,215

Total company

$
45,080

$
38,002

$
113,992

$
118,260

~~(Selected financial data by business segment and related footnotes are continued next page)~~

As of September 30,

2015

2016

(in thousands)

Total assets:

Specialty hospitals

$
2,333,049

$
2,461,751

Outpatient rehabilitation

541,435

977,431

Concentra(2)

1,332,975

1,327,438

Other(3)

106,946

78,785

Total company

$
4,314,405

$
4,845,405

	Three Months Ended March 31,
	2016			2017			% Change
	(in thousands)
Net operating revenues:
Specialty hospitals	$	598,954		$	598,787		(0.0	)%
Outpatient rehabilitation(1)	238,082			255,817			7.4
Concentra	250,877			256,149			2.1
Other(2)	417			608			N/M
Total Company	$	1,088,330		$	1,111,361		2.1	%
Income (loss) from operations:
Specialty hospitals	$	72,863		$	70,165		(3.7	)%
Outpatient rehabilitation(1)	24,843			25,011			0.7
Concentra	18,585			26,163			40.8
Other(2)	(29,405		)	(29,574		)	(0.6	)
Total Company	$	86,886		$	91,765		5.6	%
Adjusted EBITDA:
Specialty hospitals	$	86,756		$	88,665		2.2	%
Outpatient rehabilitation(1)	28,879			31,351			8.6
Concentra	34,153			42,592			24.7
Other(2)	(21,173		)	(23,718		)	(12.0	)
Total Company	$	128,615		$	138,890		8.0	%
Adjusted EBITDA margins:
Specialty hospitals	14.5		%	14.8		%
Outpatient rehabilitation(1)	12.1			12.3
Concentra	13.6			16.6
Other(2)	N/M			N/M
Total Company	11.8		%	12.5		%
Total assets: (3)
Specialty hospitals	$	2,434,405		$	2,622,220
Outpatient rehabilitation(1)	974,264			980,261
Concentra	1,310,317			1,297,672
Other(2)	103,878			102,784
Total Company	$	4,822,864		$	5,002,937
Purchases of property and equipment, net:
Specialty hospitals	$	33,675		$	32,357
Outpatient rehabilitation(1)	4,974			6,673
Concentra	3,210			8,686
Other(2)	4,909			2,937
Total Company	$	46,768		$	50,653

N/~~M —~~ M—Not ~~Meaningful~~Meaningful.

(1) The outpatient rehabilitation segment includes the operating results of our contract therapy businesses through March 31, 2016 and Physiotherapy beginning March 4, 2016. Total assets presented under outpatient rehabilitation at March 31, 2016 reflect the disposition of assets sold as a result of the sale of our contract therapy businesses.

(2) ~~Concentra’s operating results are consolidated with Select’s effective June 1, 2015.~~

~~(3)~~ Other includes our corporate services and certain other non-consolidating joint ventures and minority investments in other healthcare related ~~businesses~~businesses.

(3) Reflects the retrospective adoption of ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. Total assets as of March 31, 2016 were retrospectively conformed to reflect the adoption of the standard, resulting in a reduction to total assets of $25.1 million.

Three Months Ended ~~September 30, 2016,~~March 31, 2017 Compared to Three Months Ended ~~September 30, 2015~~

In the following, we discuss our results of operations related to net operating revenues, operating expenses, Adjusted EBITDA, depreciation and amortization, income from operations, equity in earnings of unconsolidated subsidiaries, non-operating gain (loss), interest expense, income taxes, and non-controlling interest, which, in each case, are the same for Holdings and Select.

~~Net Operating Revenues~~

~~Our net operating revenues increased by 3.2% to $1,053.8 million for the three months ended September 30,~~March 31, 2016 ~~compared to $1,021.1 million for the three months ended September 30, 2015, principally due to the acquisition of Physiotherapy on March 4, 2016.~~

~~Specialty Hospitals~~. Our specialty hospitals segment net operating revenues declined 3.2% to $544.5 million for the three months ended September 30, 2016, compared to $562.3 million for the three months ended September 30, 2015. The primary reason for this decrease was a decline in our patient days which decreased 12.5% to 296,202 days for the three months ended September 30, 2016, compared to 338,412 days for the three months ended September 30, 2015. As discussed above under “~~Regulatory Changes — Medicare Reimbursement of LTCH Services — Patient Criteria~~,” new Medicare regulations, which establish new payment limits for Medicare patients discharged from an LTCH who do not meet specified patient criteria, began to be phased in to our LTCHs in the fourth quarter of 2015. We experienced fewer Medicare patient days during the three months ended September 30, 2016 due to changes we implemented at our LTCHs operating under the new Medicare patient criteria regulations, and specialty hospital closures and sales. This decrease in patient days was offset in part by increases in our Medicare net revenue per patient day. Our average net revenue per patient day for all of our specialty hospitals increased 7.9% to $1,642 for the three months ended September 30, 2016, compared to $1,522 for the three months ended September 30, 2015, principally as a result of increases in our Medicare net revenue per patient day. The increase in our Medicare net revenue per patient day resulted primarily from the increase in patient acuity at LTCHs now operating under the Medicare patient criteria

~~regulations. Our occupancy percentage declined to 62% for the three months ended September 30, 2016, compared to 71% for the three months ended September 30, 2015.~~

~~Outpatient Rehabilitation~~. Our outpatient rehabilitation segment net operating revenues increased 25.6% to $250.7 million for the three months ended September 30, 2016, compared to $199.6 million for three months ended September 30, 2015. This increase resulted from growth in our outpatient rehabilitation clinics, offset in part by the sale of our contract therapy businesses. Patient visits in our outpatient clinics were 2,052,678 for the three months ended September 30, 2016, compared to 1,306,637 for the three months ended September 30, 2015. This increase resulted principally from our newly acquired outpatient rehabilitation clinics, as well as growth in our existing owned outpatient rehabilitation clinics. Net revenue per visit in our owned outpatient rehabilitation clinics was $102 for the three months ended September 30, 2016, compared to $103 for the three months ended September 30, 2015.

~~Concentra Segment~~. Net operating revenues were $258.5 million for the three months ended September 30, 2016, compared to $259.0 million for the three months ended September 30, 2015. Net revenue per visit was $119 and visits were 1,906,242 in the centers for the three months ended September 30, 2016, compared to net revenue per visit of $114 and 1,980,496 visits in the centers for the three months ended September 30, 2015. This decrease in visits was primarily driven by declines in consumer health and employer services. Visits related to workers compensation services were comparable in both periods. The decline in consumer health visits has resulted from our decision to emphasize our efforts on workers compensation services. The increase in revenue per visit was principally due to an increase per visit for workers compensation services.

~~Operating Expenses~~

Our operating expenses include our cost of services, general and administrative expense, and bad debt expense. Our operating expenses increased to $960.5 million, or 91.1% of net operating revenues, for the three months ended September 30, 2016, compared to $941.4 million, or 92.2% of net operating revenues, for the three months ended September 30, 2015. The increase in operating expenses is principally due to the acquisition of Physiotherapy on March 4, 2016. Our cost of services, a major component of which is labor expense, was $915.7 million, or 86.9% of net operating revenues, for the three months ended September 30, 2016, compared to $900.9 million, or 88.2% of net operating revenues, for the three months ended September 30, 2015. The decrease in cost of services as a percentage of net operating revenues resulted principally from a decrease in expenses relative to revenues at our Concentra segment as a result of cost saving initiatives we have implemented. Facility rent expense, a component of cost of services, was $58.5 million for the three months ended September 30, 2016, compared to $47.1 million for the three months ended September 30, 2015. General and administrative expenses were $27.1 million for the three months ended September 30, 2016, compared to $22.2 million for the three months ended September 30, 2015. Our bad debt expense was $17.7 million, or 1.7% of net operating revenues, for the three months ended September 30, 2016, compared to $18.3 million, or 1.8% of net operating revenues, for the three months ended September 30, 2015.

~~Adjusted EBITDA~~

~~Specialty Hospitals.~~ Adjusted EBITDA for our specialty hospitals was $48.3 million for the three months ended September 30, 2016, compared to $53.7 million for the three months ended September 30, 2015. Our Adjusted EBITDA margin for the segment was 8.9% for the three months ended September 30, 2016, compared to 9.5% for the three months ended September 30, 2015. The reduction in Adjusted EBITDA and Adjusted EBITDA margin for our specialty hospitals segment was principally attributable to Adjusted EBITDA losses resulting from start-up specialty hospitals, Adjusted EBITDA losses on newly acquired specialty hospitals, and specialty hospital closures. Start-up specialty hospitals incurred $9.0 million of Adjusted

~~EBITDA losses in the three months ended September 30, 2016, compared to $3.1 million for the three months ended September 30, 2015, as discussed under “~~~~Summary Financial Results~~~~” above.~~

~~Outpatient Rehabilitation.~~ Adjusted EBITDA for our outpatient rehabilitation segment increased 34.4% to $32.0 million for the three months ended September 30, 2016, compared to $23.8 million for the three months ended September 30, 2015. The increase in Adjusted EBITDA for our outpatient rehabilitation segment was principally attributable to clinics acquired during the year. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 12.8% for the three months ended September 30, 2016, compared to 11.9% for the three months ended September 30, 2015. The margin increase was principally due to the sale of our contract therapy businesses, which historically operated at lower Adjusted EBITDA margins.

~~Concentra Segment.~~ Adjusted EBITDA for our Concentra segment was $40.9 million for the three months ended September 30, 2016, compared to $25.6 million for the three months ended September 30, 2015. Our Adjusted EBITDA margin for the Concentra segment was 15.8% for the three months ended September 30, 2016, compared to 9.9% for the three months ended September 30, 2015. The increases in Adjusted EBITDA and Adjusted EBITDA margins were principally due to cost reductions we have implemented.

~~Other.~~ ~~Adjusted EBITDA loss was $23.1 million for the three months ended September 30, 2016, compared to an Adjusted EBITDA loss of $18.5 million for the three months ended September 30, 2015.~~

~~Depreciation and Amortization~~

~~For the three months ended September 30, 2016, depreciation and amortization expense was $37.2 million, compared to $31.5~~ ~~million for the three months ended September 30, 2015. The increase was principally due to the acquisitions of Concentra on June 1, 2015 and Physiotherapy on March 4, 2016.~~

~~Income from Operations~~

~~For the three months ended September 30, 2016, we had income from operations of $56.2 million, compared to $~~48.2 million for the three months ended September 30, 2015. The increase was principally due to the cost saving initiatives in our Concentra segment and the acquisition of Physiotherapy on March 4, 2016.

~~Loss on Early Retirement of Debt~~

On September 26, 2016, Concentra prepaid the second lien term loan under the Concentra credit facilities. The premium plus the expensing of unamortized deferred financing costs and original issuance discount resulted in a loss on early retirement of debt of $10.9 million during the three months ended September 30, 2016.

~~Equity in Earnings of Unconsolidated Subsidiaries~~

For the three months ended September 30, 2016, we had equity in earnings of unconsolidated subsidiaries of $5.3 million, compared to equity in earnings of unconsolidated subsidiaries of $6.3 million for the three months ended September 30, 2015. The decrease in our equity in earnings of unconsolidated subsidiaries was principally due to the sale of a start-up company in which we owned a non-controlling interest.

~~Non-Operating Gain (Loss)~~

For the three months ended September 30, 2016, we had a non-operating loss of $1.0 million. For the three months ended September 30, 2015, we had a non-operating gain of $29.6 million on the sale of an equity investment. The equity investment was a start-up company investment in which we owned a non-controlling interest.

~~Interest Expense~~

Interest expense was $44.5 million for the three months ended September 30, 2016, compared to $33.1 million for the three months ended September 30, 2015. The increase in interest expense was principally the result of increases in our indebtedness used to finance the acquisition of Physiotherapy on March 4, 2016, and increases in our interest rates associated with amendments of Select’s credit facilities in the fourth quarter of 2015 and the first quarter of 2016.

~~Income Taxes~~

We recorded income tax expense of $1.1 million for the three months ended September 30, 2016, which represented an effective tax rate of 21.2%. We recorded income tax expense of $18.3 million for the three months ended September 30, 2015, which represented an effective tax rate of 35.9%.

Our quarterly effective income tax rate is derived from our full year estimated effective income tax rate and can be impacted by discrete items specific to a particular quarter and quarterly changes in our full year tax provision estimate.

~~Non-controlling Interests~~

Net losses attributable to non-controlling interests were $2.5 million for the three months ended September 30, 2016, compared to net income attributable to non-controlling interests of $3.4 million for the three months ended September 30, 2015. The decrease is principally due to losses at start-up specialty hospitals as discussed under “~~Summary Financial Results~~~~” above. These amounts represent the minority owner’s share of income and losses for these consolidated entities.~~

~~Nine Months Ended September 30, 2016 Compared to Nine Months Ended September 30, 2015~~

In the following, we discuss our results of operations related to net operating revenues, operating expenses, Adjusted EBITDA, depreciation and amortization, income from operations, loss on early retirement of debt, equity in earnings of unconsolidated subsidiaries, non-operating gain, ~~(loss),~~ interest expense, income taxes, and non-controlling interest, which, in each case, are the same for Holdings and Select.

Net Operating Revenues

Our net operating revenues increased ~~by 19.8%~~2.1% to ~~$3,239.8~~$1,111.4 million for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$2,703.5~~$1,088.3 million for the ~~nine~~three months ended ~~September 30, 2015, principally due to~~March 31, 2016. The principal changes in our net operating revenues for the ~~acquisitions~~three months ended March 31, 2017 were caused by increases at our outpatient rehabilitation segment, which were driven by our acquisition of ~~Concentra on June 1, 2015 and~~ Physiotherapy on March 4, ~~2016.~~2016, offset in part by a decrease in net operating revenues due to the sale of our contract therapy businesses on March 31, 2016, and increases in net operating revenues at our Concentra segment.

Specialty Hospitals Segment.~~. Our~~ Net operating revenues were $598.8 million for the three months ended March 31, 2017, compared to $599.0 million for the three months ended March 31, 2016 for our specialty hospitals ~~segment~~segment. Net operating revenues for the three months ended March 31, 2017 were substantially unchanged compared to the three months ended March 31, 2016. We continue to experience transitions, as described below, in our specialty hospitals operations which we expect to positively impact our net operating revenues ~~declined 1.4%~~in the future.

We recently commenced specialty hospital operations at four new inpatient rehabilitation facilities which are now contributing to ~~$1,729.3 million for~~our specialty hospital net operating revenues; however, during the ~~nine~~three months ended ~~September 30, 2016, compared to $1,753.4 million for~~March 31, 2017, the ~~nine months ended September 30, 2015. The primary reason for this decrease was a decline~~contributions from these hospitals were offset by decreases in our ~~patient days which decreased~~

~~8.0% to 951,292 days for the nine months ended September 30, 2016, compared to 1,034,166 days for the nine months ended September 30, 2015. As~~net operating revenues at our LTCHs, as discussed above under “Regulatory ~~Changes —~~ Changes—Medicare Reimbursement of LTCH ~~Services —~~ Services—Patient Criteria,,” ~~new Medicare regulations, which establish new payment limits for Medicare patients discharged from an LTCH who do not meet specified patient criteria, began to be phased in to our LTCHs in~~and closed specialty hospitals. The implementation of the ~~fourth quarter of 2015. We experienced fewer Medicare patient days due to changes we implemented at LTCHs operating under the new~~ Medicare patient criteria ~~regulations, and specialty hospital closures and sales.~~regulatory changes afforded us an opportunity to adjust our LTCH operations to better align to those patients which meet LTCH patient criteria. This ~~decrease~~has resulted in ~~patient days was offset in part by~~ increases in occupancy of higher acuity patient populations at our ~~Medicare net revenue per~~LTCHs, as our LTCHs became subject to the new rules beginning October 1, 2015. Our LTCH occupancy rates, as illustrated in the table below, reveal the sequential trend showing our occupancy rate decline as our hospitals phased in the new patient ~~day.~~ criteria eligibility requirements and the subsequent case mix index improvements we experienced to date as we transitioned our services towards higher acuity patients in our LTCH operations.

	2015			2016			2017
	Occupancy Percentage		Case Mix Index	Occupancy Percentage		Case Mix Index	Occupancy Percentage		Case Mix Index
Three months ended:
March 31	71	%	1.22	71	%	1.24	68	%	1.28
June 30	70	%	1.21	67	%	1.27
September 30	70	%	1.18	61	%	1.26
December 31	70	%	1.21	63	%	1.26

Our overall specialty hospitals average net operating revenue per patient day ~~for all of our specialty hospitals~~ increased ~~5.6%~~5.1% to ~~$1,651~~$1,716 for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$1,563~~$1,632 for the ~~nine~~three months ended September 30, 2015, principally as a result of increases in our Medicare net revenue per patient day. The increase in our Medicare net revenue per patient day resulted primarily from the increase in patient acuity at LTCHs now operating under the Medicare patient criteria regulations. Our occupancy percentage declined to 67% for the nine months ended September 30, 2016, compared to 72% for the nine months ended September 30, 2015.March 31, 2016.

Outpatient Rehabilitation Segment.~~. Our~~ Net operating revenues increased 7.4% to $255.8 million for the three months ended March 31, 2017, compared to $238.1 million for the three months ended March 31, 2016 for our outpatient rehabilitation ~~segment~~segment. The increase in net operating revenues was principally due to an increase in visits from our Physiotherapy outpatient rehabilitation clinics, which we acquired on March 4, 2016, and growth in visits at our other outpatient rehabilitation clinics. Visits increased ~~23.5%~~31.7% to ~~$745.7~~2,075,790 visits for the three months ended March 31, 2017, compared to 1,576,554 visits for the three months ended March 31, 2016. Net revenue per visit was $102 for the three months ended March 31, 2017, compared to $103 for the three months ended March 31, 2016. The decrease in net revenue per visit is the result of lower per visit rates at our Physiotherapy clinics.

Concentra Segment. Net operating revenues increased 2.1% to $256.1 million for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$603.8~~$250.9 million for ~~nine~~the three months ended ~~September 30, 2015. This~~March 31, 2016 for our Concentra segment. The increase in net operating revenues was due to an increase in visits ~~resulting~~ principally from ~~our~~ newly acquired ~~outpatient rehabilitation clinics~~ and ~~growth~~developed medical centers. We had 1,886,815 visits in our ~~existing owned outpatient rehabilitation clinics. Net revenue per visit in our owned outpatient rehabilitation clinics was $102~~centers for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$103~~1,845,715 visits for the ~~nine~~three months ended ~~September 30, 2015.~~

~~Concentra Segment~~. Net operating revenues were $764.3 million for the nine months ended September 30, 2016, compared to $345.8 million for the nine months ended September 30, 2015, which includes results beginning June 1, 2015.March 31, 2016. Net revenue per visit was $118 ~~and visits were 5,642,305 in~~for both the ~~centers for the nine~~three months ended ~~September 30, 2016, compared to net revenue per visit of $114~~March 31, 2017 and ~~2,654,330 visits in the centers for the nine months ended September 30, 2015, which includes results beginning June 1, 2015.~~2016.

Operating Expenses

Our operating expenses include our cost of services, general and administrative expense, and bad debt expense. Our operating expenses increased to ~~$2,887.8~~$977.1 million, or ~~89.1%~~87.9% of net operating revenues, for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$2,420.4~~$966.9 million, or ~~89.5%~~88.8% of net operating revenues, for the ~~nine~~three months ended ~~September 30, 2015. The increase in operating expenses is principally due to the acquisitions of Concentra on June 1, 2015 and Physiotherapy on~~ March 4,31, 2016. Our cost of services, a major component of which is labor expense, was ~~$2,755.0~~$928.4 million, or ~~85.0%~~83.5% of net operating revenues, for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$2,309.2~~$922.3 million, or ~~85.4%~~84.7% of net operating revenues, for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The decrease in our relative operating expenses is principally due to the sale of our contract therapy businesses on March 31, 2016, specialty hospital closures, and cost ~~of services as a percentage of net operating revenues resulted principally from Concentra and an increase in expenses relative to revenues at our specialty hospitals.~~reductions achieved by Concentra. Facility rent expense, a component of cost of services, was ~~$167.5~~$56.5 million for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$118.2~~$52.0 million for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. General and administrative expenses were ~~$81.2~~$28.1 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2017, compared $28.3 million for the three months ended March 31, 2016, which included $3.2 million of Physiotherapy ~~acquisition costs, compared to $67.9 million for the nine months ended September 30, 2015, which included $4.7 million of Concentra~~ acquisition costs. General and administrative expenses as a percentage of net operating revenues were 2.5% for ~~both~~ the ~~nine~~three months ended September 30, 2016 and September 30, 2015. Our general and administrative function includes our shared services activities which have grown and expanded as a result of our significant business acquisitions.March 31, 2017, compared to 2.6% for the three months ended March 31, 2016. Our bad debt expense was ~~$51.6~~$20.6 million, or ~~1.6%~~1.9% of net operating revenues, for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$43.2~~$16.4 million, or ~~1.6%~~1.5% of net operating revenues, for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The increase was principally the result of increases in bad debt expense in our outpatient rehabilitation segment, primarily due to Physiotherapy, and in our Concentra segment.

Adjusted EBITDA

Specialty ~~Hospitals.~~ Hospitals Segment.Adjusted EBITDA increased 2.2% to $88.7 million for the three months ended March 31, 2017, compared to $86.8 million for the three months ended March 31, 2016 for our specialty hospitals ~~was $217.8 million for the nine months ended September 30, 2016, compared to $241.6 million for the nine months ended September 30, 2015.~~segment. Our Adjusted EBITDA margin for the segment was ~~12.6%~~14.8% for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~13.8%~~14.5% for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The ~~reduction~~increase in Adjusted EBITDA ~~and Adjusted EBITDA margin~~ for our specialty hospitals segment was principally attributable to Adjusted EBITDA losses resulting from start-up hospitals, Adjusted EBITDA losses of newly acquired specialty hospitals, and specialty hospital closures. Start-up specialty hospitals incurred $19.4 million ofprimarily driven by reductions in Adjusted EBITDA losses in ~~the nine months ended September 30, 2016, compared to $11.9~~our start-up specialty hospitals. Adjusted EBITDA losses in our start-up specialty hospitals were $2.0 million for the ~~nine~~three months ended ~~September 30, 2015, as discussed under “~~March 31, 2017, compared to $3.8 million for the three months ended March 31, 2016.

~~Summary Financial Results~~Outpatient Rehabilitation Segment.~~” above. We also experienced a decline~~ Adjusted EBITDA increased 8.6% to $31.4 million for the three months ended March 31, 2017, compared to $28.9 million for the three months ended March 31, 2016 for our outpatient rehabilitation segment. The increase in Adjusted EBITDA infor our ~~LTCHs as a~~outpatient rehabilitation segment was principally the result of ~~a decrease~~increases in ~~patient days~~net operating revenues, as discussed above under “Net Operating Revenues.”

~~Outpatient Rehabilitation.~~ Adjusted EBITDA for our outpatient rehabilitation segment increased 32.6% to $99.0 million for the nine months ended September 30, 2016, compared to $74.7 million for the nine months ended September 30, 2015. This increase was principally due to the acquisition of Physiotherapy on March 4, 2016. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was ~~13.3%~~12.3% for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~12.4%~~12.1% for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The increase was principally due to the sale of our contract therapy businesses on March 31, 2016, which ~~historically~~ operated at lower Adjusted EBITDA ~~margins.~~margins than our outpatient rehabilitation clinics.

Concentra Segment. Adjusted EBITDA increased 24.7% to $42.6 million for the three months ended March 31, 2017, compared to $34.2 million for the three months ended March 31, 2016 for our Concentra ~~segment was $118.1 million for the nine months ended September 30, 2016, compared to $36.8 million for the nine months ended September 30, 2015, which includes results beginning June 1, 2015.~~segment. Our Adjusted EBITDA margin for the Concentra segment was ~~15.5%~~16.6% for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~10.6%~~13.6% for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The ~~increases~~increase in Adjusted EBITDA ~~and Adjusted EBITDA margins were~~for our Concentra segment was principally ~~due to~~the result of cost reductions we have ~~implemented.~~achieved.

Other. The Adjusted EBITDA loss was ~~$66.7~~$23.7 million for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to an Adjusted EBITDA loss ~~of $54.7~~was $21.2 million for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016.

Depreciation and Amortization

~~For the nine months ended September 30, 2016, depreciation~~Depreciation and amortization expense was ~~$107.9 million, compared to $70.7~~$42.5 million for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2017, compared to $34.5 million for the three months ended March 31, 2016. The increase was principally due to ~~the acquisitions of Concentra on June 1, 2015,~~new inpatient rehabilitation facilities operating in our specialty hospitals segment and Physiotherapy, which we acquired on March 4, 2016.

Income from Operations

For the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, we had income from operations of ~~$244.1~~$91.8 million, compared to ~~$212.5~~$86.9 million for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The increase ~~was~~resulted principally ~~due to~~from the ~~acquisitions of~~improved operating performance in our Concentra ~~on June 1, 2015, and Physiotherapy on March 4, 2016.~~segment.

Loss on Early Retirement of Debt

OnDuring the three months ended March ~~4, 2016,~~31, 2017, we ~~prepaid the Series D Tranche B Term Loans under the Select~~refinanced Select’s senior secured credit facilities, which consisted of the series E tranche B term loans due June 1, 2018, the series F tranche B term loans due March 31, 2021, and the revolving facility maturing March 1, 2018, which resulted in ~~the recognition of approximately a $0.8 million loss on early retirement of debt. On September 26, 2016, Concentra prepaid the second lien term loan under the Concentra credit facilities. The~~

~~premium plus the expensing of unamortized deferred financing costs and original issuance discount resulted in a loss~~losses on early retirement of debt of ~~approximately $10.9~~$19.7 million.

Equity in Earnings of Unconsolidated Subsidiaries

For the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, we had equity in earnings of unconsolidated subsidiaries of ~~$14.5~~$5.5 million, compared ~~to equity in earnings of unconsolidated subsidiaries of $12.8~~$4.7 million for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The increase in our equity in earnings of unconsolidated subsidiaries resulted principally from ~~increased earnings associated with several of~~improved performance in our inpatient rehabilitation ~~joint ventures~~businesses in which we ~~own~~have a ~~non-controlling~~minority interest.

Non-Operating Gain

~~The Company~~We recognized a non-operating gain of ~~$42.1~~$25.1 million ~~for~~during the ~~nine~~three months ended September 30, 2016. The Company sold its contract therapy businesses for $65.0 million, resulting in a non-operating gain of $33.9 million. The Company also transferred five specialty hospitals in an exchange transaction and sold nine outpatient rehabilitation clinics,March 31, 2016, principally due to ~~a non-consolidating subsidiary, which resulted in non-operating gains of $6.5 million and $1.7 million, respectively,~~ ~~as discussed above under “~~~~Significant Events~~~~.” Additionally, during the nine months ended September 30, 2016, an entity in which the Company owned a non-controlling interest was sold, which resulted in a non-operating loss of $5.1 million.~~

~~For the nine months ended September 30, 2015, we had a non-operating gain of $29.6 million on~~ the sale of ~~an equity investment. The equity investment was a start-up company investment in which we owned a non-controlling interest.~~our contract therapy businesses.

Interest Expense

Interest expense was ~~$127.7~~$40.9 million for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$79.7~~$38.8 million for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The increase in interest expense was principally the result of increases in our indebtedness ~~used to finance~~as a result of the ~~acquisitions~~acquisition of Concentra on June 1, 2015 and Physiotherapy on March 4, 2016, and increases in our interest rates associated with amendments of Select’s credit facilities in the fourth quarter of 2015 and the first quarter of 2016.Physiotherapy.

Income Taxes

We recorded income tax expense of ~~$51.6~~$13.2 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2017, which represented an effective tax rate of 36.0%. We recorded income tax expense of $17.1 million for the three months ended March 31, 2016, which represented an effective tax rate of ~~33.0%~~22.2%. ~~We recorded income tax expense of $65.0 million for the nine months ended September 30, 2015, which represented an~~Our effective tax rate ~~of 37.1%.~~

Our effective income tax rate is derived from our full year estimated effective income tax rate and can be impacted by discrete items specific to a particular quarter and quarterly changes in our full year tax provision estimate. Onfor the three months March 31, 2016 ~~we sold~~benefited from the sale of our contract therapy businesses. ~~For tax purposes, the sale was treated as a discrete tax event particular to the first quarter of 2016.~~ Our tax basis in our contract therapy businesses exceeded our selling price. As a result, we had no tax expense from the sale. Additionally, during the nine months ended September 30, 2016, we exchanged five specialty hospitals in a hospital swap transaction. For tax purposes, the exchange was treated as a discrete tax event particularrelated to the ~~second quarter~~gain on the sale of ~~2016. Our tax basis in the five specialty hospitals was less than~~ our book basis and resulted in a tax gain exceeding our book gain. The lower effective tax rate for the nine months ended September 30, 2016 resulted from the effects of the two discrete tax events discussed above.contract therapy businesses.

Net Income Attributable to Non-Controlling Interests

~~Non-controlling~~Net income attributable to non-controlling interests ~~in consolidated earnings were $9.6~~was $7.6 million for the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2017, compared to ~~$8.7~~$5.1 million for the ~~nine~~three months ended ~~September 30, 2015.~~March 31, 2016. The increase is principally due ~~to the acquisition of Concentra, offset in part by~~ the minority interest owners’ share of ~~losses~~income from ~~new specialty hospitals.~~Concentra.

Liquidity and Capital Resources

Cash Flows for the ~~Nine~~Three Months Ended ~~September 30, 2016~~March 31, 2017 and ~~Nine~~Three Months Ended ~~September 30, 2015~~March 31, 2016

For the Nine Months Ended
September 30,

2015

2016

(in thousands)

Cash provided by operating activities

$
203,431

$
280,247

Cash used in investing activities

(1,130,929
)
(463,002
)
Cash provided by financing activities

946,779

236,543

Increase in cash and equivalents

19,281

53,788

Cash and equivalents at beginning of period

3,354

14,435

Cash and equivalents at end of period

$
22,635

$
68,223

In the following, we discuss cash flows from operating activities, investing activities, and financing activities, which, in each case, are the same for Holdings and Select.

	Three Months Ended March 31,
	2016			2017
	(in thousands)
Cash flows provided by (used in) operating activities	$	111,168		$	(55,861	)
Cash flows used in investing activities	(397,674		)	(41,207		)
Cash flows provided by financing activities	357,479			63,250
Net increase (decrease) in cash and cash equivalents	70,973			(33,818		)
Cash and cash equivalents at beginning of period	14,435			99,029
Cash and cash equivalents at end of period	$	85,408		$	65,211

Operating activities ~~provided $280.2~~used $55.9 million of cash flows for the ~~nine~~three months ended ~~September 30, 2016, compared to $203.4 million of cash flows provided for the nine months ended September 30, 2015.~~March 31, 2017. The ~~increase~~decrease in operating cash flows for the ~~nine~~three months ended ~~September 30, 2016~~March 31, 2017 compared to the ~~nine~~three months ended ~~September 30, 2015~~March 31, 2016 is principally due to ~~cash flows provided from Concentra which was acquired on June 1, 2015, Physiotherapy which was acquired on March 4, 2016, and cash distributions we received from unconsolidated investments~~increases in ~~which we are minority owners.~~

our accounts receivable. Our days sales outstanding ~~were 52~~was 56 days at ~~September 30, 2016,~~March 31, 2017, compared to 5351 days at December 31, ~~2015~~2016 and 52 days at ~~September 30, 2015.~~March 31, 2016. Our days sales outstanding will fluctuate based upon variability in our collection cycles. ~~Our~~The increase in our days sales outstanding ~~at September 30, 2016, December 31, 2015~~ and ~~September 30, 2015 all fall within~~related decline in our ~~expected range.~~operating cash flows is primarily related to the current underpayments we are receiving through the periodic interim payment program from Medicare in our LTCHs. These underpayments will be corrected in future months as our periodic interim payments are reconciled and reset by our fiscal intermediaries.

Investing activities used ~~$463.0~~$41.2 million for the three months ended March 31, 2017. The principal use of cash was $50.7 million for purchases of property and equipment and $9.6 million for the acquisition of Concentra centers and outpatient rehabilitation clinics, offset in part by $19.5 million of proceeds from the sale of assets. Investing activities used $397.7 million of cash flow for the ~~nine~~three months ended ~~September 30,~~March 31, 2016, principally due to the acquisition of Physiotherapy. Investing activities also included $118.3 million for purchases of property and equipment, offset in part by proceeds from the sale of businesses of $71.4 million. Investing activities used $1,130.9 million of cash flow for the nine months ended September 30, 2015, principally due to $1,047.2 million related to the Concentra acquisition and $114.0 million for purchases of property and equipment.

Financing activities ~~for Select~~ provided ~~$236.5~~$63.3 million of cash ~~flow~~flows for the ~~nine~~three months ended ~~September 30,~~March 31, 2017. The principal source of cash was net borrowings under the Select revolving facility of $115.0 million, offset by cash used for financing costs, and $23.1 million of cash used for a principal prepayment associated with the Concentra credit facilities.

Financing activities provided $357.5 million of cash flows for the three months ended March 31, 2016. The principal source of cash was the issuance of $625.0 million aggregate principal amount of ~~Series~~series F ~~Tranche~~tranche B ~~Term Loans under the Select credit facilities, resulting in~~term loans, net ~~proceeds~~ of ~~$600.1~~discounts and debt issuance costs of $24.9 million, offset by $215.7 million of cash used to repay the ~~Series~~series D ~~Tranche~~tranche B ~~Term Loans under the Select credit facilities and $125.0 million of net repayments under the Select and Concentra revolving facilities.~~

Financing activities provided $946.8 million of cash flow for the nine months ended September 30, 2015. The principal sources of cash for financing activities were $165.0 million of net borrowings under the Select revolving facility, $646.9 million borrowed under the Concentra credit facilities, and $217.1 million attributable to a non-consolidating interest in Group Holdings.term loans.

Capital Resources

Working ~~capital~~capital. - We had net working capital of ~~$255.4~~$305.7 million at ~~September 30, 2016 compared~~March 31, 2017, compare to ~~net working capital of $19.9~~$191.3 million at December 31, ~~2015.~~2016. The increase in net working capital is primarily due to ~~the early retirement of Series D Tranche B Term Loans, which were classified as a current liability at December 31, 2015, and~~ an increase in ~~cash over the nine months ended September 30, 2016.~~our accounts receivable.

Select credit ~~facilities~~facilities. - On March ~~2, 2016,~~6, 2017, Select ~~made~~entered into a ~~principal prepayment~~new senior secured credit agreement that provides for $1.6 billion in senior secured credit facilities comprising a $1.15 billion, seven-year term loan and a $450.0 million, five-year revolving credit facility, including a $75.0 million sublimit for the issuance of ~~$10.2 million associated with the~~standby letters of credit. Select ~~term loans in accordance with the provision in~~used borrowings under the Select credit facilities ~~that requires mandatory prepayments of~~to: (i) repay the ~~Select~~series E tranche B term loans ~~as a result of annual excess cash flow as defined~~due June 1, 2018, the series F tranche B term loans due March 31, 2021, and the revolving facility due March 1, 2018 under its then existing credit facilities; and (ii) pay fees and expenses in connection with the refinancing.

Borrowings under the Select credit ~~facilities.~~

On March 4, 2016, Select entered into an Additional Credit Extension Amendment (the “Additional Credit Extension Amendment”) to Select’s senior secured credit facility with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent and lender, and the additional lenders named therein (the “Select credit facilities”). The Additional Credit Extension Amendment (i) provided for the lenders named therein to make available an aggregate of $625.0 million of Series F Tranche B Term Loans, (ii) extended the financial covenants through March 3, 2021, (iii) added a 1.00% prepayment premium for prepayments made with new term loans on or prior to March 4, 2017 if such new term loans have a lower yield than the Series F Tranche B Term Loans, and (iv) made certain other technical amendments to the Select credit facilities. The Series F Tranche B Term Loansfacilities bear interest at a rate ~~per annum~~ equal toto: (i) in the case of the Select term loan, Adjusted LIBO ~~Rate~~ (as defined in the Select credit ~~facilities, subject~~agreement) plus 3.50% (subject to an Adjusted LIBO ~~Rate~~ floor of 1.00%) ~~plus 5.00% for Eurodollar Loans~~, or ~~the~~ Alternate Base Rate (as defined in the Select credit ~~facilities)~~agreement) plus ~~4.00% for~~2.50% (subject to an Alternate Base Rate ~~Loans (as defined~~floor of 2.00%); and (ii) in the case of the Select ~~credit facilities).~~revolving facility, Adjusted LIBO plus a percentage ranging from 3.00% to 3.25% or Alternate Base Rate plus a percentage ranging from 2.00% to 2.25%, in each case based on Select’s leverage ratio.

The Select ~~is required to make principal payments on the Series F Tranche B Term Loans~~term loan amortizes in equal quarterly installments ~~on the last day of each of March, June, September and December, beginning June 30, 2016,~~ in amounts equal to 0.25% of the aggregate original principal amount of the ~~Series F Tranche B Term Loans outstanding as of the date of the Additional Credit Extension Amendment.~~Select term loan commencing on June 30, 2017. The balance of the ~~Series F Tranche B Term Loans is~~Select term loan will be payable on March 3,8, 2024; however, if the Select 6.375% senior notes, which are due June 1, 2021, are outstanding on March 1, 2021, the maturity date for the Select term loan will become March 1, 2021. ~~Except as specifically set forth in~~The Select revolving facility will be payable on March 8, 2022; however, if the ~~Additional Credit Extension Amendment,~~Select 6.375% senior notes are outstanding on February 1, 2021, the ~~terms and conditions of~~maturity date for the ~~Series F Tranche B Term Loans are identical~~Select revolving facility will become February 1, 2021.

Select will be required to ~~the terms of the outstanding Series E Term B Loans~~prepay borrowings under the Select credit facilities ~~and the other loan documents to which Select is party.~~

~~Select used the proceeds~~with (i) 100% of the Series F Tranche B Term Loans to (i) refinance in full the Series D Tranche B Term Loans due December 20, 2016, (ii) consummate the acquisition of Physiotherapy, and (iii) pay fees and expenses incurred in connection with the acquisition of Physiotherapy, the refinancing, and the Additional Credit Extension Amendment.

Asnet cash proceeds received from non-ordinary course asset sales or other dispositions, or as a result of ~~the Additional Credit Extension Amendment relating~~a casualty or condemnation, subject to reinvestment provisions and other customary carveouts and, to the ~~Series F Tranche B Term Loans,~~extent required, the payment of certain indebtedness secured by liens having priority over the debt under the Select credit facilities or subject to a first lien intercreditor agreement, (ii) 100% of the net cash proceeds received from the issuance of debt obligations other than certain permitted debt obligations, and (ii) 50% of excess cash flow (as defined in the Select credit agreement) if Select’s leverage ratio is greater than 4.50 to 1.00 and 25% of excess cash flow if Select’s leverage ratio is less than or equal to 4.50 to 1.00 and greater than 4.00 to 1.00, in each case, reduced by the aggregate amount of term loans, revolving loans and certain other debt optionally prepaid during the applicable fiscal year. Select will not be required to prepay borrowings with excess cash flow if Select’s leverage ratio is less than or equal to 4.00 to 1.00.

The Select revolving facility requires Select to maintain a leverage ratio (as defined in the Select credit agreement), which is tested quarterly, not to exceed 6.25 to 1.00. After March 31, 2019, the leverage ratio must not exceed 6.00 to 1.00. Failure to comply with this covenant would result in an event of default under the Select revolving facility and, absent a waiver or an amendment from the revolving lenders, preclude Select from making further borrowings under the Select revolving facility and permit the revolving lenders to accelerate all outstanding borrowings under the Select revolving facility. The termination of the Select revolving facility commitments and the acceleration of amounts outstanding thereunder would constitute an event of default with respect to the Select term loan. As of March 31, 2017, Select’s leverage ratio was 6.01 to 1.00.

The Select credit facilities also contain a number of other affirmative and restrictive covenants, including limitations on mergers, consolidations and dissolutions; sales of assets; investments and acquisitions; indebtedness; liens; affiliate transactions; and dividends and restricted payments. The Select credit facilities contain events of default for non-payment of principal and interest ~~rate payable on~~when due (subject, as to interest, to a grace period), cross-default and cross-acceleration provisions and an event of default that would be triggered by a change of control.

Borrowings under the ~~Series E Tranche B Term Loans was increased from Adjusted LIBO plus 4.00% (subject~~Select credit facilities are guaranteed by Holdings and substantially all of Select’s current domestic subsidiaries and will be guaranteed by substantially all of Select’s future domestic subsidiaries and secured by substantially all of Select’s existing and future property and assets and by a pledge of Select’s capital stock, the capital stock of Select’s domestic subsidiaries and up to ~~an Adjusted LIBO rate floor~~65% of ~~1.00%),~~the capital stock of Select’s foreign subsidiaries held directly by Select or ~~Alternative Base Rate plus 3.00%, to Adjusted LIBO plus 5.00% (subject to an Adjusted LIBO rate floor of 1.00%), or Alternative Base Rate plus 4.00%.~~a domestic subsidiary.

At ~~September 30, 2016,~~March 31, 2017, Select had outstanding borrowings under the Select credit facilities of ~~$1,149.3~~the $1,150.0 million of Select term ~~loans~~loan (excluding unamortized discounts and debt issuance costs of ~~$27.7~~$27.9 million) and borrowings of ~~$175.0~~$335.0 million (excluding letters of credit) under the Select revolving facility. ~~After giving effect to $39.7 million of outstanding letters of credit at September 30, 2016,~~At March 31, 2017, Select had ~~$235.3~~$74.1 million of availability under the Select revolving ~~facility.~~

~~The Select credit facilities require Select~~facility after giving effect to maintain certain leverage ratios (as defined in the Select credit facilities). For the quarter ended September 30, 2016, Select was required to maintain its leverage ratio at less than 5.75 to 1.00. Select’s leverage ratio was 5.11 to 1.00 as$40.9 million of ~~September 30, 2016.~~outstanding letters of credit.

Concentra credit ~~facilities~~facilities. - Select and Holdings are not parties to the Concentra credit facilities and are not obligors with respect to Concentra’s debt under such agreements. While this debt is non-recourse to Select, it is included in Select’s consolidated financial statements.

On ~~September 26, 2016,~~March 1, 2017, Concentra ~~entered into Amendment No. 1 (the “Concentra Credit Agreement Amendment”) to~~made a principal prepayment of $23.1 million associated with its first lien credit agreement (the “Concentra first lien credit agreement”) dated June 1, 2015. The Concentra first lien credit agreement initially provided for $500.0 million in first lien credit facilities composed of $450.0 million, seven-year term loans (“Concentra first lien term loan”) and a $50.0 million, five-year revolving credit facility (“Concentra revolving facility”).

~~The Concentra Credit Agreement Amendment provided an additional $200.0 million of~~ first lien term loans ~~due June 1, 2022,~~in accordance with the ~~proceeds~~provision in the Concentra credit facilities that requires mandatory prepayments of ~~which were used to prepay in full Concentra’s second lien~~ term ~~loan due June 1, 2023; and also amended certain restrictive covenants to give Concentra greater operational flexibility.~~

~~The Concentra first lien term loan continues to bear interest at~~loans as a ~~rate equal to Adjusted LIBO (as~~result of annual excess cash flow, as defined in the Concentra ~~first lien~~ credit agreement) plus 3.00% (subject to an Adjusted LIBO floor of 1.00%), or Alternate Base Rate (as defined in the Concentra first lien credit agreement) plus 2.00% (subject to an Alternate Base Rate floor of 2.00%). The Concentra first lien term loan amortizes in equal quarterly installments of $1.6 million through March 31, 2022, with the remaining unamortized aggregate principal due on the maturity date.facilities.

At ~~September 30, 2016,~~March 31, 2017, Concentra had outstanding borrowings ~~of $643.9 million~~ under the Concentra ~~term loans~~credit facilities of $619.2 million (excluding unamortized discounts and debt issuance costs of ~~$16.6~~$15.1 million). of first lien term loans. Concentra did not have any borrowings under the Concentra revolving facility. ~~After~~At March 31, 2017, Concentra had $43.4 million of availability under its revolving facility after giving effect to $6.6 million of outstanding letters of ~~credit at September 30, 2016, Concentra had $43.4 million of availability under its revolving facility.~~credit.

Stock Repurchase ~~Program~~Program. - Holdings’ board of directors has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2017, and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings ~~is funding~~funds this program with cash on hand and borrowings under ~~Select’s~~the Select revolving ~~credit~~ facility. Holdings did not repurchase shares during the ~~nine~~three months ended ~~September 30, 2016.~~March 31, 2017. Since the inception of the program through ~~September 30, 2016,~~March 31, 2017, Holdings has repurchased 35,924,128 shares at a cost of approximately $314.7 million, or $8.76 per share, which includes transaction costs.

~~Liquidity~~Liquidity. - We believe our internally generated cash flows and borrowing capacity under the Select and Concentra credit facilities will be sufficient to finance operations over the next twelve months. We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on

prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Use of Capital ~~Resources~~Resources. - We may from time to time pursue opportunities to develop new joint venture relationships with significant health systems and other healthcare providers, and from time to time we may also develop new inpatient rehabilitation ~~hospitals.~~hospitals and occupational medicine centers. We also intend to open new outpatient rehabilitation clinics in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth. In addition to our development activities, we may grow ~~our business~~ through opportunistic acquisitions.

Recent Accounting Pronouncements

In ~~August 2016,~~February 2017, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) ~~2016-15,~~ 2017~~Statement~~-05, Other Income—Gains and Losses from the Derecognition of ~~Cash Flows~~Nonfinancial Assets (Subtopic 610-20) —Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Asset. The standard provides guidance for recognizing gains and losses from the transfer of nonfinancial assets and in-substance non-financial assets in contracts with non-customers, unless other specific guidance applies. The standard requires a company to derecognize nonfinancial assets once it transfers control. Additionally, when a company transfers its controlling interest in a nonfinancial asset, but retains a noncontrolling ownership interest, the company is required to measure any non-controlling interest it receives or retains at fair value. The standard will be effective for fiscal years beginning after December 15, 2017. The standard requires the selection of a retrospective or cumulative effect transition method. The Company is currently evaluating the standard to determine the impact it will have on its consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic ~~230)~~805), ~~Classification~~ Clarifying the Definition of ~~Certain Cash Receipts and Cash Payments~~a Business, which ~~addresses~~clarifies the ~~diversity~~definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. ASU 2017-01 states that if substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in ~~practice in how certain cash receipts~~a single identifiable asset or a group of similar identifiable assets, the transaction should be accounted for as an asset acquisition. In addition, the ASU clarifies the requirements for a set of activities to be considered a business and ~~cash payments are presented~~narrows the definition of an output. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and ~~classified in~~consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017. Early adoption is permitted.

In October 2016, the ~~statement~~FASB issued ASU 2016-16, Income Taxes (Topic 740), Intra-Entity Transfers of ~~cash flows.~~Assets Other Than Inventory. Current GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The ASU requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard will be effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the standard to determine the impact it will have on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. This ASU includes a lessee accounting model that recognizes two types of leases; finance and operating. This ASU requires that a lessee recognize on the balance sheet assets and liabilities for all leases with lease terms of more than twelve months. Lessees will need to recognize almost all leases on the balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained the dual model, requiring leases to be classified as either operating or finance. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will depend on its classification as a finance or operating lease. For short-term leases of twelve months or less, lessees are permitted to make an accounting election by class of underlying asset not to recognize right-of-use assets or lease liabilities. If the alternative is elected, lease expense would be recognized generally on the straight-line basis over the respective lease term.

~~beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the standard to determine the impact it will have on its consolidated financial statements.~~operations.

The Company’s remaining implementation efforts will be focused principally on refining the accounting processes, disclosure processes, and internal controls.

Recently Adopted Accounting Pronouncements

In ~~April and August~~November 2015, the FASB issued ASU ~~2015-03 and ASU 2015-15, each titled~~No. 2015-17, ~~Interest- Imputation~~Balance Sheet Classification of ~~Interest~~Deferred Taxes, ~~to simplify~~which changed the presentation of ~~debt issuance costs.~~deferred income taxes. The standard ~~requires debt issuance costs~~changed the presentation of deferred income taxes through the requirement that all deferred tax liabilities and assets be ~~presented~~classified as noncurrent in ~~the balance sheet as~~ a ~~direct deduction from the carrying value~~classified statement of ~~the debt liability. The FASB clarified that debt issuance costs related to line-of-credit arrangements can be presented as an asset and amortized over the term of the arrangement.~~financial position. The Company adopted the standard on January 1, 2017. The consolidated balance sheet at ~~the beginning~~December 31, 2016 has been retrospectively adjusted. Adoption of the ~~first quarter of 2016. The balance sheet~~new standard impacted the Company’s previously reported results as of December 31, 2015 was retrospectively conformed to reflect the adoption of the standard and approximately $38.0 million of unamortized debt issuance costs were reclassified to be a direct reduction of debt, rather than a component of other assets.follows:

	December 31, 2016
	As Reported		As Adjusted
	(in thousands)
Current deferred tax asset	$	45,165	$	—
Total current assets	808,068		762,903
Other assets	152,548		173,944
Total assets	4,944,395		4,920,626

Non-current deferred tax liability	222,847		199,078
Total liabilities	3,616,335		3,592,566
Total liabilities and equity	4,944,395		4,920,626

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

~~Quantitative and Qualitative Disclosures about Market Risk~~

We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under the Select credit facilities and Concentra credit facilities.

As of ~~September 30, 2016,~~March 31, 2017, Select had ~~$1,149.3~~a $1,150.0 million term loan (excluding unamortized discounts and debt issuance ~~costs) in term loans~~discounts) outstanding ~~under the Select credit facilities~~ and ~~$175.0~~$335.0 million in revolving borrowings outstanding under the Select credit facilities, which bear interest at variable rates.

As of ~~September 30, 2016,~~March 31, 2017, Concentra had ~~outstanding borrowings under the Concentra credit facilities of $643.9~~$619.2 million (excluding unamortized discounts and debt issuance costs) ofin term loans outstanding under the Concentra credit facilities, which bear interest at variable rates. Concentra did not have any outstanding revolving ~~borrowings.~~ borrowings at March 31, 2017.

Certain of Select’s and Concentra’s outstanding borrowings that bear interest at variable rates ~~were~~may be effectively fixed ~~as of September 30, 2016~~ based upon then current interest rates ~~because~~if the Adjusted LIBO Rate ~~did~~does not ~~then~~ exceed the applicable Adjusted LIBO Rate floors for such borrowings:

· ~~Select’s aggregate $527.4~~The $1,150.0 million in Series E Tranche B Term Loans are subject to an Adjusted LIBO Rate floor of 1.00%. Therefore, until the Adjusted LIBO Rate exceeds 1.00%, Select’s interest rate on this indebtedness is effectively fixed at 6.00%.

· Select’s aggregate $621.9 million in Series F Tranche B Term Loans are subject to an Adjusted LIBO Rate floor of 1.00%. Therefore, until the Adjusted LIBO Rate exceeds 1.00%, Select’s interest rate on this indebtedness is effectively fixed at 6.00%.

· ~~The $643.9 million Concentra first lien~~Select term loan is subject to an Adjusted LIBO Rate floor of 1.00%. Therefore, ~~until~~if the Adjusted LIBO Rate ~~exceeds~~does not exceed 1.00%, Select’s interest rate on this indebtedness is effectively fixed at 4.50%.

· The $619.2 million Concentra first lien term loans are subject to an Adjusted LIBO Rate floor of 1.00%. Therefore, if the Adjusted LIBO Rate does not exceed 1.00%, Concentra’s interest rate on this indebtedness is effectively fixed at 4.00%.

However, the Select and Concentra revolving borrowings are not subject to an Adjusted LIBO Rate floor.

The following table summarizes the impact of hypothetical increases in market interest rates as of ~~September 30, 2016~~March 31, 2017 on our consolidated interest expense over the subsequent twelve month period:

Increase in
Market
Interest Rate

Interest Rate Expense
Increases Per Annum
(in thousands)(1)

0.25
%
2,230.7

0.50
%
7,151.1

0.75
%
12,071.6

1.00
%
16,992.1

Increase in Market Interest Rate		Interest Rate Expense Increases Per Annum (in thousands)(1)
0.25	%	$	5,260
0.50	%	10,521
0.75	%	15,781
1.00	%	21,042

(1) Based on the 3-month LIBOR rate of ~~0.85%~~1.15% as of ~~September 30, 2016, a change~~March 31, 2017, an increase in interest rates of up to 0.15% would only increase interest expense with respect to the Select and Concentra revolving borrowings, which are not subject to an Adjusted LIBO Rate floor. Increases in interest rates greater than 0.15% as of September 30, 2016 would impact the interest rate paid on ~~all of~~ Select’s and Concentra’s variable rate debt, as indicated in the table above.

ITEM 4.CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective as of ~~September 30, 2016~~March 31, 2017 to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized, and reported within the time periods specified in the relevant SEC rules and forms.

~~Physiotherapy Acquisition~~

On March 4, 2016, Select consummated the acquisition of Physiotherapy. SEC guidance permits management to omit an assessment of an acquired business’ internal control over financial reporting from management’s assessment of internal control over financial reporting for a period not to exceed one year from the date of the acquisition.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the ~~third~~first quarter ended ~~September 30, 2016~~March 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

~~Litigation~~

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, CMS or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

Evansville Litigation.

not to intervene. On June 19, 2015, the ~~U.S.~~United States Department of Justice notified the District Court of its decision not to intervene in the ~~case, and the District Court thereafter approved a case management plan imposing certain deadlines.~~case.

and premature discharging of patients with the requisite particularity, and dismissed those claims. The District Court declined to dismiss the plaintiff-relators’ claims arising from conduct from and after March 23, 2010 relating to delayed discharging of patients and ~~upcoding~~up-coding and the plaintiff-relators’ retaliation claims.

Knoxville Litigation.

Wilmington Litigation

ITEM 1A. RISK FACTORS

There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, ~~2015.~~2016.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Issuer

Holdings’ board of directors has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2017 and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings did not repurchase shares during the three months ended ~~September 30, 2016~~March 31, 2017 under the authorized common stock repurchase program.

The following table provides information regarding repurchases of our common stock during the three months ended ~~September 30, 2016:~~March 31, 2017:

Total Number of
Shares Purchased(1)

Average Price
Paid Per Share

Total Number of Shares
Purchased as Part of
Publically Announced
Plans or Programs

Approximate
Dollar Value of Shares that
May Yet Be Purchased
Under Plans or Programs

July 1 - July 31, 2016

—

$
—

—

$
185,249,408

August 1 - August 31, 2016

—

—

—

185,249,408

September 1 - September 30, 2016

116,975

12.26

—

185,249,408

Total

116,975

$
12.26

—

$
185,249,408

	Total Number of Shares Purchased(1)	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publically Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
January 1 - January 31, 2017	1,868	$	13.25	—	$	185,249,408
February 1 - February 28, 2017	10,350	12.70		—	185,249,408
March 1 - March 31, 2017	—	—		—	185,249,408
Total	12,218	$	12.78	—	$	185,249,408

(1) Represents shares of common stock surrendered to us to satisfy tax withholding obligations associated with the vesting of restricted shares issued to employees, pursuant to the provisions of our equity incentive plans.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not ~~applicable.~~applicable

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The exhibits to this report are listed in the Exhibit Index appearing on page 6849 hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrants have duly caused this Report to be signed on their behalf by the undersigned, thereunto duly authorized.

	SELECT MEDICAL CORPORATION


	By:	/s/ Martin F. Jackson
		Martin F. Jackson
		Executive Vice President and Chief Financial Officer
		(Duly Authorized Officer)

	By:	/s/ Scott A. Romberger
		Scott A. Romberger
		Senior Vice President, Chief Accounting Officer and Controller
		(Principal Accounting Officer)
Dated: ~~November 3, 2016~~May 4, 2017


	SELECT MEDICAL HOLDINGS CORPORATION


	By:	/s/ Martin F. Jackson
		Martin F. Jackson
		Executive Vice President and Chief Financial Officer
		(Duly Authorized Officer)

	By:	/s/ Scott A. Romberger
		Scott A. Romberger
		Senior Vice President, Chief Accounting Officer and Controller
		(Principal Accounting Officer)
Dated: ~~November 3, 2016~~May 4, 2017

EXHIBIT INDEX

~~Exhibit~~Number		Description

10.1		~~Third Amendment to the Lease~~Credit Agreement, ~~dated September 19, 2016, between Old Gettysburg II, LP and Select Medical Corporation.~~

~~10.2~~		~~Amendment No. 1,~~ dated as of ~~September 26, 2016,~~March 6, 2017, among ~~Concentra Inc., Concentra~~Select Medical Holdings ~~Inc., JP Morgan~~Corporation, Select Medical Corporation, JPMorgan Chase Bank, ~~N.A,~~N.A., as ~~the administrative agent, collateral agent~~Administrative and ~~lender~~Collateral Agent, Wells Fargo Securities, LLC and Deutsche Bank Securities Inc., as Co-Syndication Agents and RBC Capital Markets, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Goldman Sachs Bank USA, PNC Bank, National Association and Morgan Stanley Senior Funding, Inc., as CoDocumentation Agents and the ~~additional~~other lenders ~~named therein,~~and issuing banks party thereto, incorporated ~~herein~~ by reference to Exhibit 10.1 of the Current Report on Form 8-K of Select Medical Holdings Corporation and Select ~~Medical Corporation~~ filed on ~~September 28, 2016 (Reg.~~March 7, 2017 (Reg Nos. ~~001-34405~~001- 34465 and ~~001-31441)~~001-314411).

~~10.3~~10.2		~~Office Lease~~Change of Control Agreement, dated ~~as of October 28, 2016,~~February 16, 2017, between Select Medical Corporation and ~~Old Gettysburg Associates V, L.P.~~John A. Saich.

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended ~~September 30, 2016~~March 31, 2017 formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2017 and 2016, ~~and 2015,~~ (ii) Condensed Consolidated Balance Sheets as of ~~September 30, 2016~~March 31, 2017 and December 31, ~~2015,~~2016, (iii) Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~September 30,~~March 31, 2017 and 2016, ~~and 2015,~~ (iv) Condensed Consolidated Statements of Changes in Equity and Income for the ~~nine~~three months ended ~~September 30, 2016~~March 31, 2017 and (v) Notes to Condensed Consolidated Financial Statements.

6849

Delaware ~~Delaware~~ ~~(State or other jurisdiction of~~ ~~incorporation or organization)~~		20-1764048
Delaware	23-2872718
(State or Other Jurisdiction of	(I.R.S. ~~employer identification~~ ~~number)~~Employer
Incorporation or Organization)	Identification Number)

Large accelerated filer x		Accelerated filer o

Non-accelerated filer o		Smaller reporting company o
(Do not check if a smaller reporting company)		~~Smaller reporting company~~Emerging Growth Company o

Large accelerated filer o		Accelerated filer o

Non-accelerated filer x		Smaller reporting company o
(Do not check if a smaller reporting company)		~~Smaller reporting company~~Emerging Growth Company o

	Select Medical Holdings Corporation						Select Medical Corporation
	For the Three Months Ended September 30,						For the Three Months Ended September 30,
	2015			2016			2015			2016

Net operating revenues	$	1,021,123		$	1,053,795		$	1,021,123		$	1,053,795

Costs and expenses:
Cost of services	900,949			915,703			900,949			915,703
General and administrative	22,201			27,088			22,201			27,088
Bad debt expense	18,287			17,677			18,287			17,677
Depreciation and amortization	31,472			37,165			31,472			37,165
Total costs and expenses	972,909			997,633			972,909			997,633

Income from operations	48,214			56,162			48,214			56,162

Other income and expense:
Loss on early retirement of debt	—			(10,853		)	—			(10,853		)
Equity in earnings of unconsolidated subsidiaries	6,348			5,268			6,348			5,268
Non-operating gain (loss)	29,647			(1,028		)	29,647			(1,028		)
Interest expense	(33,052		)	(44,482		)	(33,052		)	(44,482		)

Income before income taxes	51,157			5,067			51,157			5,067

Income tax expense	18,347			1,075			18,347			1,075
Net income	32,810			3,992			32,810			3,992

Less: Net income (loss) attributable to non-controlling interests	3,404			(2,479		)	3,404			(2,479		)

Net income attributable to Select Medical Holdings Corporation and Select Medical Corporation	$	29,406		$	6,471		$	29,406		$	6,471

Basic	$	0.22		$	0.05
Diluted	$	0.22		$	0.05

Weighted average shares outstanding:
Basic	127,386			127,848
Diluted	127,649			127,989

						Select Medical Holdings Corporation Stockholders										Non-
	Comprehensive Income		Total			Common Stock Issued		Common Stock Par Value		Capital in Excess of Par			Retained Earnings			controlling Interests
Balance at December 31, 2015			$	908,517		131,283		$	131	$	424,506		$	434,616		$	49,264
Net income	$	93,037	93,037										95,239			(2,202		)
Net income - attributable to redeemable non-controlling interests	11,752
Total comprehensive income	$	104,789
Issuance and vesting of restricted stock			12,344			1,089		1		12,343
Tax benefit from stock based awards			514							514
Repurchase of common shares			(1,939		)	(155	)	0		(883		)	(1,056		)
Stock option expense			4							4
Exercise of stock options			1,488			178		0		1,488
Non-controlling interests acquired in business combination			2,514													2,514
Distributions to non-controlling interests			(6,939		)											(6,939		)
Issuance of non-controlling interests			50,178							2,377						47,801
Purchase of redeemable non-controlling interests			466										466
Other			(198		)					(33		)	(672		)	507
Balance at September 30, 2016			$	1,059,986		132,395		$	132	$	440,316		$	528,593		$	90,945

Cash and cash equivalents	$	3,772
Identifiable tangible assets, excluding cash and cash equivalents	406,926
Identifiable intangible assets	254,990
Goodwill	651,152
Total assets	1,316,840
Total liabilities	248,797
Acquired non-controlling interests	17,084
Net assets acquired	1,050,959
Less: Cash and cash equivalents acquired	(3,772		)
Net cash paid	$	1,047,187

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2015		2015		2016
	(in thousands, except per share amounts)
Net revenue	$	1,099,857	$	3,350,131	$	3,293,286
Net income attributable to Holdings	26,277		88,502		93,407
Income per common share:
Basic	$	0.20	$	0.67	$	0.71
Diluted	$	0.20	$	0.67	$	0.71

	December 31, 2015						September 30, 2016
	Face Value		Carrying Value		Fair Value		Face Value		Carrying Value		Fair Value
	(in thousands)
Select 6.375% senior notes(1)	$	710,000	$	700,867	$	623,948	$	710,000	$	702,124	$	698,853
Select credit facilities(2)	1,048,277		1,038,071		1,023,616		1,324,315		1,296,655		1,318,943
Concentra credit facilities(3)	652,750		629,659		645,392		643,870		627,262		642,260

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2015		2016		2015		2016
	(in thousands, except per share amounts)
Numerator:
Net income attributable to Select Medical Holdings Corporation	$	29,406	$	6,471	$	101,409	$	95,239
Less: Earnings allocated to unvested restricted stockholders	923		209		2,925		2,852
Net income available to common stockholders	$	28,483	$	6,262	$	98,484	$	92,387

Denominator:
Weighted average shares — basic	127,386		127,848		127,541		127,659
Effect of dilutive securities:
Stock options	263		141		303		145
Weighted average shares — diluted	127,649		127,989		127,844		127,804

Basic income per common share	$	0.22	$	0.05	$	0.77	$	0.72
Diluted income per common share	$	0.22	$	0.05	$	0.77	$	0.72

	As of September 30,
	2015		2016
	(in thousands)
Total assets:
Specialty hospitals	$	2,333,049	$	2,461,751
Outpatient rehabilitation	541,435		977,431
Concentra(2)	1,332,975		1,327,438
Other(3)	106,946		78,785
Total company	$	4,314,405	$	4,845,405

	Total Number of Shares Purchased(1)	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publically Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
July 1 - July 31, 2016	—	$	—	—	$	185,249,408
August 1 - August 31, 2016	—	—		—	185,249,408
September 1 - September 30, 2016	116,975	12.26		—	185,249,408
Total	116,975	$	12.26	—	$	185,249,408